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Avant propos 
Organisation de la thèse 
Quelques mots sont nécessaires pour décrire le plan de la thèse. La thèse est 
divisée en plusieurs parties. Le premier chapitre est en français, résume toute la 
thèse et constitue aussi l’introduction de thèse. Il contient un résumé de la revue sur 
BARD1, les objectifs et le plan de la thèse, un résumé précis des résultats et 
discussions, divisés en 7 sous-chapitres, ainsi qu’une petite conclusion. Le reste de 
la thèse est en anglais à cause des publications. Le deuxième chapitre est une 
préface philosophique sur le rôle des tumeurs dans la population. Le troisième 
chapitre est une revue complète sur BARD1 qui sera prochainement soumis pour 
une publication dans un journal et qui a déjà servi en partie comme chapitre pour un 
livre. Le quatrième chapitre regroupe tous les résultats et est divisé en 7 parties 
distinctes. Ces parties sont reliées entre elles par la même thématique. Vu que tous 
les résultats sont publiés avec des collaborateurs, les sous-chapitres sont introduits 
par un petit résumé où je décris aussi ma contribution. Les sous-chapitres résultats 
(1 à 4) sont des publications. Le sous-chapitre (5) a été soumis pour publication et 
les deux derniers sous-chapitres (6 et 7) sont présentés, par soucis de concision, 
très succinctement avec quelques figures. Ces deux derniers chapitres représentent 
beaucoup de travail et sont en cours d’étude. La thèse se termine par une petite 
conclusion et les références. Bonne lecture ! 
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Résumé de la thèse 
Introduction sur BARD1 
Les cancers du sein et de l’ovaire sont prévalents dans les pays développés. En 
effet, le risque cumulé dans la vie d’une femme de développer un cancer du sein est 
de 11% aux Etats Unis. La plupart des cas sont sporadiques, et, seulement environ 
10% sont d’origine héréditaire. Deux gènes principaux de susceptibilité aux cancers 
gynécologiques ont été identifiés : BRCA1 et BRCA2 (Breast Cancer susceptibility 
genes 1 and 2). Ces deux gènes sont responsables d’environ la moitié des cas de 
tumeurs héréditaires. Des mutations dans d’autres gènes tels que PTEN, TP53, 
ATM, FANCD2 peuvent aussi prédisposer au cancer du sein, mais avec un risque 
très faible. BRCA1 et BRCA2 sont décrits comme des suppresseurs de tumeurs ; en 
effet, des mutations dans ces gènes prédisposent à des tumeurs du sein et de 
l’ovaire et les cellules de ces tumeurs perdent leurs allèles de type sauvage, 
produisant une perte de fonction. La nécessité d’étudier les mécanismes de 
suppression de tumeurs contrôlés par BRCA1 et de découvrir d’autres facteurs 
génétiques prédisposant aux cancers gynécologiques, a mené à la découverte de 
BARD1 (BRCA1 Associated RING Domain 1). Un criblage deux-hybrides dans la 
levure, en utilisant le bout N-terminal de BRCA1 comme appât, a permis 
l’identification d’une protéine interagissant avec BRCA1. Cette protéine, BARD1, est 
aussi un suppresseur de tumeur, car des mutations dans son gène semblent 
prédisposer au cancer du sein et parce que son absence n’est pas viable à l’état 
embryonnaire.  
 
La structure de BARD1 
BARD1 est une protéine de 777 acides aminés chez l’homme et de 765 chez la 
souris. BARD1 est un homologue de BRCA1. Elle contient deux domaines 
homologues hautement conservés pendant l’évolution. Ces domaines sont le 
domaine RING finger en N-terminal et le domaine BRCT en C-terminal. De plus, 
BARD1 contient trois domaines ankyrines que l’on ne se retrouve pas chez BRCA1. 
BARD1 et BRCA1 interagissent à travers leurs domaines RING. Deux chaînes en 
hélice-α de part et d’autre de la séquence primaire du RING assurent les liaisons 
hydrophobes permettant l’assemblage des deux domaines RING entre eux. Le RING 
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a une structure conservée qui contient deux atomes de zinc, nécessaires à l’activité 
enzymatique de l’hétérodimère BRCA1/BARD1. BARD1 a plusieurs orthologues chez 
d’autres espèces comme chez le Xenopus laevis et le nématode Caenorhabditis 
elegans, avec une fonction conservée.  
 
Les modèles génétiques 
Pour comprendre la fonction de BARD1, une analyse génétique a été effectuée dans 
des souris. Comme pour BRCA1 ou BRCA2, les souris knock-outs pour BARD1 ne 
sont pas viables et meurent toutes au stade embryonnaire. Les embryons meurent 
prématurément parce que les cellules ne prolifèrent plus normalement et pas à cause 
de la mort cellulaire par apoptose. En revanche, les souris possédant un knock-out 
inductible développent des tumeurs du sein au bout d’une année. De plus, les 
cellules avec une délétion du gène de BARD1 génèrent rapidement une instabilité 
chromosomique et une morphologie néoplasique. Ces résultats montrent 
l’importance de l’expression de BARD1 dans le maintien du génome et dans la 
suppression de cancers.  
 
L’activité ubiquitine ligase de BARD1 
La fonction biochimique principale de BARD1 réside dans sa capacité à ubiquitiner 
des protéines. Cette fonction E3 ubiquitine ligase est augmentée en présence de 
BRCA1. Bien que des homodimères de BARD1 et de BRCA1 aient été observés in 
vitro, seule la forme hétérodimèrique est fonctionnelle in vivo. La fonction ubiquitine 
ligase de l’hétérodimère est nécessaire dans la suppression tumorale. En effet, les 
mutations connues, telles que C61G et C64G, inhibant l’activité ubiquitine ligase du 
domaine RING prédisposent à des tumeurs gynécologiques. Ces mutations 
déstabilisent la structure tridimensionnelle contenant le zinc, mais ne détruisent pas 
les liaisons hydrophobes de l’hétérodimère. Le domaine RING est caractéristique des 
ubiquitine ligases. Ces ubiquitine ligases sont très utiles, voire indispensables, dans 
le métabolisme de protéines contrôlant la progression du cycle cellulaire, telles que 
des cyclines D1, E1, p27, etc., et de ce fait peuvent jouer un rôle important dans le 
cancer et sa suppression. Les cibles de l’ubiquitination de BARD1/BRCA1 sont peu 
connues, probablement importantes dans la régulation du cycle cellulaire, mais on 
sait que BARD1/BRCA1 peut s’auto-ubiquitiner. De plus, BARD1/BRCA1 peut 
ajouter une protéine d’ubiquitine sur les histones H2A et H2AX, et sur FANCD2. Une 
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autre cible de l’ubiquitination de BRCA1/BARD1 est la γ-tubuline ce qui est important 
dans la régulation de la duplication des centrosomes. En outre, la 
nucleophosmine/B23 est aussi une cible candidate pour une ubiquitination par 
BRCA1/BARD1, confirmant un rôle pour BARD1 dans la régulation des centrosomes. 
Finalement, l’hétérodimère BRCA1/BARD1 peut se lier la RNA polymérase II 
(RNAPII) et peut ubiquitiner la sous-unité Rbp1 de RNAPII. 
 
Les fonctions de BARD1 dépendantes de BRCA1 
BARD1 a plusieurs fonctions. BARD1 se lie à BRCA1, et semble partager beaucoup 
de fonctions qui sont attribuées à BRCA1. Cependant, BARD1 possède des 
fonctions indépendantes de BRCA1. Sa fonction la plus importante est partagée 
avec BRCA1 dans la réparation de l’ADN. BARD1 interagit avec BRCA1 dans la 
réparation de l’ADN cassé en doubles brins (DSB, double strand breaks) et est 
activée par ATM, ATR et en se liant au DNA-PKs et aux protéines Ku70 et 80. La 
réparation peut se faire par HR (homology directed repair), par NHEJ (Non-
homologous end joining), ou par MMR (mismatch repair) en interagissant avec 
hMSH2, hMSH3, hMSH6. L’expression de BARD1 peut être régulé pendant le cycle 
cellulaire, mais pour la réparation de l’ADN, BARD1 est localisé dans des complexes 
nucléaires pendant la phase S avec BRCA1 et Rad51 au niveau des sites de 
fourches de réplication et peut se re-agréger dans des complexes de réparation 
d’ADN avec PCNA et Rad51 après traitement hydroxyurée. La localisation nucléaire 
n’est pas exclusive et le déplacement de BARD1 dans le cytoplasme sera discuté 
dans la partie résultats. 
 
BARD1 et BRCA1 jouent un rôle dans la régulation de la transcription car elles 
peuvent se lier au complexe RNA polymerase II holoenzyme (holo-pol). En outre, 
holo-pol est dégradée par ubiquitination après dommage de l’ADN. L’arrêt de la 
transcription à des sites de dommages d’ADN est associé à la dégradation de holo-
pol suggérant un rôle pour BRCA1/BARD1 ubiquitine ligase dans la régulation de la 
transcription. De plus, il semblerait que le domaine BRCT de BARD1 comme celui de 
BRCA1 peut activer la transcription in vitro. BRCA1 peut se lier directement à l’ADN, 
sans doute à des sites de fourches de réplication. BARD1, en outre, peut se lier avec 
le facteur CstF-50 dans le but d’inhiber la polyadenylation et la maturation des ARN 
messagers in vitro, indiquant que BARD1 a effectivement un rôle dans la régulation 
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de l’expression de gènes. La sous-unité p50 de NF-kB peut se lier indirectement à 
BARD1 par l’intermédiaire de Bcl-3. L’interaction Bcl-3-BARD1 pourrait avoir lieu au 
niveau de leurs domaines ankyrines. Cette interaction est une indication 
supplémentaire quant au rôle de BARD1 dans la régulation de la transcription de 
certains gènes.  
 
Les fonctions de BARD1 indépendantes de BRCA1 
En plus des fonctions de BARD1 dépendantes de BRCA1, BARD1 a aussi une 
fonction indépendante de BRCA1, car sa surexpression dans des cellules en cultures 
est suffisante pour induire l’apoptose. Cette fonction est importante mais sera donc 
discutée plus en détails dans la thèse. 
 
Objectifs de la thèse 
Le but de cette thèse est d’étudier les mécanismes de suppression tumorale 
contrôlée par BARD1 et de comprendre comment BARD1 maintient une stabilité 
génomique. La première partie de la thèse consiste à répondre aux questions 
suivantes : quelle est la partie de BARD1 qui est nécessaire à l’induction de 
l’apoptose ; quels sont les déterminants de cette voie apoptotique ; quels sont les 
protéines qui interagissent avec BARD1 dans la suppression tumorale ; est-ce que 
p53 interagit dans cette voie signalétique de l’apoptose? En outre, on a voulu 
montrer la dynamique de BARD1 et déterminer son expression et sa localisation 
pendant l’apoptose ainsi que pendant la mitose ; d’identifier les protéines qui 
interagissent avec BARD1 pendant la mitose et qui régulent son expression en 
caractérisant son promoteur. Dans un deuxième temps, nous avons étudié le 
phénomène de l’instabilité chromosomique dans les cellules cancéreuses et identifié 
certains déterminants de la stabilité génomique pendant la mitose, l’effet de BARD1 
sur la régulation des télomères et sur la ségrégation des chromosomes.  
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Résultats et discussion 
1. BARD1 : un médiateur de l’induction de l’apoptose en réponse à un 
stress génotoxique, dépendant de p53 
BARD1 et BRCA1 ont des fonctions communes dans la réparation de l’ADN, dans la 
stabilité génomique, ainsi que dans des fonctions antitumorales. En effet, ces deux 
protéines homologues sont liées par leurs domaines RING respectifs. Dans une 
étude précédente, nous avons montré que la répression de BARD1 provoque des 
répercussions au niveau de la stabilité chromosomique ainsi que sur la morphologie 
et physiologie cellulaires, ce qui suggère une évolution vers un phénotype 
néoplasique. Dans cette première publication, nous montrons que BARD1 peut avoir 
des fonctions indépendantes de BRCA1 ainsi que l’importance de BARD1 face à un 
stress endommageant l’ADN. En cas de stress cellulaire et nucléaire, l’expression de 
BARD1 est augmentée à l’instar de celle de p53. Ces augmentations concomitantes 
de BARD1 et de p53 ont été observées in vitro en culture cellulaire, et in vivo dans 
des cas d’hypoxies induites par la formation d’une ischémie vasculaire cérébrale 
chez la souris. Nous avons démontré que cette augmentation se fait au niveau de la 
protéine et de son ARN messager. Il est intéressant de noter que les cellules qui sont 
réprimées pour BARD1 sont moins aptes à entrer en apoptose quand elles sont 
soumises à un stress. En effet, la fragmentation de l’ADN, normalement activée par 
des endonucléases spécifiques, de même que la présence de la caspase-3 activée 
sont réduites dans les cas où BARD1 est réprimée ou supprimée. La surexpression 
de BARD1 par transfection induit une mort cellulaire programmée. Les cellules 
produisent les mêmes signes qu’en cas de stress génotoxique, à savoir la 
fragmentation de l’ADN évaluée sur gel d’agarose, et mesurée quantitativement par 
cytométrie de flux (méthode TUNEL). Un mutant de BARD1 comprenant une 
mutation ponctuelle Q564H est incapable d’induire l’apoptose. De plus, l’induction de 
l’apoptose peut se faire même en l’absence de BRCA1. Les cellules souches de 
souris homozygotes BRCA1-/- peuvent être également induites en apoptose. Ceci 
démontre que BARD1 a une action cellulaire indépendante de BRCA1. Par contre, 
les effets pro-apoptotiques de BARD1 sont dépendants de p53 active et 
fonctionnelle. De plus, nous avons montré que BARD1 peut interagir avec p53 
physiquement par des expériences de co-immunoprécipitations.  
 
 7
2. La translocation de BARD1 du noyau vers le cytoplasme est liée à son 
activité apoptotique 
BARD1 est un suppresseur de tumeur ainsi qu’une protéine pro-apoptotique. 
Puisqu’une augmentation de l’expression de BARD1 peut suffire à induire une 
réponse apoptotique dépendante de p53, nous avons cherché à identifier le domaine 
protéique de BARD1 responsable de la signalisation menant à l’apoptose. Pour cela, 
une série de mutants de délétion de BARD1 a été transfectée dans des cellules en 
culture et nous avons mesuré la capacité des protéines recombinantes à induire 
l’apoptose. Une région de la séquence de BARD1 comprenant les acides aminés de 
510 à 604 est nécessaire à l’induction de l’apoptose. Cette partie de la séquence de 
BARD1 se trouve entre deux domaines fonctionnels : les répétitions d’ankyrines et le 
domaine BRCT en C-terminal. Ce domaine ne correspond pas à une structure 
conservée de la protéine. Ce domaine a la particularité de contenir les deux 
mutations répertoriées dans les tumeurs du sein C557S et Q564H. La partie pro-
apoptotique de BARD1 corrèle donc avec la fonction de suppresseur de tumeur. De 
plus, cette étude démontre que la localisation nucléaire de BARD1 n’est pas 
exclusive, malgré la présence de nombreux NLS (signaux de localisation nucléaire). 
En effet, des expériences d’immunofluorescence ou avec la protéine de fusion 
BARD1-EGFP, et des protéines de délétion fusionnées avec EGFP ont montré que 
BARD1 peut également être exporté dans le cytoplasme. La détection cytoplasmique 
de BARD1 a pu se faire in vivo et in vitro : sur des sections de tissus de rate de 
souris par immunohistochimie d’une part, et sur des cellules en culture par 
immunofluorescence et par microscopie électronique d’autre part. Les extraits de 
cytoplasme et de noyau montrent par western blot une présence de BARD1 dans le 
cytoplasme qui augmente en fonction du temps après induction de l’apoptose. Cette 
augmentation sensible de BARD1 dans le cytoplasme est accompagnée de la 
présence d’une protéine tronquée de p67 qui est peut-être le résultat d’un clivage 
protéolytique. La double localisation nucléaire et cytoplasmique de BARD1 dénote 
une double fonction : nucléaire dans la réparation de l’ADN et cytoplasmique dans la 
mort cellulaire programmée.  
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3. L’expression de BARD1 pendant la spermatogenèse est associée à 
l’apoptose et peut être régulée hormonalement 
L’expression protéique de BARD1 est élevée dans les tissus germinaux males et 
pendant l’embryogenèse. Dans cette étude, nous démontrons que BARD1 est en fait 
exprimé à tous les stades de la spermatogenèse contrairement à BRCA1 qui est 
seulement exprimé dans les spermatides ronds et les spermatocytes primaires 
méiotiques. Alors que les spermatogonies expriment le messager complet de 
BARD1, les spermatocytes précurseurs tardifs expriment une nouvelle forme de 
BARD1, plus courte, qui est prédominante et qui est désignée BARD1β. Ce 
messager codant pour BARD1 tronquée, dépourvue de son RING domaine, a perdu 
sa capacité à se lier et d’interagir avec BRCA1. Par contre, BARD1β conserve son 
aptitude à induire l’apoptose. Ce fait est important dans la mesure où les 
spermatogonies qui prolifèrent rapidement ont besoin d’un système efficace pour 
éliminer les cellules surnuméraires par apoptose. La mort cellulaire par le truchement 
de BARD1, permet cette régulation. De plus, il a été démontré que la forme tronquée 
de BARD1β peut induire l’apoptose in vitro par transfection transitoire de cellules en 
culture. L’apoptose a été suivie in vivo par immunohistochimie sur des sections de 
testicules de souris. L’expression de BARD1 est corrélée avec l’expression de BAX 
et de la caspase-3 active ainsi que la fragmentation de l’ADN. Finalement, nous 
avons montré dans cette étude que, dans des cas de pathologies testiculaires telles 
que l’azoospermie obstructive, la cryptorchidie et le syndrome de Sertoli, l’expression 
de BARD1 est augmentée. 
 
4. BARD1 induit l’apoptose en catalysant la phosphorylation de p53 par 
une kinase activée en réponse aux dommages de l’ADN 
Il a déjà été démontré que BARD1 joue un rôle dans la réponse apoptotique 
indépendamment de BRCA1, mais cela nécessite la présence de p53. Sans p53, la 
surexpression de BARD1 ne peut pas induire l’apoptose dans des cultures de 
cellules transfectées. Cette thèse est renforcée par le fait que BARD1 peut co-
immunoprécipiter p53 et le stabiliser. L’activation de p53 pendant l’apoptose se fait 
par l’ajout post-traductionnel de groupements phosphates sur plusieurs résidus, 
notamment sur les serines 15 et 37. Les kinases identifiées à ce jour dans la réponse 
aux dommages de l’ADN sont multiples et se fait par ATM, ATR et DNA-PK. Dans 
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cet article, nous montrons que BARD1 peut catalyser la phosphorylation de p53 sur 
la serine 15. Cette phosphorylation est effectuée par une kinase, qui a donc besoin 
de la présence de BARD1 fonctionnel. Elle est sans doute effectuée à travers le 
rapprochement et l’attachement de BARD1 à p53. Pour démontrer que l’interaction 
est nécessaire nous avons co-immunoprécipité p53 avec des mutants de délétions 
fusionnés à la EGFP permettant la reconnaissance de la protéine recombinante. Les 
divers mutants nous indiquent que la zone d’attachement de BARD1 à p53 est 
relativement importante, puisqu’elle couvre pratiquement toute la séquence primaire 
de BARD1. Néanmoins, cette expérience nous montre que le mutant qui ne contient 
pas la séquence codant pour le RING domaine, ainsi que la EGFP seule, sont 
incapables de co-immunoprécipiter p53. Ce résultat nous indique également que 
BARD1 se lie à p53 sans le soutient de BCRA1. Dans cette étude, nous montrons 
que BARD1 peut aussi co-immunoprécipiter Ku-70, une kinase impliquée dans la 
reconnaissance de cassure d’ADN double brin. Cette kinase est activée après 
exposition à un stress nucléaire et cellulaire et elle peut être la kinase responsable 
de la phosphorylation de la serine 15 de p53 induite par BARD1, puisque BARD1 
peut se lier à elle. 
 
5. BARD1 interagit avec BRCA2 afin de réguler la progression du cycle 
cellulaire 
BARD1, BRCA1 et BRCA2 sont des suppresseurs de tumeurs qui permettent le 
maintien de l’intégrité des chromosomes pendant la mitose. La ségrégation des 
chromosomes doit se faire sans perte ou gain sinon la résultante est une instabilité 
génomique. Dans les souris knock-out, la suppression des gènes susmentionnés 
provoque une mort embryonnaire précoce due à des problèmes de prolifération 
cellulaire et non à l’apoptose. Les cellules dépourvues de BARD1, BRCA1 ou 
BRCA2 par knock-down siRNA ont une grande propension à devenir instables 
génétiquement, la marque universelle des cellules tumorales. Cette étude vise donc 
à identifier les déterminants et les liens entre la suppression tumorale réglée par 
BARD1 et la maintenance de l’instabilité chromosomique dans les cellules en 
division. En utilisant un siRNA de BARD1 pour réduire l’expression de son messager 
et par conséquent de son produit protéique, nous observons une augmentation de 
temps du cycle cellulaire, sa complétion est donc ralentie. De surcroît, les cellules 
déficientes en BARD1 présentent des anomalies dans la cytokinèse. En examinant 
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l’état du génome, après analyse du caryotype des cellules transduites avec le siRNA 
de BARD1, nous avons constaté l’apparition de cellules génétiquement instables 
contenant des chromosomes surnuméraires ou présentant des pertes 
chromosomiques. De plus, il a été démontré par nous et par d’autres groupes que 
BARD1 varie pendant le cycle cellulaire et atteint un pic d’expression pendant la 
mitose, soit en G2/M. Cette augmentation de BARD1 s’accompagne d’une co-
localisation partielle de BARD1 avec les microtubules du fuseau mitotique. Cette co-
localisation a été observée par microscopie à fluorescence. L’expérience étant basée 
sur la spécificité de l’anticorps, les contrôles de spécificité de l’anticorps dans ces cas 
sont importants. Nous avons montré que l’anticorps anti-BARD1 choisi réagit 
uniquement avec la protéine de fusion BARD1-EGFP et non avec les protéines 
tronquées en N-terminal, ce qui défini la région de l’épitope. Pour comprendre les 
mécanismes de BARD1 dans la cytokinèse, nous avons voulu savoir si BARD1 
pouvait interagir avec les kinases qui sont impliquées dans la cytokinèse. 
Effectivement, BARD1 co-immunoprécipite Aurora B kinase et non Aurora A. De 
plus, et à notre surprise, BRCA2 peut co-immunoprécipiter avec BARD1 seulement 
dans la phase G2/M au moment de la phosphorylation de BRCA2. Ces résultats 
nous donnent une indication supplémentaire sur le rôle de BARD1 dans la régulation 
du cycle cellulaire. Les voies signalétiques de cette régulation ne sont néanmoins 
pas encore connues, bien que la fonction ubiquitine ligase de l’hétérodimère peut 
être mise en cause. 
 
6. Le rôle de BARD1 dans le maintien des télomères 
Nous savons que la majorité des cellules cancéreuses ont une instabilité 
chromosomique ainsi qu’une télomèrase active. Nous avions précédemment vu que 
la non expression de BARD1 dans des cellules en culture ou bien dans des souris 
knock-out produit une augmentation de l’instabilité génomique. De plus, il a été 
démontré que BARD1 et BRCA1 sont des facteurs qui s’agrègent dans les corps 
nucléaires, PML, dans les cellules négatives pour la télomèrase et que le complexe 
BRCA1-Mre11-Rad50-Nbs1, qui intervient dans la réparation d’ADN, est aussi 
présent dans le complexe télomèrique. En sachant que BARD1, tout comme les 
télomères, s’assemblent en agrégats nucléaires, et que les protéines télomèriques 
sont nécessaires dans le maintien de l’intégrité des chromosomes, nous avons voulu 
déterminer s’il y avait un lien de causalité entre un dysfonctionnement de BARD1, 
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des télomères et une instabilité chromosomique. En d’autres termes, est-ce que 
BARD1 peut moduler le fonctionnement des protéines télomèriques et le maintien 
des télomères? Nous avons voulu savoir si BARD1 avait une influence fonctionnelle 
sur la longueur des télomères, sur l’activité de la télomèrase et si BARD1 pouvait se 
localiser avec les structures télomèriques. Les résultats d’immunohistochimie avec 
des sondes télomèriques et l’anticorps dirigé contre BARD1 sur des cellules en 
cultures et sur des sections de tissus nous montrent qu’une fraction de BARD1 a 
tendance à se localiser sur ou près des régions télomèriques. De plus, il apparaît 
dans certains cas que BARD1 peut co-localiser avec TRF-2 une protéine couvrant la 
longueur des télomères. Afin de voir s’il y avait une interaction directe entre BARD1 
et les télomères, nous avons tenté d’immunoprécipiter l’ADN télomèrique avec un 
anticorps anti-BARD1. Le résultat obtenu par chromatine IP (ChIP) s’est révélé peut 
concluant ne démontrant pas d’interaction forte entre BARD1 et la chromatine 
télomèrique. La longueur des télomères des cellules épithéliales de glande 
mammaire de souris, qui ont été réprimées pour BARD1, a été mesurée par des 
méthodes de flow-FISH et de TRF. Il semblerait que ces cellules, comparées aux 
cellules normales, aient subit dans certains cas un raccourcissement des télomères. 
En fait, la longueur des télomères devient surtout beaucoup plus hétérogène dans 
les cellules BARD1 réprimées, ce qui est peut être l’expression d’un dérèglement du 
maintien des télomères. Puisque l’inactivation de BARD1 peut induire un phénotype 
néoplasique, et que la majorité des cellules tumorales ont une réactivation de la 
télomèrase, nous avons voulu savoir si la diminution de l’expression de BARD1 avait 
une influence négative sur l’activité de la télomèrase. Nous avons donc mesuré 
l’activité de la télomèrase par un test enzymatique et par PCR (TRAP) dans les 
cellules où l’expression de BARD1 était réduite. Ces expériences n’ont pas apporté 
de résultats concluants. En effet, les cellules de glandes mammaires de souris 
utilisées sont négatives pour la télomèrase à l’état sauvage. Les prochaines 
expériences tenteront de voir s’il y a une diminution de la longueur des télomères 
dans des lignées de cellules primaires et cancéreuses où on a réduit l’expression de 
BARD1 par transduction lentivirale de siRNA. La mesure de la diminution de la 
longueur des télomères devra s’effectuer sur plusieurs générations par la méthode 
dite de « Southern », par hybridation d’une sonde télomèrique marquée sur un gel 
d’ADN télomèrique (méthode TRF, telomere restriction fragment assay). Les 
résultats sont préliminaires et ne permettent pas de statuer sur une fonction de 
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BARD1 sur les télomères. Il est possible qu’en dépit d’un effet de BARD1 sur les 
télomères, que son action soit indirecte, un épiphénomène.  
 
7. Caractérisation du promoteur de BARD1 
Nous avons déjà constaté que BARD1, au niveau de son messager et de sa 
protéine, est augmentée dans des cas de stress génotoxique et qu’il est régulé 
hormonalement. De plus l’expression et la stabilité de BARD1 et de BRCA1 sont 
interdépendantes. Afin d’étudier les mécanismes de régulation d’expression de 
BARD1 dans les diverses conditions de stress cellulaire, de tumeurs, de réponse à 
une exposition aux hormones, de son rôle dans l’inflammation, de mort cellulaire, ou 
même dans le développement embryonnaire, il était important d’isoler et de 
caractériser le promoteur de BARD1 et la région promotrice minimale requise pour 
répondre à tous ces stimuli. Nous avons donc, dans un premier temps, caractérisé la 
région initiatrice de la transcription, le site cap en 5’ en amont de l’exon 1. Par une 
expérience 5’RACE et par PCR nous avons défini le site cap en amont de ce qui a 
déjà été publié. Nous avons amplifié par PCR à partir d’ADN génomique humain une 
région promotrice supposée que nous avons cloné dans un vecteur contenant le 
gène reporteur de la luciférase. Après transfection dans différentes lignées de 
cellules animales, nous avons constaté que la séquence de 856 paires de bases en 
amont du 5’UTR est suffisante pour l’activation constitutive de BARD1, mais en 
revanche ne semble pas contenir de sites de liaison à d’éléments régulateur. En 
effet, après une exposition à un stress cellulaire ou un traitement hormonal, les 
cellules transfectées avec le gène reporter ne montrent pas de variation notoire dans 
l’expression de la luciferase. Néanmoins, des travaux sont en cours pour caractériser 
une région qui pourrait réguler sensiblement l’expression du gène de BARD1. 
Notamment, une région de 2402 paires de bases en amont du 5’UTR a été clonée 
pour effectuer des tests par le système du gène reporter. Cette région contient des 
sites putatifs d’attachement à la p53 et au NF-κB entre autres, qu’il convient 
d’évaluer par des « shifts assay », « super shifts » et du DNA « footprinting » par 
exemple, en présence ou non de facteurs stimulants tels que des cytokines ou du 
TNF-α. Il serait intéressant de voir si cette région promotrice peut être activée par 
des cytokines, puisqu’on sait que la surexpression de BRCA1 fait augmenter la 
production cellulaire de NF-κB et que la sous-unité p50 peut se lier à BARD1 par 
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l’intermédiaire de Bcl-3. Ce serait une voie possible de régulation de l’expression de 
BARD1 par BRCA1, puisque l’on sait que BARD1 et BRCA1 se stabilisent 
mutuellement. 
 
Conclusion 
Cette thèse divisée en plusieurs points se concentre sur une même thématique : le 
rôle de BARD1 dans la suppression de tumeurs et dans le maintien de la stabilité 
chromosomique et génétique d’une manière générale. Nous montrons que BARD1 
agit souvent dans l’ombre de BRCA1, mais qu’elle peut avoir des fonctions 
indépendantes de BRCA1 dans plusieurs processus cellulaires. BARD1 possède une 
fonction proapoptotique. Bien que BARD1 soit décrite comme une molécule 
nucléaire, elle est également une protéine dynamique pouvant se localiser dans le 
cytoplasme. De plus, la fonction apoptotique est corrélée à sa localisation 
cytoplasmique. En outre, BARD1 joue un rôle dans l’apoptose des spermatocytes 
surnuméraires. BARD1 se lie à p53, la stabilise et est impliquée dans sa 
phosphorylation. Elle régule la complétion du cycle cellulaire, par TACC1, Aurora B 
et BRCA2 et semble avoir un rôle dans le maintien de l’intégrité des télomères. 
BARD1 est donc une protéine multifonctionnelle qui doit encore nous révéler bien 
des secrets au niveau de ses voies signalétiques et de ses fonctions.  
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Preface 
The purpose of cancer 
Question. Cancer is one of the leading causes of death in the world. In fact, it is the 
second leading cause of death after cardiovascular diseases. It has been predicted 
that one person in four will be afflicted with cancer during their life time. It is without 
any doubt a terrible and devastating disease. However, for a Doctor of Philosophy, 
that should not be the only reason for studying cancer. Compellingly, tumour 
development raises profound questions about life and death, and particularly, on the 
proliferation, survival and death of a single cell. So what is cancer, how does it occur 
and what purpose does it serve? 
 
What. Cancer is a paradox: it is life and death at the same time. Cancer is life 
because it is nothing else but the story of a cell escaping the sentence of death and 
becoming immortal. The cancer cell will divide and make a clone. It will create a 
population of cells that have acquired non-stop cell division. Cancer cells, like 
unicellular organisms, behave selfishly. The never ending self-replication is the 
default survival mechanism of all unicellular organisms, a mechanism without which 
life on earth would not be possible. However, in higher organisms, homeostasis and 
renewal of complex tissues requires regulated cell proliferation. Regulated cell 
proliferation means that cell division needs to be flawlessly counter-balanced by 
apoptosis, i.e. programmed cell death. In essence, the number of dividing cells 
should equal precisely the number of eliminated cells. Disrupting that equilibrium with 
a shift towards cell survival and uncontrolled proliferation is cancer. Unfortunately, 
neoplasia, or malignant cellular transformation, inexorably ensues in death, in the 
decease of its host. Therefore, cancer is also the expression of death. 
 
How. A large body of evidence has demonstrated that evolution is a consequence of 
genetic mutability in germ cells followed by a selection process under the pressure of 
the environment. Consequently, genetic variability emerging either in point mutations 
or genome alterations during meiosis is the necessary driving force of evolution and 
speciation. Likewise, tumour cells arise through a series of pair-wise mutations, 
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clonal selection and waves of expansion, which may be considered as a 
consequence of Darwinian selection. Therefore, cancer can well be regarded as an 
evolutionary consequence of genetic instability in somatic cells. Although 
environmental stress increases mutation rate, genetic instability, and cancer 
incidence, tumour cells may acquire mutations at a normal rate. However, cancer 
remains a naturally occurring genetic disease. Consequently, all cancers go through 
a state of genomic instability, resulting in chromosomal alterations and in aneuploidy.  
 
Why. Our own desire of eradicating cancer is, in a way, the expression of our 
yearning for immortality, or perhaps more modestly, a healthy long life. Because 
evolution requires the removal of old and deleterious genes and the renewal of the 
gene pool, the fitness and survival of an entire species relies on the elimination of a 
living organism at a pre-reproductive stage, but also at a post reproductive stage. 
Furthermore, in order to avoid depletion of limited resources in a finite environment 
by overcrowding and to provide an efficient turnover of generations, death of the 
individual at a post-reproductive age is essential. Thus, if we humans could be 
immortal, we would be considered as cancers, because we would be a liability to our 
natural environment. In other words, programmed cell death is a necessity for the 
survival of the whole organism, such as the death of an individual is a necessity for 
the perpetuation of the species and its evolution.  
 
Solution. Because mutations occur naturally over time, cancer incidence increases 
with age. Coincidently, the process of aging is also a by-product of genetic instability, 
just like cancer. Therefore, if we humans lived long enough, we would all eventually 
die of cancer, unless we genetically acquired “anti-cancer” mutations. Since death of 
a human being is a prerequisite for the survival of the human race and that there is 
no selective pressure preventing death, cancer would ensure, over time, death of an 
individual. Finally, it could simply mean that cancer is a necessity maintained through 
natural selection, in order to provide speciation and survival. In this case, cancer 
would be the ultimate barrier to an extended lifespan in a disease-free world. 
 
Question. Is cellular immortality a natural suicidal mechanism of an individual? 
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Review on BARD1 and its diverse functions 
 
I. Breast cancer and the BRCA genes 
BRCA1 and BRCA2 mutations in cancer 
Breast and ovarian cancers are highly prevalent in western societies. For instance, in 
the United States, the cumulative risk of developing breast cancer is 11% of women 
by the age of 80 (Casey et al., 1997)1. Most cases of breast and ovarian cancers are 
sporadic since only about 10% are hereditary (Wooster and Weber, 2003)2. Less 
than half of the familial breast and ovarian cancers, carry germ-line mutations in the 
breast cancer susceptibility gene 1 or 2 (BRCA1 or BRCA2) (Hall et al., 1990; Futreal 
et al., 1994; Miki et al., 1994, Wooster et al.,1994, 1995)3-7 (Figure 1).  
 
Other known inherited mutated genes in familial breast and ovarian cancers include 
PTEN (Shugart, 1999)8, and CHEK2 (Meijers-Heijboer, 2002; Schutte et al., 2003; 
Caligo, 2004)9-11. Mutations in other genes such as TP53, associated with Li-
Fraumeni syndrome, ATM in Ataxia telangectasia, FANCD2,which is inactivated in 
Breast and Ovarian Cancer Genes
other genes
BRCA1 20%
BRCA2 20%
CHEK2 5%
TP53 <1%
PTEN <1%
STK11/LKB1 <1%
ATM <1%
FANCD2 <1%
Figure 1. Representation of susceptibility genes predisposing to breast and ovarian tumours. Only half of the 
hereditary genes have been discovered, the other half is probably polygenic and could have environmental 
and multifactorial origins. These genes represent only 10% of all breast and ovarian cancers. The rest are 
sporadic cases. (Data compiled from Wooster and Weber, 2003). 
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Fanconi anaemia, and STK11/LKB1 mutated in cases of Peutz-Jeghers syndrome, 
are also associated with breast cancer, but predispose at low frequencies (Smith et 
al., 1993; Ford et al., 1995; Chen et al., 2000)12-14. The other familial breast and 
ovarian cancers do not have an apparent autosomal dominant inheritance pattern 
and are probably polygenic with environmental influences (Mincey, 2003)15. 
 
BRCA mutations are highly penetrant, since women harbouring mutations in either 
BCRA1 or BRCA2 have a 80-90% life-time risk of developing tumours in the breast or 
in the ovaries, and account for about 40-50% of early onset of breast and ovarian 
cancers (Easton et al., 1993,1994; Ford et al., 1994, Rahman and Stratton, 1998)16-19. 
Moreover, in tumours from patients with inherited mutations in either BRCA1 or 
BRCA2, the mutation of one allele is typically associated with the loss of their wild-
type allele, incurring a loss of function. This loss of function, also termed loss-of-
heterozygosity (LOH), means that BRCA1 and BRCA2 act as potent tumour 
suppressors (Futreal et al., 1994)4 and correlates with the occurrence of breast and 
ovarian cancer (Ford et al., 1998)20. Moreover, BRCA1 acts as a tumour suppressor 
because its overexpression in tumour cells injected in nude mice induces growth 
retardation of the tumour cells (Holt et al., 1996)21. Some sporadic breast and ovarian 
tumours show defects in BRCA1 and BRCA2 genes or in their activity in tumour 
tissues. This underpins the importance of epigenetic silencing pathways in breast and 
ovarian tumours, adding another factor of complexity to BRCA-related tumours. 
BRCA1 is a highly ubiquitous protein as it is expressed in almost all tissues. However, 
tumours arise only in the breast and ovaries that have lost the remaining healthy wild-
type allele of individuals carrying germ-line mutations in the BRCA1 gene. LOH 
occurring in other tissues has not been reported. Possibly because nullizygous Brca1 
mutation in mice is non-viable for a developing embryo (Hakem et al., 1996; Gowen et 
al., 1996)22,23. In these heterozygous individuals, other tissues are not affected and do 
not develop tumours, and they do not appear to be able to lose their wild-type allele. 
This conundrum, discussed in numerous reviews on BRCA1 (Monteiro, 2003; Starita 
and Parvin, 2003; Venkitaraman, 2002, 2004)24-27, raises fundamental questions on 
the function of BRCA1 and its differential activity in breast and ovaries. One may ask 
why and how breast and ovarian tissues bear this permissive BRCA1 dysfunction 
compared to other tissues. 
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Genetic models for BRCA1 and BRCA2 
To assess the function of BRCA1 and BRCA2 genes in breast cancer, knockout 
mouse models were generated. The knockout mice, Brca1-/- or Brca2-/-, are not 
viable and die early in embryogenesis. Several groups have shown that mouse 
embryos with homozygous deletion in the Brca1 gene, die early in embryogenesis, 
between days E5.5 and E13.5 depending on the type of deletion effectuated (Gowen 
et al., 1996; Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997)22,23. Such mice 
typically showed several defects in gastrulation and in cellular proliferation. The 
Brca2 knockout mice, carrying a homozygous truncation of exon 11 in Brca2, 
displayed embryonic death at days E8.5-9.5 (Hakem et al., 1998)28. Mice which were 
heterozygous for either Brca1 or Brca2 developed normally and were not more 
susceptible to breast cancer than the normal wild-type littermates. However, mice 
carrying conditional deletion knockout mutants for Brca1, driven under a mammary 
tissue specific promoter, displayed mammary gland tumours by 10-13 months of age 
(Xu et al., 1999a)29. 
 
Overview of BRCA1 and BRCA2 functions 
The structure and functions of BRCA1 and BRCA2 as well as the mechanisms-of-
action of BRCA-driven tumours have been widely discribed in numerous reviews 
(Zheng et al., 2000; Scully and Livingston, 2000; Wang et al, 2000; Kerr and 
Ashworth, 2001; Mueller and Roskelley, 2002; Moynahan, 2002; Narod and Foulkes, 
2004; Venkitaraman, 2004)27,30-36. The BRCA1 and BRCA2 proteins interact with a 
large number of proteins. They have a wide spectrum of activities since they play 
roles in a variety of different pathways, coordinate and integrate various pathways, 
which include DNA repair pathways and DNA replication cycle on one hand, and 
centrosome duplication and mitotic checkpoints on the other. 
 
BRCA1 is a ubiquitously expressed protein of 1863 amino acids consisting of two 
highly conserved domains: a RING finger domain and two BRCT domains. Without 
going into the detail of the multitude of BRCA1 functions, BRCA1 is involved in 
diverse pathways such as DNA damage repair of double stranded breaks (DSB), 
transcription-coupled repair, transcriptional regulation, chromatin remodelling, 
ubiquitination, centrosome duplication and cell-cycle checkpoints (Deng and Brodie, 
2000; Khanna, 2001; Starita and Parvin, 2003; Venkitaraman, 2004; Narod and 
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Foulkes, 2004; Deng, 2002; Hsu and white, 1998; Hsu, 2001; Lotti et al.,2002; 
Schlegel et al., 2003)25,27,36-41. One hypothesis could be that BRCA1 serves as a 
scaffolding protein for the assembly of a multi-protein complex that plays a role in 
integrating the aforementioned mechanisms. 
 
The BRCA2 gene codes for a large protein of 3,418 amino acids, highly conserved 
throughout evolution, and widely expressed in adult and embryonic tissues (Rajan et 
al., 1997)42. It is structurally and phylogenetically unrelated to BRCA1 and bears no 
homology with amino acid sequences of BRCA1 whatsoever. The function of BRCA2 
is less diverse than that of BRCA1. Like BRCA1, BCRA2 is specifically involved in 
homologous-directed repair (HDR or HR) and in non-homologous end joining 
(NHEJ). BRCA2 attaches to Rad51 through its BRC repeats and binds directly to 
DNA domains at sites of double stranded breaks (DSB). 
 
To summarize, all the functions of BRCA1 and BRCA2 converge towards one goal 
which is to maintain genome integrity. Since BRCA1 and BRCA2 are involved in DSB 
repair, the common phenotypical feature of BRCA1 and BRCA2-deficient cells is that 
they have a hypersensitivity to DNA damage-inducing agents such as ionising 
radiation and inter-strand cross-linking drugs. These BRCA deficient cells display 
increased genomic instability, as manifested by visible chromosomal aberrations and 
aneuploid karyotypes (reviewed by Jasin, 2002; Moynahan, 2002)35,43. Chromosomal 
aberrations are common to all, if not most, cancers and could be the pathogenic 
basis of breast and ovarian cancers caused by mutations in BRCA1 or BRCA2. 
However, investigating the function of these tumour suppressors, their associated 
proteins and their molecular pathways is paramount in the fight over gynaecological 
cancers. 
 
 
II. BARD1 protein structure 
BARD1 discovery and phylogenetic analysis 
In the search for novel partners of BRCA1, BARD1 (BRCA1-Associated RING finger 
Domain protein 1) was discovered in a yeast-two-hybrid screen using the N-terminus 
fragment of BRCA1 containing the RING domain as bait (Wu et al., 1996)44.  
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The human BARD1 gene is localized on chromosome 2 (2q34-q35) and the cDNA 
encodes for a protein of 777 amino acids (Wu et al., 1996; Thai et al., 1998)44,45. 
However, a doubt remains on the initiation site of translation, which could be situated 
either at amino acid position 1 or 26. The BARD1 structure resembles BRCA1’s 
structure, in that BARD1 shares sequence homology with BCRA1’s conserved 
domains (Figure 2). Like BRCA1, the cloned human BARD1 contains a RING finger 
domain at its N-terminus (residues 46-90) and two BRCT domains at the C-terminus 
(residues 616-653 and 743-777). Moreover, BARD1, albeit less than half the size of 
the BRCA1 protein (1863 residues), contains in addition three ankyrin domains 
(ANK). Apart from the conserved domains, the rest of BARD1 bears no homology 
with other proteins. BRCA1 is the only vertebrate protein that shares homology with 
BARD1 in both the RING and BRCT domains. Homology in gene structure and 
protein sequence of BARD1 and BRCA1 suggests that both proteins are 
phylogenetically related. In contrast, BRCA1 and BRCA2 show a poor degree of 
conservation through evolution. Indeed, mouse and human orthologues of BRCA1 or 
BRCA2 share less than 60% of identical amino acid residues, but the functional 
domains are conserved. The fact that the mouse Brca1 and Brca2 proteins share 
mBARD1
Ankyrin repeatsRING Finger BRCT 
9566 53 97 77 91 % of conservation with hBARD1
BRCA1
NLS 131 NLS 408 NLS 693
765 aa
1823 aa
BRCA2
777 aahBARD1
3418 aa
BRC repeats NLSTransactivation 
domain
(Not to scale)
Figure 2. Schematic of human and mouse BARD1, BRCA1 and BRCA2 proteins showing conserved 
functional domains. BARD1 and BRCA1 are homologues since they share two conserved domains with high 
homology, whereas BRCA2 is completely unrelated to either BARD1 or BRCA1. 
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less than 60% homology with their human counterparts, contrasts with other known 
tumour suppressors such as p53 or NF1, with 78% and 98% identity, respectively 
(Connor et al.1997b)46. Comparison of amino acid homology between BARD1 and 
BRCA1 shows that they had a common genetic ancestor and that they have co-
evolved at similar rates during evolution providing further clues that these proteins 
may function in the same complex. 
 
BARD1 orthologues 
Alignment of human and mouse BARD1 orthologues shows low levels of amino acid 
sequence homology, i.e. 70.4% over the total protein, whereas the RING, ANK and 
BRCT motifs have 86.7% and 90.1% an 79.8% identity respectively (Irminger-Finger 
et al., 1998; Ayi et al.,1998)47,48 (Figure 2). The fact that RING, BRCT and ANK 
domains of BARD1 are highly conserved throughout evolution, and the rest of the 
protein shows poor levels of homology, suggests that the three functional domains 
mediate essential functions that are conserved through evolution. Furthermore, since 
the isolation of BARD1 (Wu et al., 1996)44, orthologues from other species have been 
cloned: Xenopus laevis (773 aa) (McCarthy et al., 2003), Rattus norvegicus (768 aa), 
and Mus musculus (765 aa) (Figure 3).  
 
Since then, other assumed orthologues from other species have been deduced from 
their sequence homologies by reciprocal BLAST analysis. A predicted BARD1 
Gallus gallus (chicken)
Gallus gallus (chicken)
Xenopus laevis (toad)
Rattus norvegicus (rat)
Mus musculus (mouse)
Takifugu rubripes (fugu fish)
Caenorhabditis elegans (nematode)
Pan troglodytes (chimpanzee)
Arabidopsis thaliana (thale cress)
Homo sapiens (human)
similar domain architectures
777 aa
765 aa
768 aa
772 aa
670 aa
734 aa
602 aa
1548 aa
750 aa
1083 aa
Figure 3. Representation of known BARD1 orthologues in other species with conserved identical domains 
showing similar domain architectures (source: http://www.ncbi.nlm.nih.gov/entrez/) 
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orthologue encoding two of the three motifs exists in Arabidopsis thaliana (Joukov et 
al., 2001; Irminger-Finger et al., 1998)47,49. The Caenorhabditis elegans BARD1 
orthologue has been identified and conserves the same function as human BARD1 
(Boulton et al., 2004)50. The chimpanzee orthologue has an overall homology of 99%, 
but lacks the C-terminus and the two BRCT domains (Figure 3). In addition to the 
three functional domains, human BARD1 contains 6 predicted nuclear localizing 
signal (NLS) sequences, situated in the vicinity or embedded in each of the three 
functional domains, inferring a predicted nuclear localization of BARD1. In 
comparison to human BARD1, mouse BARD1 has only three NLS sequences with a 
marginally lower prediction score for nuclear localization (Jefford et al., 2004)51.  
Figure 4. Solution structure of the N-terminal and C-terminal domains of BARD1 and BRCA1. The RING 
finger domain permits the interaction of BARD1 and BRCA1 creating a 4 alpha-helix bundle, held together 
by hydrophobic bonds. The RING domain is flanked by the two alpha helices in the primary structure. The 
RING motif contains the zinc binding domain. The two BRCT domains pack together forming a compact 
structure (Modified from Baer; 2001, with reproductions from Brzovic et al., 2001; Williams et al., 2001). 
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RING finger domain 
The most studied domain in BARD1 and in BRCA1 is the RING finger domain. The 
RING finger protein sequence motif was discovered 15 years ago and stands for 
Really Interesting New Gene (Borden et al., 1998)52. The RING sequence motif is 
defined as a unique array of conserved cysteine and histidine residues found at the 
extreme N- or C-terminus of proteins that are typically involved in ubiquitination 
pathways (Freemont, 2000)53. RING finger domains mediate also protein-protein 
interactions and are involved in supra-molecular self-assemblies (Kentsis and Borden 
2004)54. The conserved RING motif of BARD1 includes residues 50 to 86 and 
corresponds to residues 24 to 64 in BRCA1 (Figure 4b). The RING finger binds two 
atoms of zinc in a unique “cross-brace” conformation. The spacing between the 
second and third pairs of cysteine and histidine residues implies that the distance is 
conserved between the two zinc binding sites. BARD1 is the main binding partner of 
BRCA1 and both proteins heterodimerize through their N-terminal RING finger 
domains to form the active enzymatic complex (Figure 4a). The heterodimeric 
interaction is strong, and although BRCA1 and BARD1 homodimers may be 
produced in vitro, it is usually the heterodimers that are found in vivo (Meza et 
al.,1999)55. Limited proteolysis analysis has defined that the region necessary for 
heterodimerization includes residues 1-109 of BRCA1 and 26-119 of BARD1 (Meza 
et al., 1999)55, (fig 5a). The cognate BARD1 and BRCA1 proteins heterodimerize by 
forming an extensive 4-helix bundle each consisting of two anti-parallel alpha helices 
and bind through their hydrophobic residues (Brzovic et al.,2001a; Morris et al., 
2002)56,57. The resolution of the crystal structure reveals that BARD1 has two alpha 
helices, which flanks the RING motif in the primary sequence, and two short beta 
sheets of the RING motif is separated by a loop which has the conserved pattern of 
seven cysteine and one histidine residues which houses the two separate zinc-
binding sites (I and II) (Brzovic et al., 2001b)58 (fig. 4b). On the other hand, the 
BRCA1 RING domain which has a similar structure contains three alpha helices and 
two beta-sheets. RING finger domains are essential for the proper function of 
proteins that contain them and for ubiquitination function. This is evidenced by the 
multiple cancer predisposing mutations within the BRCA1 RING domain which 
destroys BRCA1/BARD1 tumour suppressor and ubiquitin ligase activities (see 
below). Several known cancer-predisposing mutations have been identified within 
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this region. A missense mutation at either cysteine residue C39G, C64G, or C61G of 
BRCA1 alters the Zn2+ binding site II and prevents the metal atom from binding to site 
II. The site II cancer predisposing mutations C61G and C64G do not disrupt 
heterodimer formation, but only the RING domain’s zinc binding capabilities (Morris 
et al., 2002)57. Several residues have been identified within the alpha helices of 
BARD1 that are required for heterodimer formation (Figure 5); these residues do not 
participate in binding the zinc atom (Morris et al., 2002)57. Furthermore, site II cancer-
predisposing mutations in BARD1 RING domain have not yet been discovered, 
possibly because the binding site for the E2/UbcH5 conjugating enzyme is localized 
on the face of BRCA1 RING domain (Brzovic et al., 2003)59. It is rather mutations in 
the hydrophobic interface that affect structural stability, even though some mutations 
away from helical core are also capable of inhibiting heterodimer formation (Morris et 
al., 2002)57. 
 
 
 
Figure 5. Identification of residues of BARD1 required for the BRCA1/BARD1 heterodimer interaction. A)   
Depiction of the positions of the amino acids which can inhibit heterodimer formation when mutated. The zinc 
atoms are the grey spheres. B) Summary of mutations that inhibit heterodimer formation that were discovered 
in a yeast two-hybrid screen. (Reproduced from Morris et al., 2002). 
BARD1
BRCA1
A
B
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Ankyrin repeats 
Ankyrin domains are usually found in sets of repeats, usually of 3 or 4, but can have 
up to 20 repeats. They mediate protein-protein interactions in very diverse families of 
proteins, (for a review, refer to Mosavi et al., 2004)60. Their precise functions in 
BARD1 remain elusive, but could be responsible for the numerous interactions 
BARD1 may have with several classes of proteins implicated in tumour suppression. 
 
BRCT domain 
The BRCT domain (BRCA1-C-terminus) was first identified in BRCA1 (Koonin et al., 
1996). It is a conserved domain which is defined by distinct clusters of hydrophobic 
residues folding into a unit of approximately 95 amino acids. The crystal structure of 
XRCC1 BRCT domain has been elucidated and showed that pairs of these structures 
may form homodimers as well as heterodimers (Zhang et al., 1998, Huyton et al., 
2000)61,62. The two BRCT domains of BCRA1 may bind together head-to-tail fashion 
tethered by a poorly defined 23 amino acid linker (Williams et al., 2001)63 (Figure 4c), 
forming a functional domain that can mediate transactivation functions and serve as a 
multi-protein scaffold for several protein-protein interactions (Huyton et al., 2000)62. 
BRCT repeats are found in many proteins involved in cell-cycle checkpoint pathways 
responsive to DNA damage, DNA repair and recombination, such as 53BP1, RAD9, 
RAD4, DNA ligase III and XRCC1 which bind to each other strongly (Ljunquist et al., 
1994; Caldecott et al., 1995)64,65. The BRCT domain of BRCA1 is essential for DNA 
repair, transcriptional regulation, as well as several tumour suppressor functions (Hall 
et al., 1990, Miki et al., 1994; Futreal et al., 1994; Friedman et al., 1994)3-5,66. BRCT 
may bind to other BRCT repeats and other proteins with various unrelated structures. 
Also, several studies have shown that the BRCT element of BRCA1 may bind or 
interact with a number of proteins involved in transcriptional regulation, such as CtIP 
co-repressor, histone deacetylases, p53, p300 and the DNA damage-associated 
helicase BACH1 (Cantor et al., 2001; Deng and Brodie 2000)37,67. Furthermore, a 
study showed that the tumour suppressor function of BRCA1 requires that the two 
BRCT domains remain packed together (Huyton et al., 2000; Williams et al., 
2001)62,63. Two missense mutations within the BRCT domains of BRCA1 that were 
found to be linked to breast and ovarian cancer (Miki et al., 1994, Futreal 1994)4,5 
have been shown to impair correct BRCT homodimerization (Williams et al., 2001)63. 
The tandem BRCT domains of BARD1 are predicted to behave in the same fashion, 
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but its exact function still remains to be elucidated (Huyton et al. 2000)62. It would be 
interesting to see whether the BRCT domains of BARD1 and BRCA1 interact. 
 
III. Ubiquitin ligase function of BRCA1/BARD1 
RING finger domain proteins are ubiquitin ligases 
Many proteins containing a RING domain exhibit ubiquitin (Ub) ligase activity (E3) 
(Freemont, 2000). The BRCA1/BARD1 heterodimer is an E3 ubiquitin ligase. There 
are 890 genes in Homo sapiens that contain a RING domain and 213 are known to 
be involved in ubiquitin-related processes (PubMed). Represented in all species, 
except in prokaryotes, the function of the RING finger domain proteins is very well 
conserved. The roles of ubiquitination are multiple and are essential in cellular 
homeostasis, cell cycle progression and in cancer. E3 ubiquitin ligases regulate the 
expression of many cell-cycle regulators which are targeted for degradation through 
the proteasome pathway (Yew, 2001). Some of these cell cycle regulators, which are 
over-expressed in several tumours, include cyclin D1 and E1, p27, p21, and INK4A. 
Furthermore, ubiquitination plays an important role in tumorigenesis, because the 
RING finger domain is found in many tumour suppressors, such as BRCA1, BARD1, 
MDM2, Cbl, and Rbx1 (Freemont, 2000; Ohta and Fukuda, 2004)68. Moreover, 
several nuclear oncoproteins like c-myc, c-fos, and E1A are degraded by the 
ubiquitin system (Ciechanover et al., 1991). Therefore, defects in ubiquitination affect 
a range of cellular processes such as cell-cycle progression, cell differentiation, 
apoptosis, DNA damage pathways, and transcriptional regulation (Weissman, 2001; 
Pickart, 2001; Hicke, 2001)69-71.  
 
Ubiquitination and de-ubiquitination 
Ubiquitination is a post–translational modification of proteins by attachment of 
ubiquitin side chains. It is a function that modulates protein half-life by degradation of 
substrates targeted with ubiquitin. Ubiquitinated proteins may either undergo 
proteolysis through the proteasomal pathway or be reused after cleavage of the 
ubiquitin chains by cysteine proteases, called de-ubiquitinating enzymes (DUBs). The 
ubiquitin-proteasome machinery is classically composed of five essential elements: 
the ubiquitin polypeptide of 76 amino acids (Ub), a ubiquitin-activating enzyme (E1), 
a ubiquitin-conjugating enzyme or transferase (E2 or Ubc), a ubiquitin ligase (E3), 
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and the proteasome unit (for an extensive review see Hershko and Ciechanover, 
1998; short review see Wilkinson, 2000; or Freemont, 2000)53,72,73. The E1 ubiquitin-
activating enzyme binds ubiquitin by forming a thiolester bond, in an ATP dependent 
way, and then transfers ubiquitin to the E2 conjugating enzyme which, in turn, forms 
an isopeptide bond with the substrate via the E3 ligase. The substrates may be 
ubiquitinated in several ways and therefore may serve various functions. Substrates 
may be either mono- or poly-ubiquitinated (or even multiubiquitinated), and may be 
linked to each other by several different residues (Ohta and Fukuda, 2004)68. 
Proteins tagged with a polyubiquitin chain attached by their K48 residues are usually 
targeted for degradation through the 26S proteasome pathway. However, other 
polyubiquitin chains can also be synthesized with links between the C-terminus of 
ubiquitin and the K6, K11, K29 and K63 on the adjacent ubiquitin. Proteins with 
polyubiquitinated chains linked by their K63 residues are a signal for endocytosis, IκB 
kinase activation, ribosome activation and DNA repair, whereas monoubiquitination 
plays a role in the regulation of histones (Pickart, 2000)70.  
 
BRCA1/BARD1 heterodimer is an E3 ubiquitin ligase 
There are two main groups of E3 ligases, the HECT domain ligases such as the E6-
AP (Huibregste et al., 1995)74 and the RING finger ligases, such as BRCA1 and 
BARD1 (Joazeiro and Weissman, 2000)75. BRCA1 is a bona fide E3 ubiquitin ligase 
that may ubiquitinate its substrates or itself (Lorick et al., 1999). Cancer predisposing 
mutations, C61G and C64G, within the RING domain of BRCA1, abolish the E3 
ubiquitin-ligase activity of the BRCA1/BARD1 heterodimer and its tumour suppressor 
function (Hashizume et al., 2001; Ruffner et al., 2001; Brzovic et al, 2001b)58,76,77. 
Furthermore, these cancer mutations display hypersensitivity to γ-irradiation, showing 
a link between ubiquitination, DNA repair and tumour suppression (Ruffner et al., 
2001). The stability of BRCA1 is increased in the presence of BARD1. Expression of 
both is required proteins equally for high Ub-ligase activity (Hashizume et al., 
2001)76. Although, BARD1 and BRCA1 may individually carry out ubiquitination in 
vitro, BRCA1 ubiquitin ligase activity is significantly enhanced when bound to BARD1 
through their RING domains (Hashizume et al., 2001; Xia et al., 2003)76,78. The 
aforementioned cancer predisposing mutations such as C61G and C64G perturb 
binding of the E2/UbcH5c and E2/UbcH7 conjugating enzymes to BRCA1 (Brzovic et 
al., 2003)59 (Figure 6). In vitro experiments with purified RING structures from 
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unrelated proteins such as promyelocytic leukaemia protein (PML), KAP-1/TIF1B, Z, 
Mel18, BRCA1 and BARD1 self-assemble in supra-molecular structures that 
resemble the ones they form in cells (Kentsis et al., 2002). The same report shows 
that these structures may enhance ubiquitination reactions performed by the 
BRCA1/BARD1 E3 ligase and its auto-ubiquitination (Kentsis et al., 2002)79. 
Therefore, the main biochemical function attributed to BARD1 is its ubiquitin ligase 
activity, which is essentially mediated through its RING domain together with BRCA1. 
This ubiquitination function is therefore driven mostly by the BRCA1/BARD1 
heterodimer and could be responsible for mediating all cellular functions attributed to 
BRCA1 and BARD1 (reviewed in Baer and Ludwig, 2002).  
 
Ubiquitin targets of the BARD1/BRCA1 heterodimer  
In the search for novel targets of the BRCA1/BARD1 E3 ubiquitin ligase function, it 
was found that BRCA1 and BARD1 can be auto-ubiquitinated in vitro and in vivo in 
the presence of the E2 conjugating enzyme Ubc5c and ubiquitin (Chen et al., 
2002)80. This auto-ubiquitination occurs on non-K48 residues, since a missense 
mutation on this residue did not hinder poly-ubiquitination reactions in vitro. However, 
BARD1 and BRCA1 auto-ubiquitination was postulated not to be a signal for 
proteasomal degradation, but could rather serve other signalling pathways. 
Figure 6. Representation of E2 ubiquitin conjugating binding site on BRCA1. A) Ribbon structure showing 
mutation sites that perturb binding of E2 conjugating enzymes UbcH5c and UbcH7. B) Surface structure 
showing that the ubiquitin conjugating enzymes only contact BRCA1 and not BARD1 (Brzovic et al., 2003). 
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Furthermore, this auto-ubiquitination increases ubiquitin ligase activity of the 
BRCA1/BARD1 heterodimer on itself 20-fold (Mallery et al., 2002). The auto-
ubiquitination reactions promote formation of poly-linked ubiquitin chains attached at 
K6 (Wu-Baer et al., 2003; Nishikawa et al., 2003)81,82. Specifically, BRCA1/BARD1 
induces formation of K6-linked conjugated ubiquitin structures at sites of DNA 
replication and repair (Morris et al., 2004)83.  In vitro ubiquitination reactions may be 
performed with a truncated BRCA1 (1-639) (Chen et al., 2002)80 and full length forms 
of BRCA1 and BARD1 (Mallery et al., 2002)84. Although the minimal interacting 
regions for RING formation are BRCA1aa1-109 and BARD1aa26-119, they are not 
sufficient for E3 ligase activity inferring that a larger domain is required for proper 
ligase activity (Mallery et al., 2002)84. BARD1 may serve an accessory role in 
ubiquitination, since the BARD1 protein or a truncated form from residues 8 to 142, in 
which the RING finger domain lacked Ub-ligase activity in vitro, significantly 
enhanced the E3 ligase activity of BRCA1/BARD1 duplex (Xia et al., 2003)78. 
Furthermore, through NMR spectroscopic analysis and site-directed mutagenesis the 
binding site of the E2 conjugating enzyme, UbcH5c or UbcH7, maps to the BRCA1 
RING domain and not to BARD1 (Figure 6) (Brzovic et al., 2003)59. Although it was 
shown that it is the heterodimer which is auto-ubiquitinated, no studies have shown 
where and on which molecule this ubiquitination takes place and whether BARD1 is 
mono-ubiquitinated. Since expression of BARD1 and BRCA1 proteins are cell-cycle 
dependent and it was proposed that BARD1 and BRCA1 are degraded by the 
proteasome pathway (Choudhury et al., 2004)85. 
 
Some of the first identified targets of BRCA1/BARD1 ubiquitin ligase function are the 
histones H2A and H2AX (Ruffner et al., 1998). The BARD1/BRCA1 heterodimer is 
capable of catalysing the mono-ubiquitination of the histone H2A/H2AX in vitro (Chen 
at al., 2002)80. Attachment of a single ubiquitin to histones H2A and H2B leads to 
alteration of chromatin structure and opens DNA for transcriptional activity (Levinger 
and Varshavsky 1982; Davie et al., 1990, 1991)86-88, underpinning a role for 
BRCA1/BARD1 in transcriptional activation.  
 
Another potential target for BRCA1/BARD1 ubiquitination is the FANCD2 protein, 
since its mono-ubiquitination is reduced in cells that are defective for BRCA1 (Garcia-
Higuera et al., 2001)89. FANCD2 can be mono-ubiquitinated in vitro by 
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BRCA1/BARD1 heteroduplex, together with E1 and UbcH5a (Vanderberg et al., 
2003)90. However, although the depletion of BRCA1 by siRNA in human cells 
resulted in defective localization of FANCD2 to sites of DNA damage, it did not lead 
to loss of mono-ubiquitination of FANCD2 (Vanderberg et al., 2003)90. Therefore, the 
BRCA1/BARD1 E3 ligase is not necessary for mono-ubiquitination of FANCD2.  
 
 
Recently some light was shed on the role of BARD1 and BRCA1 in cell-cycle events 
through ubiquitination processes. Indeed, it was shown that BRCA1/BARD1 mono-
ubiquitinates γ-tubulin which regulates centrosome number and duplication cycle 
(Starita et al., 2004)91. Another purported target for BRCA1/BARD1 E3 ligase is 
nucleophosmin/B23 which may be ubiquitinated for its stabilization and not for 
proteasomal degradation (Sato et al., 2004)92. Another a study shows that 
BRCA1/BARD1 ubiquitin ligase activity is down-regulated in a cell-cycle dependent 
manner by CDK2-cyclin E1/A1, but not by CDK1-cyclin B1 (Hayami et al., 2005)93. A 
role for BRCA1/BARD1 ubiquitin ligase has been unveiled in DNA repair, since a 
Figure 7. Ubiquitination function of BRCA1/BARD1 showing known targets of the BRCA1/BARD1 E3 
ubiquitin ligase. BRCA1/BARD1 autoubiquitinates which increases ubiquitination function. The BRCC36-
BRCC45 appears also to increase autoubiquitination function. 
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recombinant four-subunit complex comprising BRCA1/BARD1/BRCC45/BRCC36 
enhanced E3 ligase activity compared to that of the BRCA1/BARD1 heterodimer 
alone (Dong et al., 2003)94. These studies expand further the range of 
BRCA1/BARD1 ubiquitination towards various cell cycle actions, and increase the 
weight of a tumour suppressor role for BARD1 and BRCA1. 
 
In the search for BRCA1 binding partners, BAP1, a ubiquitin hydrolase was 
discovered in a yeast two-hybrid screen and interacts with the RING domain of 
BRCA1 (Jensen et al., 1998)95. However, it is not clear if BAP1 competes with 
BARD1 for the binding sites on BRCA1 or if it binds to the heterodimer forming a 
novel functional complex. In any case, it does not appear that BAP1 is capable of de-
ubiquitinating poly-ubiquitinated BRCA1/BARD1 heterodimers in vitro (Mallery et al., 
2002). However, BAP1 could possibly deubiquitinate some of the unknown 
BRCA1/BARD1 E3 targets.  
 
 
IV. BARD1 functions and interacting proteins 
Most breast and ovarian molecular cancer research was focused on BRCA1 and 
BRCA2, as testified by more than 6000 publications on the matter during the last ten 
years, compared to the 100 odd articles on BARD1. This discrepancy does not reflect 
the importance that BARD1 may have in tumour suppression in gynaecological or 
other tumours. However, BARD1’s function is tightly related to BRCA1 function since 
it is the heterodimer which is the main functional form. However, a high number of 
proteins interact or associate with BARD1 (Figure 8). BARD1 may, through BRCA1 
or independently regulate, chaperone and serve as a scaffold for numerous proteins 
involved in a number of cellular pathways ranging from DNA repair, transcription-
coupled repair, transcriptional regulation, apoptosis, genomic integrity and mitotic 
events like centrosome duplication and cell division (Jasin, 2002)43 (Figure 9). It is 
likely that most of these functions are mediated through the ubiquitin function of the 
BRCA1/BARD1 heterodimer. 
 
 
 
 32
 
Knockout mouse models and genomic instability phenotype 
BARD1 shares a common feature with tumour suppressors BRCA1 and BRCA2 in 
that knockout mouse follows in embryonic death and displays genomic instability 
(Gowen et al.,1996; Hakem 1996; Liu 1996; Ludwig 1997; McCarthy 2003)22,23,96-98. 
Cell lines lacking wild type BRCA1 are also deficient in DNA repair and homologous 
recombination (Gowen et al., 1998; Moynahan et al., 1999; Scully et al., 1999)99-101. 
Human BARD1 and BRCA1 counterparts of Xenopus laevis show that essential 
functions as well as structure are conserved since knockouts of these genes are non-
viable (Joukov et al., 2001)49. The BARD1-null mouse embryos died in utero between 
day E7.5 and E9.5 post-fecundation (McCarthy et al., 2003)98. Death was due to 
severe cell proliferation defects and not to apoptosis. Partial rescue was obtained in 
BARD1-/-;p53-/- double knockout embryos, since embryonic death was delayed until 
day E9.5. Cytogenetic analysis of the BARD1-/-; p53-/- cells displayed an increase of 
structural and numerical chromosome aberrations compared to p53-/- cells 
(McCarthy et al., 2003)98. Furthermore, conditional knockout experiments of BARD1 
results in mammary cancers, chromosomal instability and proliferation defects 
(personal communication Thomas Ludwig) and manifest the same characteristics of 
human breast cancers. The drastic phenotypes of the knockout mice means that 
BARD1 is essential for a wide panel of cellular events (reviewed by Jasin, 2002)43. It 
is clear that BARD1 assures vital functions for cell cycle progression and 
maintenance of genome integrity (Figure 9). 
Figure 8. Illustration showing the known proteins that interact with BARD1. Proteins that are thought to 
have a direct interaction are shown in colour. Proteins that are known to bind indirectly with BARD1 are 
shown in grey, all of which may be detected in biochemical complexes. 
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BARD1 in DNA-damage repair 
It has been established that BARD1, in conjunction with BRCA1, is essential for 
maintaining chromosomal stability. This is done partly through mechanisms of 
homology-directed repair of DNA double-strand breaks. In fact, BRCA1 regulates a 
variety of DNA damage pathways. Cells lacking functional BRCA1 have severe 
defects in transcription-coupled repair, homology-directed repair (HDR), non-
homologous-end-joining (NHEJ) and microhomology-end-joining repair pathways 
(Gowen et al., 1998; Abbott et al., 1999; Moynahan et al., 1999; Snouwaert et al., 
1999; Zhong et al., 2002a, 2002b)99,100,102-105. It is now clear that BARD1 is also 
reqired in those DNA repair pathways (Westermark et al., 2003)106. It is the 
BRCA1/BARD1 heterodimer which is the functional unit in DSB repair (Jasin, 
2002)43. However, it is not known whether BARD1 plays other roles in these 
pathways. 
 
A functional interaction between hMSH2 and BRCA1 was discovered in a yeast-two-
hybrid screen, which was confirmed by co-localization and immunoprecipitation 
studies (Wang et al., 2001)107. Further investigation showed that hMSH2 associates 
with BARD1. In fact, BARD1 may also associate with other enzymes of the same 
pathway such hMSH3 and hMSH6. The interaction of BARD1 with hMSH2-hMSH6 
substantiates a role for BARD1 and BRCA1 in DNA mismatch repair, and suggests 
that BARD1 cannot be dissociated from its partner in DNA damage sensing and 
signalling (Wang et al., 2001)107. It is noteworthy that BRCA1 interacts with numerous 
other proteins involved in the repair pathways, the list is long, but one may note that 
ATM, ATR, DNA-PKs, Ku-70 and Ku-80 are involved in sensing DNA breaks and 
signalling through phosphorylation of BRCA1 that the DNA repair pathways should 
be switched on. Lastly, it would be interesting to evaluate the participation of BARD1 
in all these interactions. Finally, it was shown that the BRCA1/BARD1 orthologues in 
C. elegans are also required for DNA repair (Boulton et al., 2004)50, supporting the 
thesis that these proteins have highly conserved functions in different species. 
 
Cellular localization of BARD1 and BRCA1 during DNA repair 
At the cellular level, the expression levels of BARD1 protein were first reported to be 
relatively constant throughout the cell cycle, in contrast to the elevated levels of 
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BRCA1 in S-phase (Jin et al. 1997)108. Subsequently, it was shown that cells that 
were arrested in G0-G1 by serum withdrawal express low levels of BRCA1. The 
levels progressively accumulate after release from starvation in G1 phase, peaking at 
the G1/S border. They remain high during S-phase, mirroring cyclin A expression 
levels (Chen et al., 1996; Vaughn, 1996; Gudas et al., 1996; Rajan et al. 1996; Jin et 
al., 1997)108-112. These reports obviously suggest a role for BRCA1 during S phase. 
However, further studies show that BARD1 expression levels fluctuate in a cell-cycle-
dependent manner, with an increase during mitosis (Jefford et al., 2004; Choudhury 
et al., 2004; Hayami et., 2005)51,85,93. Concomitant expression of BARD1 and BRCA1 
was observed during S-phase (Hayami et al., 2005)93. Evidence of a BRCA1/BARD1 
interaction came from immunofluorescence experiments, where BARD1 co-localized 
with BRCA1 and Rad51 during S-phase in “nuclear foci” (Scully et al., 1997b, Jin et 
al., 1997 108,113. Upon DNA damage by hydroxyurea (HU), the BRCA1 and BARD1 
nuclear dots disperse, but re-aggregate at new foci containing PCNA (Proliferating 
Cell Nuclear Antigen). The BRCA1/BARD1/Rad51 appears to relocate to areas of 
DNA damage and play a role in repairing damaged DNA (Scully et al., 1997b)113. 
These data are supported by other findings, demonstrating that BRCA1/BARD1 
heteroduplex associates with DNA at stalled replication forks (Paull et al., 2001)114. 
The loss of the BRCA1 foci was accompanied by a dose-dependent increase of 
BCRA1 phosphorylation. Concordantly with these findings, BARD1 was 
biochemically identified with BRCA1 in hydroxyurea-inducing complexes (HUIC) 
formed after treatment with HU (Chiba and Parvin, 2001)115. The BRCA1 protein was 
reported to interact with the Mre11-Rad-50-Nbs1 (MRN) repair complex (Zhong et al., 
1999)116. However, the HUIC complex is distinct from the BRCA1-Mre11-Rad50-
Nbs1 complex (Chiba and Parvin, 2001)115. 
 
BARD1 in transcriptional regulation and chromatin remodelling 
Because BRCA1 and BARD1 share a homologous BRCT domain, the first clues of a 
purported role for BARD1 in transcription derived from transient transfection 
experiments with BRCA1. BRCA1 was shown to be able to activate transcription in 
vitro (Chapman et al., 1996; Monteiro et al., 1996, 1997)117-119. Further evidence 
showed that the BRCT domains of BRCA1 induces transcriptional activation in vitro 
(Haile et al., 1999)120. Additionally, BRCA1 interacts with the RNA polymerase II 
holoenzyme (holo-pol) in association with RNA Helicase A, a protein also involved in 
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transcription (Anderson et al., 1998)121. On the other hand, it is not known whether 
BARD1 is required for these transcription-related interactions. In later experiments, it 
was shown that BRCA1 can bind to DNA at sites of DNA branching (Paull et al., 
2001)114. This direct binding is another clue for BRCA1-driven transcription. However, 
conclusive evidence for a BRCA1-induced transcription activation came from 
biochemical experiments demonstrating that BRCA1 is a bona fide component of the 
RNA polymerase II holoenzyme, since BRCA1 co-purifies with the holoenzyme 
complex (Scully et al., 1997; Neish et al., 1998)122,123. Further studies showed that 
BARD1 was also part of this multimeric complex (Chiba and Parvin, 2002)124, 
implicating BARD1 in transcriptional regulation. By using deletion mutants of BRCA1, 
it was also shown that the N-terminal end of BRCA1 containing the RING domain 
was necessary for the activity of the holoenzyme, whereas the C-terminal end 
deletion showed little reduction in regulation of transcription (Chiba and Parvin, 
2002)124. This latter fact also implies that BARD1 is the linking protein tethering 
BRCA1 to the holo-pol thereby confirming BARD1’s role as transcriptional co-factor. 
 
More evidence on BARD1’s role in transcription came from the discovery that BARD1 
interacts with the NF-κB/Rel transcription factors. The NF-κB signalling pathway is 
conserved through evolution. The NF-κB transcription factors play numerous, crucial 
roles in inflammation, immunity and apoptosis; being over expressed in many 
tumours (Baldwin 1996, 2001)125,126. BARD1 binds to Bcl-3, which is part of the IκB 
family of NF-κB inhibitors. Bcl-3 serves as a bridge between the p50, one of the five 
known components of the NF-κB co-factors, and BARD1 (Dechend et al., 1999)127. 
This binding could be mediated through Bcl-3’s and BARD1’s ankyrin domains. 
Furthermore, it has also been shown that the p65/RelA subunit of NF-κB binds to 
BRCA1, and so causing an increase of the transcription levels of NF-κB target genes, 
such as Fas and interferon β (IFNβ) (Benezra et al., 2003)128. Transcription can be 
diminished by BARD1 and a BRCA1 RING domain mutants (Benezra et al., 2003)128. 
The plot between NF-κB and BARD1 thickens, because BARD1 has a slight binding 
affinity with IκBα (Dechend et al., 2003)127  and because IκBα is ubiquitinated for 
degradation by the proteasome after being phosphorylated on serines 32 and 36. 
(reviewed in Chen and Greene, 2003)129. The question remains open as to whether it 
is the BARD1/BRCA1 E3 ubiquitin ligase that is responsible for tagging IκBα with 
 36
ubiquitin. However, the complexity of these pathways, (which are never linear), 
increases, because p50 and RelA are acetylated at multiple serine residues probably 
by the CBP/p300 acetyltransferase, which was evidenced by BRCA1 and CBP/p300 
interactions seen in vitro and in vivo (Cui et al., 1998; Pao et al., 2000)130,131. It is also 
noteworthy that CBP (CREB binding protein) is a component of the polymerase II 
holoenzyme (von Mikecz et al., 2000)132. BARD1 is the main co-partner of BRCA1 in 
a CBP/p300 mediated transcription. The cAMP response element binding protein 
(CREB) binding protein (CBP) and p300 are paralogous proteins involved in 
transcriptional regulation because they may bind CREB and other transcription 
factors like TFIIB and TATA box-binding protein. The CBP/p300 can function as a co-
activator in a BRCA1-mediated transactivation (Pao et al., 2000)131. The CBP/p300 
proteins are also histone acetyltransferases (HATs) (Ogryzko et al., 1996; Bannister 
and Kouzarides, 1996)133,134, and may recruit other HAT proteins. Acetylation of N-
terminal lysine residues of histones enables chromatin decondensation so favouring 
transcriptional activation. Other factors are also involved in chromatin remodelling. 
The SWI/SNF-related complex binds to BRCA1 further confirming a role for 
BRCA1/BARD1 in transcriptional activity (Neish et al., 1998; Bochar et al., 
2000)123,135. In the same line of thought, BARD1 and BRCA1 may also be directly 
involved in heterochromatin re-structuring and in X chromosome inactivation because 
BRCA1 and BARD1 co-associate with XIST RNA (Ganesan et al., 2002)136. It was 
first discovered that BRCA1 decorates the unpaired X chromosome in human 
pachytene spermatocytes upon staining of meiotic chromosomes (Scully et al., 
1997b)137.  
 
BARD1 in mRNA processing 
BARD1, together with BRCA1 interacts with the mRNA polyadenylation factor CstF-
50 and represses the activity of the polyadenylation machinery in vitro (Kleiman and 
Manley, 1999)138. The cleavage stimulation factor (CstF) is a protein complex 
involved in the polyadenylation process of all eukaryotic mRNAs. The CstF is 
required for the endonucleolytic cleavage step of mRNA and it helps to properly 
identify the site of processing (Takagaki, 1990,1997)139,140. It is a heterotrimeric 
protein with subunits of 77, 64 and 50 kDa. In a yeast two hybrid screen using CstF-
50 as bait, BARD1 was identified as having one of the strongest interactions with 
CstF-50 (Kleiman and Manley, 1999)138. Furthermore, CstF/BARD1/BRCA1 complex 
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Figure 9. The BARD1 network. This illustration shows the various pathways in which BARD1 is involved. 
BARD1 is up-regulated upon DNA damage, genotoxic insult and in the G2/M phase of the cell cycle. 
BARD1 down-regulation induces a genetic instability phenotype and a tumour phenotype. BARD1 is 
involved in DNA repair pathways, in replication, and in transcriptional regulation. 
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is involved in the inhibition of mRNA 3’ processing in cell lines that were treated with 
DNA damage-inducing agents such as HU or UV (Kleiman and Manley, 2001)141. 
Furthermore, addition of exogenous BARD1 may also inhibit polyadenylation. 
Regulation of polyadenylation could play an important role in the control of cellular 
proliferation (Colgan et al., 1997; Zhao and Manley, 1998)142,143. It is therefore 
possible that BARD1-mediated inhibition of CstF polyadenylation prevents specific 
RNA processing during DNA damage-induced repair, thus helping to stall the cell 
cycle during a BRCA1/BARD1-mediated DNA repair. Further evidence of the 
involvement of BARD1 in tumour suppression through mRNA processing, came from 
the fact that the Ewing’s sarcoma gene product EWS interact via its NH2 terminus to 
BARD1 (Spahn et al., 2002)144. However, its modus operandi remains speculative. 
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BRCA1-independent pro-apoptotic functions of BARD1  
Since BARD1 and BRCA1 were not consistently expressed in all tissues, differential 
expression led to the hypothesis that BARD1 might play a role in a BRCA1-
independent function (Irminger-Finger et al., 1998)47. Indeed, the first clues on the 
crucial role of BARD1 function in tumorigenesis, independently of BRCA1, came from 
BARD1 repression experiments, through ribozyme and mRNA anti-sense production 
in a mouse mammary epithelial cell line in vitro culture. The abrogation of BARD1 
expression induced a spectrum of biological alterations, such as drastic 
morphological cell change, loss of contact inhibition, aberrant cell-cycle progression 
and abnormal DNA content, suggestive of a premalignant phenotype and genomic 
instability(Irminger-Finger et al., 1998)47. These data were later confirmed by others 
showing chromosomal instability in BARD1-/- cells as evidenced by aneuploidy and 
abnormal karyotypes (Joukov et al., 2001; McCarthy et al., 2003)49,98. Indeed, the 
main characteristic of cells with a deficient BRCA1 or BARD1 expression, following 
RNA interference treatment, is an increase of chromosomal alterations, as observed 
by cytogenetic analysis of karyotypes. Depletion of BRCA1 mRNA by siRNA 
expression can cause genomic instability in Fanconi anaemia cells (Bruun et al, 
2003)145. 
 
Since BARD1 has a vital role in normal cell survival, BARD1 expression was 
measured during apoptosis. It was found that BARD1 expression, through 
transcription, was up-regulated in response to genotoxic stress or after induction of 
an ischemic stroke in mouse (Irminger-Finger et al. 2001)146. Additionally, over-
expression of exogenous BARD1 leads to DNA fragmentation and caspase-3 
activation indicative of apoptosis (Irminger-Finger et al., 2001)146. It is dependent of 
p53, but independent of BRCA1, since BARD1 may trigger apoptosis in the absence 
of BRCA1 and not in p53 deficient cell lines (Irminger-Finger et al. 2001)146. These 
experiments identified BARD1 as a mediator between pro-apoptotic stress and p53-
dependent apoptosis. The fact that Q564H missense mutation of BARD1 was 
defective in inducing apoptosis when transfected in cultured cells, implies that the 
region of BARD1 around Q564H could serve a role necessary for tumour 
suppression and for the pro-apoptotic function of BARD1. Furthermore, it was also 
shown that BARD1 co-immunoprecipitates with p53, suggesting a physical interaction 
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between p53 and BARD1 in order to induce apoptosis. BARD1 up-regulation upon 
genotoxic stress is accompanied by p53 expression and stabilization (Irminger-Finger 
et al., 2001). Activation and stabilization of p53 depend on its phosphorylation at 
multiple sites, by a number of kinases, including phosphorylation on serine 15. 
(Meek, 1994; Milczarek et al., 1997)147,148. Moreover, the stabilization and 
phosphorylation of p53 may be performed through BARD1, since the absence of 
functional BARD1 is sufficient for abolishing p53 phosphorylation on serine 15 
(Fabbro et al, 2004)149. It was shown that the BRCA1/BARD1 heterodimer is required 
for phosphorylation of p53 on serine 15. This phosphorylation of p53 is necessary for 
a G1/S cell cycle arrest following DNA damage induced by ionising radiation (Fabbro 
et al., 2004a)149. Further evidence showed that BARD1 overexpression can catalyse 
the phosphorylation of p53 on serine 15 by a DNA-damage response kinase (Feki et 
al., 2005)150. It was also shown that BARD1 binds to Ku-70 in co-immunoprecipitation 
experiments as well as phosphorylated p53, identifying a candidate kinase for p53 
phosphorylation (Feki et al., 2005)150. Identification of the region of BARD1 which 
binds to p53 was performed through a series of co-immunoprecipitations experiments 
of deletion mutants fused to EGFP. BARD1 may co-immunoprecipitate p53 over a 
large, domain but not the RING finger domain. Even the deletion mutants lacking the 
RING functional domain, which normally binds BARD1 to BRCA1, are capable of co-
immunoprecipitating p53 (Feki et al., 2005)150. These experiments exclude the 
preconception that p53 was pulled down through an interaction with BRCA1. The p53 
protein must be phosphorylated on serine residues for a function in apoptosis. It 
appears that BARD1 stabilizes p53 for DNA repair and for apoptosis.  
 
BRCA1 may also bind to p53 in two regions: to the region 224-500 and to the BRCT 
domain 1760-1863 (Chai et al., 1999)151. This interaction is functional since BRCA1 
may regulate p53-dependent gene expression (Ouchi et al., 1998)152 and that, 
conversely, p53 is required to modulate BRCA1 expression (Arizti et al., 2000)153. It 
appears that BARD1 follows a similar BRCA1 behaviour since BRCA1 over-
expression triggers apoptosis (Harkin et al., 1999)154 and causes growth retardation 
in several breast or ovarian cell lines (Holt et al., 1996; Jensen et al., 1996; 
1998)21,95,155. 
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Mapping of the pro-apoptotic domain of BARD1 
BARD1’s function in the nucleus is mainly linked to DNA repair and transcriptional 
activity, but little is known on its dynamic properties and its role within the cytoplasmic 
compartment. BARD1, like BRCA1, has been described until now mostly as nuclear 
protein. However, BARD1 is synthesized in the cytoplasm and translocated into the 
nucleus localizing to foci (Scully et al., 1997)113. Human BARD1 has 6 predicted NLS 
(Nuclear Localizing Signal) sequences, whereas the mouse has only 3 NLSs. In both 
species, the prediction score for nuclear localization is high. BARD1 even serves as a 
chaperone for BRCA1, by retaining BRCA1 in the nucleus by masking BRCA1’s NES 
(Nuclear Export Signal) sequence when the two are bound together (Rodriguez et al., 
2000; Fabbro et al., 2002; Schuechner et al., 2005)156-158. 
 
However, contrary to previous reports stipulating that BARD1 had an exclusive 
nuclear localization, we showed that BARD1 is also localized in the cytoplasm in vitro 
and in vivo, albeit in discreet levels (Jefford et al., 2004)51. We showed that apoptosis 
is concomitant with enhanced cytoplasmic localization of BARD1, as well as the 
appearance of a p67 cleavage product (Jefford et al., 2004)51. Moreover similar 
observations suggest that BARD1 can shuttle from the nucleus to the cytoplasm, 
increasing its apoptotic activity (Rodriguez et al.,2004)159. Mapping the apoptotic 
domain of BARD1 was performed by using deletion constructs, which confirmed the 
apoptotic-inducing region to residues 510-604 in between the ankyrin repeats and 
the BRCT domains. This region coincides with two known cancer predisposing 
mutations C557S and Q564H (Thai et al., 1998; Ghimenti et al., 2002; Karppinen et 
al., 2004; Jefford et al., 2004)45,51,160,161. This region is necessary for BARD1-induced 
apoptosis, but it is not known if it is sufficient. BARD1 post-translational modifications 
and its degradation have not been investigated thoroughly, but it was shown that a 
p67 BARD1 proteolytic product cleaved by calpain can act as a tumour antigen. It is 
associated with apoptotic bodies in rat colon cancer cells (Gautier et al., 2000)162. 
 
BRCA1 and BARD1 functions in cell cycle 
BARD1 and BRCA1 have several roles in cell-cycle progression that are mediated 
through their ubiquitin function and controlled by a cyclin dependent kinase, CDK2 
(Hayami et al. 2005). Furthermore, BARD1 is phosphorylated by CDK1/2 on its NH2 
terminus (Hayami et al., 2005)93. A role for BRCA1 in centrosome duplication has 
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been described, since BRCA1 associates with centrosomes during mitosis (Hsu and 
White, 1998)39 and co-immunoprecipitates with γ-tubulin. The γ-tubulin binding site 
was mapped to exon 11 of BRCA1 (Hsu and White, 2001)40. BRCA2 is also 
implicated in stages of cytokinesis, since depletion of BRCA2 increases cell division 
defects (Daniels et al., 2004)163. To further ascertain the role of BARD1 in cell cycle 
progression and cytokinesis, immunoprecipitation studies were performed in our 
laboratory and show that BARD1 co-aggregates withTacc1/AuroraB/BRCA2 at the 
midbody during completion of cytokinesis (Jefford and Irminger-Finger, submitted). 
Furthermore, this study has also shown that depletion of BARD1 clearly disrupts cell-
cycle progression, cytokinesis and creates cellular fusion. These results provide an 
explanation for the mechanisms leading to aneuploid karyotypes and chromosomal 
instability as a cause for carcinogenesis in cells with deficient expression of BARD1 
and BRCA1. 
 
 
Figure 10. Mutations in BRCA1 span the entire gene. A total of 657 BRCA1 breast and ovarian cancer 
predisposing mutations have been documented.  
(Human Gene Mutation Database: http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html) 
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V. BARD1 mutations and expression in cancer 
BARD1 tumour suppressor mutations in breast and ovarian cancers 
It was demonstrated that BRCA1 and BRCA2 mutations predispose women to cancer 
(Miki et al., 1994)5, but do not account for all familial breast and ovary cancer 
predispositions. The cancer predisposing mutations of BRCA1 span the entire gene 
and are numerous (Figure 10). A specific cancer predisposing mutation, C61G, within 
the RING domain of BRCA1, disrupts formation of the BRCA1 homodimer (Figure 4b) 
(Brzovic et al., 1998)164. Moreover, this mutation impedes ubiquitin protein ligase 
activity and tumour suppressor function of the BRCA1/BARD1 heterodimer 
(Hashizume et al., 2001; Ruffner et al., 2001)76,77. It was therefore hypothesized that 
BARD1 mutations should also predispose to cancer. After screening a panel of 
sporadic breast, ovarian and endometrial cancers, three missense alterations were 
identified in the BARD1 gene at the amino acid positions Q564H, V695L, and S761N 
(Thai et al., 1998)45. Loss-of-heterozygosity was accompanied in two cases (Q564H 
and S671N), substantiating BARD1’s role as a tumour suppressor. The V695L and 
S761N mutations arose in somatic breast tissue and were not found in the germ-line, 
whereas the Q564H mutation was found in the germ line of a patient with clear cell 
adenocarcinoma of the ovary (Thai et al., 1998)45. The latter mutation was screened 
against a panel of over 300 healthy individuals, suggesting that this alteration is not a 
polymorphism. Five alterations were discovered in an Italian cohort with familial 
breast and ovarian cancers that was chosen for its absence of BRCA1 and BRCA2 
gene alterations in its proband (Ghimenti et al., 2002)160. These mutations include 3 
missense mutations, K312R, C557S, N295S, and an in-frame deletion of 7 amino 
acid residues, 1139Del21-(PLPECSS). The last alteration is a C1579G transversion 
with no amino acid change at position A502, which was found in 15 probands, 
indicative of a novel polymorphism variant (Ghimenti et al., 2002)160. The mutations 
C557S and 1139Del21 were described previously by Thai et al., (1998) but were 
considered as polymorphisms. However, segregation analysis showed that the 
C557S mutation may be linked with the tumour with a statistically borderline 
significance (Ghimenti et al., 2002)160. This mutated allele was further confirmed as 
being involved in hereditary susceptibility to breast cancer in a Finnish population of 
gynaecological cancers (Karppinen et al., 2004)161. Individuals carrying the C557S 
allele showed a significantly increased risk of breast cancer. The observed incidence 
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of 7.4% for breast cancer against 1.4% in healthy controls suggests that it could be a 
common susceptibility allele with low penetrance (Karppinen et al.,2004)161. 
Mutational analysis of BARD1 in familial breast cancer patients in Japan, that were 
tested negative for BRCA1 or BRCA2 germ-line mutations, revealed six alterations: 
(S241C, G378S, N470S, V507, 1139Del21) (Ishitobi et al., 2003)165. Of the six 
mutations, only one missense mutation, N470S, was found in the germ-line of a 
patient and defined as a cancer predisposition mutation, because it did not appear in 
a large background of healthy controls (Ishitobi et al., 2003)165. So far, these 
observations show that BARD1 germ-line mutations have a low association with non 
BRCA hereditary breast and ovary tumours and account for a very small fraction of 
familial breast cancers (Figure 11). This fact may question the implication of BARD1 
in predisposition to gynaecological cancers. However, expression of BARD1 is 
necessary in developing embryos, since homozygous Bard1 knockout mice die in 
utero at an early stage (McCarthy et al., 2003)98 and that the conditional knockout of 
the Bard1 allele causes tumours in mammary glands several months after induction 
(personal communication Thomas Ludwig). 
 
BARD1 expression in normal and tumour tissues 
The regulation of transcription of BARD1 has not been totally elucidated, but BARD1 
gene structure spans a 10 kb region close to the telomere on chromosome 2q34-q35 
(Wu et al., 1996; Thai et al., 1998)44,45. BARD1 cDNA is 2530 base pairs in length 
and is composed of 11 exons. Several splice variants have been identified for 
BRCA1 (Orban and Olah, 2000; McEachern et al.,2003)166,167. Likewise, BARD1 has 
also several transcripts supplied by alternative splicing (Feki et al., 2004, 2005)150,168. 
Nevertheless, BARD1 and BRCA1 mRNA expression patterns as observed from 
northern blots are coordinated in several tissues. 
 
In most murine tissues, Bard1 and Brca1 are concomitantly expressed. Northern blot 
experiments showed that BARD1 RNA messengers were abundantly expressed in 
spleen and testis, but not in heart, brain, liver, lung, skeletal muscle or kidney tissues 
(Ayi et al., 1998)48. RNase protection assays showed high expression levels in 
spleen and testis, but that Bard1 was also expressed in various other murine tissues, 
but less than Brca1 (Irminger-Finger et al., 1998)47. Hormonally regulated organs 
were also assayed for mBard1 expression, and showed that Bard1 in uterus is 
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increased from di-oestrus through post-oestrus phase, whereas Brca1 increases from 
diestrus to early oestrus and decreases during oestrus and post-oestrus (Irminger-
Finger, 1998)47. This non-coordinate expression of Bard1 with Brca1 was the first 
indication of a BRCA1-independent role of BARD1. In our laboratory, Bard1 
expression in testis was further explored, showing that Bard1 is expressed at all 
stages of spermatocyte maturation, whereas Brca1 expression is only seen in meiotic 
and early round spermatocytes (Feki et al. 2004)169. Furthermore, it was shown that 
BARD1 transcripts result from alternative splicing. The messenger RNA mBARD1β 
and mBARD1γ from rat testis, could have a role in triggering apoptosis (Feki et al., 
2004)169. Finally it was also found that cells from the cytotrophoblast express also 
splice variants for BARD1 and protein expression was detected in the extra cellular 
matrix. Secretion of BARD1 is presently being investigated (personal communication 
by Bischof and Irminger-Finger). 
 
Expression of BRCA1 mRNA is often reduced in sporadic breast carcinomas 
(Thompson et al., 1995)170, even in the absence of distinct BRCA1 mutations. This 
gene silencing anomaly is often imputed to epigenetic effects such as BRCA1 
promoter methylation on CpG rich islands (Mueller and Roskelley, 2003)34. Abnormal 
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Figure 11. Diagram showing all the documented mutations pertaining to BARD1. No cancer predisposing 
mutations were found in the RING domain. A total of 7 mutations were found in a population of cases of breast 
cancer that were negative for BRCA1 or BRCA2, which were screened against a large background of healthy 
individuals. Only two cases of loss-of-heterozygosity were found in the tumours of breast cancer patients (Q564H 
and S761N). (Compiled from Thai et al., 1998; Ghimenti et al., 2002; Ishitobi et al., 2003; Karppinen, 2004). 
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reduction of BRCA1 expression was observed in about 30% of breast carcinomas 
cases in a Japanese population (Yoshikawa et al., 2000)171. In contrast, expression 
of BARD1 and of the two mismatch repair enzymes, hMLH1 and hMSH2, was not 
reduced as frequently (Yoshikawa et al., 2000)171. Furthermore, p53 expression in 
sporadic breast cancers is diminished, which is accompanied by the frequent 
detection of a mutated p53 (Feki and Irminger-Finger, 2004)168. A recent report has 
examined the expression pattern of several genes, Smad7, Smad2 and Bard1, 
implicated in the TGFβ signalling pathways of normal and breast cancers. The 
expression of these genes are induced by TIEG (TGF-β inducible early gene) which 
is a nuclear zinc-finger transcription factor (Rheinholz et al., 2004)172. The expression 
was measured by real-time RT-PCR and the result was a decrease in breast cancer, 
which supports the notion that these genes are tumour suppressors repressed in 
tumours (Rheinholtz et al., 2004)172. Another study also showed a diminution of 
BARD1 expression at the mRNA level in breast carcinomas (Qiu et al., 2004)173. 
However, this contrasts with a recent study, where it was found that a mutated form 
of BARD1 was over-expressed in a number of cancerous breast tissues and its 
expression was localized in the cytoplasm (Jian-Wu et al., 2005 in press). This 
abnormal cytoplasmic over-expression could be due to a dysfunctional negative 
feedback loop, which explains the accumulation of BARD1 in the cytoplasm, since its 
down stream effectors are non-responsive. These apparently contrasting results 
demonstrate the discrepancies between mRNA expression and protein expression. 
The explanation could be that in abnormal or precancerous cells BARD1 up-
regulation is necessary for a signalling towards apoptosis, resulting in cytoplasmic 
localization for programmed cell death signalling. However, since the tumour tissues 
do not respond to the BARD1 protein, BARD1 accumulates in the cytoplasm, which 
results in a negative feedback loop thereby switching off mRNA transcription. 
 
 
VI. Conclusion 
BARD1 activities reflect the mirror image of BRCA1 functions in DNA repair, 
transcription and in maintenance of genome integrity, because BARD1 may perform 
the cellular roles imputed to BRCA1. However, on the other side of the coin, BARD1 
may be involved in several BRCA1-independent functions, just as BRCA1 may have 
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several BARD1-independent functions. Indeed, BARD1, with differential expression, 
has functions in DNA repair mediating, through p53, but independently of BRCA1, an 
apoptotic response. BARD1 is possibly the effector or the co-activator in an 
apoptosis-signalling pathway, since it is up-regulated in apoptosis, it contributes to 
p53 phosphorylation and its over-expression may induce apoptosis. 
 
Clearly, ordinate cellular functions, mediated by the heterodimer, must rely on the 
BARD1/BRCA1 equilibrium. BRCA1 stabilizes BARD1 and vice versa. For instance, 
BRCA1 over-expression induces BARD1 up-regulation. Moreover, it is worth noticing 
that BARD1 post-translational expression is modified in the absence of BRCA1, since 
BARD1 loses its ubquitinating functions and its ubiquitin moiety. 
 
Like BRCA1, BARD1 interacts with a high number of proteins involved in various 
cellular functions. BRCA1 and BARD1 have several ubiquitination targets that affect 
many and various systems. It is likely that BRCA1 and BARD1 serve as a platform for 
coordinating a large number of cellular functions, probably through its main 
ubiquitinating functions. The BARD1 and BRCA1 proteins, either together or 
independently, play important roles in various systems, which include DNA-related 
functions (DNA repair, replication, chromatin remodelling and transcription) and 
mitotic events (centrosome duplication and checkpoint kinases). Thus, BARD1 and 
BRCA1 could serve as the main mediator between the DNA-related functions and 
cell cycle events.  
 
The multitude of interacting proteins and pathways that BARD1 and BRCA1 are 
involved in is flabbergasting. The unifying model proposes that all the pathways that 
BARD1 is involved in converge towards a unique goal, an integrated system 
safeguarding the integrity of the genome. Epigenetic effects of BARD1 and BRCA1 
may be partly explained from this point of view. In all cases, it looks like BARD1 and 
BRCA1 are at the crossroads of multiple pathways coordinating different systems in 
an integrated network.  
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Publications 
 
1.  Identification of BARD1 as a mediator between proapoptotic stress and 
p53-dependent apoptosis 
Irminger-Finger I, Leung WC, Li J, Dubois-Dauphin M,Harb J, Feki A, Jefford CE, 
Soriano JV, Jaconi M, Montessano R, Krause KH. Mol Cell. 2001 Dec; 8(6):1255-66. 
This seminal paper shows that BARD1 is a mediator between proapoptotic stress 
signals and induction of programmed cell death through p53 activation. Although my 
contribution was small, it is a crucial report since its premises serves as a basis of  
subsequent work and constitutes the hypotheses for my thesis. In this study, we 
showed that BARD1 expression at the mRNA and protein levels is augmented upon 
genotoxic stress in vitro, and by hypoxia in vivo in cerebral ischemia. Upregulation of 
BARD1 expression upon cell death induced by genotoxic insult, such as UV and 
doxorubicin treatment, is accompanied by elevated p53 expression in mouse 
mammary gland and embryonic stem cells. Cells devoid of functional BARD1 appear 
not to undergo apoptosis as measured by DNA fragmentation assays and caspase-3 
activity. We showed that BARD1 over-expression in transient transfection 
experiments may induce apoptosis even in the absence of a functional BRCA1, but 
not in the absence of p53, which identifies BARD1 as a bona fide signalling molecule 
towards apoptosis. BARD1 induces apoptosis in concentration-dependent and time-
dependent manners. The pro-apoptotic activity of BARD1 coincides with p53 
elevation. Furthermore, we showed that p53 co-immunoprecipitates with BARD1, 
indicative of a physical interaction between BARD1 and p53. This interaction implies 
the participation of BARD1 in the signalling towards cell death. My contribution 
consisted in the various assays, the preparation of cells, transfection experiments, 
and the repetition of the functional apoptotic assays, in which apoptosis was 
measured by DNA fragmentation assays. Furthermore, I also worked on optimising 
the BARD1-p53 co-immunoprecipitation assays.  
Molecular Cell, Vol. 8, 1255–1266, December, 2001, Copyright 2001 by Cell Press
Identification of BARD1 as Mediator
between Proapoptotic Stress
and p53-Dependent Apoptosis
nant phenotype and genomic instability (Irminger-Finger
et al., 1998). The BARD1/BRCA1 complex was shown
to associate with the polyadenylation factor CstF-50
(Kleiman and Manley, 1999), presumably to prevent RNA
processing at sites of DNA repair (Kleiman and Manley,
Irmgard Irminger-Finger,1,7 Wai-Choi Leung,5
Jian Li,1 Michel Dubois-Dauphin,2 Jean Harb,6
Anis Feki,1,3 Charles Edward Jefford,1
Jesus V. Soriano,4 Marisa Jaconi,1
Roberto Montesano,4 and Karl-Heinz Krause1
1 Biology of Aging Laboratory 2001). The BRCA1-BARD1 heterodimeric RING finger
complex was recently shown to possess ubiquitin ligaseDepartment of Geriatrics
2 Department of Psychiatry activity in vitro (Hashizume et al., 2001). However,
BARD1 and BRCA1 are not consistently coexpressed3 Department of Gynecology and Obstetrics
4 Department of Morphology in different tissues (Irminger-Finger et al., 1998), sugges-
tive of the existence of independent functions for bothFaculty of Medicine
University of Geneva genes. Of particular interest in this context is the pre-
viously observed high expression level of BARD1 butSwitzerland
5 Department of Pathology and Tulane Cancer Center undetectable BRCA1 concentrations in mouse uterus
during the estrus phase (Irminger-Finger et al., 1998),Tulane University School of Medicine
New Orleans, Louisiana i.e., the moment of the estrous cycle when massive cell
death (in part through apoptosis) of the endometrium6 Institut de Biologie
INSERM U419 occurs (Ferenczy, 1993). As induction of apoptosis is
an important mechanism for tumor suppression, we hy-Nantes
France pothesized that BARD1 is involved in the regulation of
cell death.
Summary Results
The BRCA1-associated protein BARD1 is a putative BARD1 Upregulation in Response to Hypoxia In Vivo
tumor suppressor. We suggest that BARD1 is a media- To investigate a putative role of BARD1 in cell death,
tor of apoptosis since (1) cell death in vivo (ischemic we used a well-established mouse stroke model (Mar-
stroke) and in vitro is accompanied by increased levels tinou et al., 1994). To induce ischemic stroke, median
of BARD1 protein and mRNA; (2) overexpression of cerebral artery occlusion (MCAO) was performed in the
BARD1 induces cell death with all features of apopto- right brain hemisphere. Necrotic cell death occurs dur-
sis; and (3) BARD1-repressed cells are defective for ing the first few days in the stroke region, while apopto-
the apoptotic response to genotoxic stress. The pro- sis develops over several weeks in the surrounding tis-
apoptotic activity of BARD1 involves binding to and sue, the penumbra (Martinou et al., 1994). In the brain
elevations of p53. BRCA1 is not required for but par- of untreated animals, no BARD1 was found (Figure 1Aa),
tially counteracts apoptosis induction by BARD1. A consistent with the previously described absence of
tumor-associated mutation Q564H of BARD1 is defec- BARD1 mRNA in the central nervous system (Ayi et al.,
tive in apoptosis induction, thus suggesting a role of 1998). Positive BARD1 immunostaining was detected
BARD1 in tumor suppression by mediating the signaling after ischemia predominantly in the penumbra (Figure
from proapoptotic stress toward induction of apoptosis. 1Ac), increasing from day 1 up to day 14 in the ischemic
hemisphere (Figure 1B, left panel). In contrast, BRCA1
Introduction was detected neither in the brain of untreated animals
nor of animals treated with MCAO (Figures 1Ab and 1B,
BARD1 (BRCA1-associated RING domain 1) is described right panel). As positive control for the BRCA1 antibody,
as a nuclear protein that associates with the breast cancer sections of mouse ovarian tissue were analyzed and
susceptibility gene product BRCA1 (Wu et al., 1996; Miki showed expression of BARD1 and BRCA1 in ovarian
et al., 1994). The two proteins interact in vivo and in vitro follicles (Figure 1Ad–f). These results suggest that the
through their respective RING finger domains (Wu et al., role of BARD1 in hypoxia-induced brain damage is inde-
1996; Meza et al., 1999; Scully et al., 1997). As mutations pendent of BRCA1. BARD1 induction in ischemia would
in the BRCA1 RING finger domain (Bienstock et al., 1996) be compatible with its involvement in cellular stress re-
lead to increased cancer susceptibility, BARD1 was sponse and possibly the induction of apoptosis. To fur-
thought to be implicated in BRCA1-mediated tumor sup- ther clarify the potential role of BARD1 in apoptosis, we
pression. Consistent with this hypothesis, BARD1 muta- proceeded with in vitro studies.
tions were found in breast, ovarian, and uterine tumors
(Thai et al., 1998), and reduced expression of BARD1 BARD1 Expression in Response
is associated with spontaneous breast cancer cases to Genotoxic Stress In Vitro
(Yoshikawa et al., 2000). The in vitro repression of BARD1 We first studied the response of various cell lines to pro-
in murine mammary gland epithelial cells led to a premalig- apoptotic stress. Addition of the DNA-damaging chemo-
therapeutic agent doxorubicin to mouse mammary epithe-
lial TAC-2 cells (Soriano et al., 1995) not only led to an7 Correspondence: iirminger@cmu.unige.ch
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Figure 1. BARD1 Expression Is Upregulated upon Stress
(A) BARD1 but not BRCA1 is upregulated in a mouse stroke model. In brains from untreated animals, neither BARD1 (a) nor BRCA1 (not
shown) was detected by immunocytochemistry. As shown at day 7 after MCAO, BARD1 was not detected in the infarct core region (*) but in
the penumbra (c); staining remained negative for BRCA1 (b). Similar results were obtained at days 3 and 14. Bar, 550 m. Unlike in the brain,
BRCA1 (d) and BARD1 (e) are expressed in the mouse ovary. Primary antibody was omitted in (f). Bar, 100 m.
(B) As assessed by Western blotting, an increase of BARD1 can be observed from day 1 through day 14 after MCAO, in extracts from the
treated hemisphere () but not in the untreated hemisphere () (left panel). Expression of BARD1 and BRCA1 was compared on liver and
nontreated (nt) or ischemic (isch) brain tissue (right panel). For both immunocytochemistry and Western blotting, the BARD1 antibody N-19
(Santa Cruz sc-7373) was used. The same staining was observed with a C-terminal anti-BARD1 antibody (Santa Cruz sc-7372). Anti-BRCA1
antibody was M-16 (Santa Cruz). Antibody preabsorption with specific peptides (Santa Cruz) or omission of primary antibody resulted in
absence of the signal (not shown).
(C–E) BARD1 protein and mRNA is upregulated in cells exposed to genotoxic stress. Increase of p53 and BARD1 protein in TAC-2 cells,
treated with doxorubicin (0, 5, or 10 g/ml) for 12 hr, is demonstrated by Western blotting (C). Similarly, BARD1 expression is increased after
exposure to UV light for 1 to 4 min (2.5 to 10 Jm2) (D). The expression of BARD1 was tested with anti-Bard1 antibody (PVC, Irminger-Finger
et al., 1998), and p53 expression was probed with anti-p53 antibody (FL-393, Santa Cruz). (E) RT-PCR of RNA from mouse ES cells exposed
to UV light for 0, 1, or 4 min (0, 2.5, or 10 Jm2) or treated with doxorubicin (10 g/ml) shows an increase of BARD1 expression, while expression
of the control housekeeping gene -tubulin remains constant.
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Figure 2. BARD1 Overexpression Induces Apoptosis In Vitro
(A) TAC-2 cells were transfected with pcDNA3 vector sequences, BARD1, or the p53 sequences cloned into pcDNA3. Apoptosis induction
was monitored by TUNEL staining 24 hr after transfection. Ten photographic fields were randomly chosen to evaluate the mean percentage
of stained nuclei (bar chart).
(B) DNA laddering was observed in cells transfected with BARD1 or p53 containing plasmids but not in cells transfected with pcDNA3. “Marker”
indicates molecular weight marker smart ladder (Stratagene).
(C) Caspase-3 activity assays were performed, and the fluorometric results of five independent transfection experiments are presented.
Caspase-3 activity was significantly increased in BARD1 and p53-transfected cells.
(D) BARD1 protein levels after doxorubicin treatment and after BARD1 transfection were compared in different cell lines on Western blots.
Western blots were stripped and reprobed with anti--tubulin antibodies.
(E) Comparison of mean expression levels of BARD1 in TAC-2 cells by flow cytometry after anti-BARD1 antibody staining, presented as x
values of anti-BARD1-FITC. The increase of mean x values (arrow heads) in cells treated by doxorubicin or transfected by BARD1 as compared
to untreated cells is a direct measure of the increase in cellular BARD1 content. This increases of BARD1-derived fluorescence are similar in
doxorubin-treated and BARD1-transfected cells.
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Figure 3. Mapping of Proapoptotic Activity
BARD1 wild-type or mutant protein was expressed by transient transfection in mouse ES cells.
Apoptosis induction in control transfectants and transfected cells was monitored 24 hr after transfection by DNA laddering (A) or TUNEL
assays, analyzed by flow cytometry (B). The expression after transfection was tested on Western blots of nontransfected (nt), BARD1-
transfected, or BARD1Q564H (BARD1QH) mutant-transfected cells (C). An increase of 97 kDa BARD1 protein can be observed, while
expression of actin is constant. Transfection efficiency was tested by cotransfection of GFP and was at least 20%.
increase in cellular p53 levels but also to marked elevations trol transfectants (empty vector or GFP) showed either
no or only marginal signs of apoptosis. Thus, BARD1of cellular BARD1 levels (Figure 1C). Similar increase of
BARD1 in response to doxorubicin treatment was also transfection induced cell death, which displayed fea-
tures of apoptosis. We also observed apoptosis inducedobserved in HeLa cells and human SH-SY5Y neuro-
blastoma cells (data not shown), as well as in mouse by BARD1 transfection in mouse ES, human SH-SY5Y,
HeLa, and MCF-7 breast cancer cells, albeit to differentembryonic stem (ES) cells (see below). To test whether
cellular damage induced by means other than doxorubi- extents (data not shown). Thus, BARD1 is a potent in-
ducer of apoptosis in cells of different tissue or speciescin also resulted in an increase of BARD1, cells of differ-
ent tissue origins were exposed to UV light. BARD1 was origins. The relative increase of BARD1 protein levels
observed after transient transfection were comparableinduced in HeLa and TAC-2 cells (data not shown) and
mouse ES cells (Figure 1D) after UV treatment and fur- to the increase after doxorubicin treatment, as assessed
by Western blotting (Figure 2D). However, since not allther incubation for 3 hr. The increase of BARD1 might
be regulated by transcriptional activation, as is demon- cells express BARD1 in a transient transfection assay,
we also investigated BARD1 levels in individual cells bystrated by RT-PCR. Most strikingly in mouse ES cells,
no BARD1 mRNA could be detected in untreated cells, flow cytometry. Mean values of BARD1 levels in doxoru-
bicin-treated cells were increased on average by a factorwhile BARD1 mRNA was clearly present after UV or
doxorubicin treatment (Figure 1E). These results sug- of 3.7 ( 2.4) with 5 g/ml doxorubicin (Figure 2E), while
mean values for BARD1 levels in BARD1-transfectedgest that BARD1 upregulation upon genotoxic stress is
transcriptionally regulated. cells increased 2.5-fold ( 1.8) over controls, showing a
broader distribution (Figure 2E). Thus, the mean cellular
BARD1 levels are raised to comparable levels in doxoru-Elevated Expression of BARD1 Leads to Apoptosis
bicin-treated and BARD1-transfected cells.To address the question of whether BARD1 upregulation
To study the mechanisms of proapoptotic signalingcauses cell death, we transfected TAC-2 cells with a
by BARD1, we analyzed the induction of apoptosis byBARD1 expression plasmid. Attempts to establish sta-
a BARD1 deletion mutant and the Q564H missense mu-ble BARD1-transfected cell lines were unsuccessful.
tation (Figures 3A and 3B). TAC-2 cells or mouse ESOnly mock-transfected (empty vector or GFP) but not
cells were transfected with pcDNA, BARD1, or theBARD1-transfected cells yielded viable cell lines, sug-
BARD1Q564H mutant. Transfection efficiency was stan-gesting deleterious effects of BARD1 overexpression.
dardized, and the protein expression levels of exoge-We therefore analyzed transiently transfected cells.
nously expressed BARD1 and BARD1Q564H were com-Transient transfection of TAC-2 cells with BARD1 led to
parable (Figure 3C). DNA laddering and TUNEL assaysapoptosis as assessed by TUNEL staining, DNA lad-
were performed to monitor apoptosis induction. Inter-dering, caspase-3 activity tests (Figures 2A–2C), as well
estingly, the BARD1Q564H point mutation was largelyas annexin V staining and nuclear condensation moni-
devoid of apoptosis-inducing activity. Since the Q564Htored by DAPI staining (data not shown). Transfection
mutation was shown to be associated with breast andof cells with the bona fide proapoptotic protein p53
endometrial cancer (Thai et al., 1998), its reduced apo-(Sionov and Haupt, 1999) led to a similar extent of apo-
ptosis as transfection of BARD1 (Figures 2A–2C). Con- ptotic capacity provides a possible link between the
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Figure 4. BARD1-Induced Apoptosis Is Independent of BRCA1
Transfection of pcDNA, BARD1, or BRCA1 expression plasmids was performed, and apoptosis induction was monitored 24 hr after transfection.
Efficiency of transfection was 20% as determined by transfection of GFP expressing plasmids. DNA laddering was observed in BARD1-
transfected cells but not in BRCA1- or pcDNA-transfected cells (A). Inhibition of BARD1-induced apoptosis by BRCA1 is presented in
cotransfection experiments in ES cells (B). Transient transfection assays were performed with pcDNA, BARD1, BARD1  BRCA1, or BRCA1.
The extent of apoptosis induction was measured by TUNEL staining and monitored by flow cytometry. Results presented are mean x (TUNEL-
fluorescence)  range (n  2).
Expression of BARD1 and BRCA1 was monitored on Western blots (C). Gels were scanned, and increase of BARD1 and BRCA1 was measured
and were similar for both proteins.
Influence of BRCA1 on apoptosis induction by BARD1 was analyzed in Brca1/ and wild-type (wt) ES cells. DNA laddering was performed
to qualitatively demonstrate apoptosis induction after doxorubicin treatment (5 g/ml) or transient BARD1 transfection (D). Apoptosis induction
under the same conditions was quantified by TUNEL assays of wild-type and Brca1/ ES cells (E). Results presented are mean x (TUNEL-
fluorescence)  range (n  2).
tumor suppressor function of BARD1 and its proapo- 4B). Similar increase of expression was monitored for
ptotic activity. BRCA1 and BARD1 after transfection (Figure 4C). Inter-
estingly, the cotransfection of BRCA1 diminished rather
than enhanced apoptosis induction by BARD1, as deter-Apoptosis Induction by BARD1 Is Independent
mined by TUNEL staining and flow cytometry. To defini-of Functional BRCA1
tively clarify whether apoptosis induction by BARD1 oc-An involvement of BRCA1 in apoptotic signaling had
curs independently of BRCA1, we studied apoptosisbeen suggested previously (Harkin et al., 1999; Thangar-
induction in Brca1-deficient mouse ES cells (Aprelikovaaju et al., 2000). Thus, the BARD1 effects might be medi-
et al., 2001). As assessed by DNA laddering (Figure 4D),ated through or require BRCA1. To investigate this ques-
BARD1 transfection induced apoptosis in Brca1-defi-tion further, we transfected BRCA1 into ES cells (Figure
cient cells as efficiently as doxorubicin. These results4A) and into TAC-2 cells (data not shown); no apoptosis
demonstrate unequivocally that BRCA1 is not requiredoccurred under these conditions, while DNA laddering
for BARD1-induced apoptosis.and positive TUNEL staining was observed after trans-
When apoptosis was assessed quantitatively byfection of BARD1 (Figure 4A). Thus, overexpression of
TUNEL assay, the Brca1-deficient cells clearly showedBRCA1 by itself does not induce apoptosis. To test
increased sensitivity to apoptosis induction by bothwhether BRCA1 synergized with BARD1 in apoptosis
induction, we cotransfected BRCA1 and BARD1 (Figure BARD1 and doxorubicin (Figure 4E). Thus, cotransfection
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Figure 5. Repression of BARD1 Reduces the Apoptotic Response to Genotoxic Stress
BARD1 repression was achieved by stable transfection of BARD1 ribozyme in ES cells (ES riboBARD1) or a BARD1 antisense in murine
mammary cells (TAC-2/ABI). After treatment with doxorubicin (5 g/ml, 6 hr), apoptosis was monitored by flow cytometric analysis of TUNEL
staining, as shown for ES cells and ES/riboBARD1 cells (A). Comparison of results obtained for ES, ES/riboBARD1, TAC-2, TAC-2/ABI, or ES/
riboNox4 (transfected with an unrelated ribozyme) is shown in (B) with mean x (TUNEL-fluorescence)  SEM (n  3).
Cell numbers of TAC-2 cells or BARD1-repressed TAC-2/ABI cells in the absence or presence of doxorubicin (10 g/ml) were monitored after
2 and 4 days (C). Five fields of cells from each time point and each cell type were analyzed, and the mean  SEM remaining adherent cells
are shown (right panel). Caspase-3 activity (Molecular Probes) was measured by fluorometry after treatment with doxorubicin (10 g/ml) for
the indicated periods of time (D). Results are mean  SEM (n  3). Experiments were performed in the presence and absence of the caspase-3
inhibitors DEVD.
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Figure 6. BARD1-Induced Apoptosis Is Associated with p53 Accumulation
The p53 protein is upregulated in cells overexpressing BARD1 (A). Expression of p53 protein in cells harvested 24 hr after transfection with indicated
amounts of BARD1 and pcDNA3 or BARD1 was analyzed on Western blots (top panel). Effects of BARD1 and BARD1Q564H mutant (BARD1QH)
on p53 expression were compared (middle and lower panels). While BARD1 increase is observed in BARD1- and BARDQ564H mutant-transfected
cells, significant increase of p53 is observed only in BARD1-transfected cells. The bar graph shows a comparison of p53 expression of cells
transfected with pcDNA3 or BARD1Q564H mutant (BARD1QH) as a percentage of p53 expression in BARD1-transfected cells.
Increase of p53 in response to doxorubicin is compared in ES and TAC-2 cells, in BARD1-repressed ES/riboBARD1 and TAC-2/ABI cells, and
in control transfectants ES/riboNox4 (B). Cells were incubated for 12 hr with doxorubicin (0, 5, or 10 g/ml), and p53 and BARD1 accumulation
was monitored by Western blotting. Unchanged levels of actin are shown.
p53 upregulation is not due to transcriptional upregulation (C). p53 mRNA expression is tested by RT-PCR of RNA prepared from untransfected,
pcDNA-, or BARD1-transfected cells (left panel). Protein (-p53) and mRNA (RTPCR) expression are compared in TAC-2 cells after the indicated
time of incubation with doxorubicin (right panel). Control of independent gene expression was performed with primers against mouse -tubulin.
of BRCA1 diminishes BARD1-induced apoptosis, and the exert its proapoptotic activity either as a homodimer or
in a complex with other proteins.Brca1/ genetic background enhances BARD1-induced
apoptosis. This suggests that BRCA1 actually antagonizes
BARD1. Indeed, a BARD1 deletion mutant (RING finger Repression of BARD1 Reduces Apoptotic
Response to Genotoxic Stressdeletion of amino acids 1 through 237) retains apoptosis
inducing activity (data not shown). Taken together, these So far we have demonstrated that BARD1 levels in-
crease in response to apoptotic stimuli and elevation ofresults suggest that the BRCA1/BARD1 complex is not
involved in apoptosis induction and that BARD1 must BARD1 levels is sufficient to induce apoptosis. To as-
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Figure 7. BARD1 Induces Apoptosis through Interaction with Functional p53
BARD1-p53 interaction was assayed by coimmunprecipitation (A). Anti-p53 (agarose-coupled; Santa Cruz) or anti-BARD1 antibodies (N-19;
Santa Cruz) were used for immunoprecipitations (IP) from nontreated (non-treat) and doxorubicin-treated (doxo) cells, and Western blots were
incubated with anti-BARD1 (PVC, Irminger-Finger et al., 1998) and anti-PCNA (Santa Cruz) or anti-p53, respectively. Supernatants (S) and
pellet (P) fractions are presented.
Efficiency of BARD1-p53 interaction is compared in transient transfections of BARD1 or BARD1Q564H (BARD1QH) mutant (B). Western
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sess whether BARD1 is required for the induction of mRNA after doxorubicin treatment were compared.
While p53 protein levels were undetectable in untreatedapoptosis, we studied the effect of BARD1 repression.
For this purpose, we used two different systems for cells and increased after a few hours of treatment, p53
mRNA levels, as detectable by RT-PCR, were elevatedBARD1 repression, ribozymes and antisense RNA.
Mouse ES cells stably expressing anti-BARD1 ribo- in untreated cells and did not increase significantly after
exposure to doxorubicin (Figure 6C, right panel). It iszymes were generated, and TAC-2 cells stably express-
ing BARD1 antisense RNA were described previously therefore unlikely that BARD1 and doxorubicin-induced
p53 protein accumulation are due to transcriptional(TAC-2/ABI; Irminger-Finger et al., 1998). In both sys-
tems, doxorubicin induced much less apoptosis (i.e., upregulation. It rather appears that BARD1 exerts its
action on p53 at a posttranslational level, consistentTUNEL-positive cells), as compared to control cells or
cells transfected with an irrelevant ribozyme (Figures 5A with the concept of posttranslational regulation of p53
levels during apoptosis (Lakin and Jackson, 1999).and 5B). Resistance to doxorubicin-induced apoptosis
through BARD1 antisense expression could also be
monitored by simple cell count (Figure 5C) or by measur- BARD1-p53 Interaction Is Required
ing caspase-3 activity (Figure 5D). In control cells, doxo- for BARD1-Induced Apoptosis
rubicin led to almost 100% cell death within a few days, To determine how BARD1 induces p53 accumulation,
whereas BARD1-repressed cells showed delayed and we investigated whether the two proteins interact physi-
reduced response. Taken together, these results sug- cally by performing coimmunoprecipitation experiments
gest that the apoptotic response to doxorubicin is, at (Figure 7A). Cell lysates from TAC-2 cells (Figures 7A–
least in part, mediated through BARD1. 7C), mouse ES cells, or HeLa cells (data not shown),
untreated or after treatment with doxorubicin, were
tested. When using either anti-BARD1 antibodies orApoptosis Induction by BARD1 Affects
p53 Protein Accumulation anti-p53 antibodies, BARD1 and p53 coimmunoprecipi-
tated. Using p53 antibodies, 36% (4; n  2) of BARD1To further study the mechanism of BARD1-induced apo-
ptosis, we investigated the relationship between BARD1 was found in the pellet after treatment with doxorubicin
(Figure 7A, upper panel), and p53 coimmunprecipitationand the p53 pathway of apoptosis. Transfection of
BARD1 into TAC-2 cells, which express wild-type p53 with BARD1 antibodies resulted in 52% (3; n  2)
of the protein in the pellet fraction after doxorubicin(see Experimental Procedures; RT-PCR), led to a
marked increase in p53 protein levels (Figure 6A), signifi- treatment (Figure 7A, lower panel). The nuclear protein
PCNA, shown previously to be associated with BRCA1cantly higher than after transfection of vector sequences
(Figure 6A) or expression of unrelated proteins (data not in DNA repair functions (Scully et al., 1997) did not coim-
munoprecipitate under our experimental conditions,shown). Importantly, transfection of the BARD1 mutation
Q564H, which showed reduced apoptotic capacity when demonstrating specificity of the p53-BARD1 interaction.
However, this coimmunoprecipitation was observedexpressed in TAC-2 cells or ES cells (Figure 3), resulted
in significantly less p53 accumulation than that obtained only in doxorubicin-treated cells. The lack of coimmuno-
precipiation of BARD1 and p53 in nontreated cells maywith wild-type BARD1 (Figure 6A, middle panel).
If BARD1 were a relevant link between DNA damage simply be due to the very low p53 protein levels in non-
treated cells. The interaction between BARD1 and p53and p53 elevations, a decreased expression of p53 in
BARD1-suppressed cells could be expected. Indeed, was also observed in TAC-2 cells in which p53 elevations
were induced by BARD1 transfection (Figure 7B). How-BARD1 repression led to reduced p53 elevations in dox-
orubicin-treated cells, as shown for the two cell lines ever, coimmunoprecipitation was markedly decreased
for the BARD1 mutant Q564H (Figure 7B). Only 19% (2;described above (Figure 6B, top and middle panels).
Transfection of an irrelevant ribozyme (Nox4) did not n  3) of p53 coimmunprecipitated with BARD1Q564H,
while cells transfected with wild-type BARD1 showedalter p53 induction (Figure 6B, lower panel). The upregu-
lation of p53 observed at the protein level could be 58% of p53 protein in the pellet fraction. Thus, the tumor-
associated BARD1Q564H mutant interacts less avidlydue to transcriptional upregulation of p53. RT-PCR was
performed to determine the changes in the p53 mRNA with p53 than wild-type BARD1.
To further ascertain the role of p53 in BARD1-inducedlevels. No significant differences, either of p53 mRNA
or of the control housekeeping gene -tubulin, were apoptosis, we investigated the apoptotic activity of BARD1
in p53-deficient mouse ES cells (Corbet et al., 1999). Trans-observed in mock-transfected or pcDNA-transfected
cells when compared to BARD1-transfected cells (Fig- fection of BARD1 into p53/ cells did not lead to apopto-
sis, as determined by annexin V staining (Figure 7C) andure 6C, left panel). To further analyze p53 accumulation,
the time course of expression of p53 protein and p53 DNA ladder assay (Figure 7D), while apoptosis was in-
blots were probed with anti-p53 and anti-BARD1 antibodies. BARD1-induced apoptosis depends on functional p53, as demonstrated by
annexin V staining (C) and DNA ladder assay (D) of wild-type or p53/ ES cells transiently transfected with pcDNA3 or BARD1. BARD1 is
required for p53 stabilization through protein-protein interaction as demonstrated by cotransfection of BARD1 and p53 in p53-deficient ES
cells (E); p53/ ES cells were transfected with p53 or BARD1 plus p53. Increase of p53 was monitored on Western blots, and p53 protein
bands were quantified. Bar graph presents intensities of band as arbitrary units.
Model of dual functionality of BARD1 (F). Increase of BARD1 upon stress: pathway (1) BRCA1-BARD1 heterodimer formation, observed as
nuclear dots (Scully et al., 1997), induction of DNA repair functions; pathway (2) BARD1 excess over BRCA1 (possibly as homodimers), BARD1
interaction with p53, affecting p53 stability and induction of apoptosis.
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duced in the corresponding wild-type cells. Thus, p53 in Brca1-deficient embryos contribute to embryonic le-
thality? Likewise, there is a high frequency of p53 muta-is required for BARD1-induced apoptosis.
The data presented so far demonstrate that increase tions in tumors with BRCA1 mutations (Buller et al., 2001;
Greenblatt et al., 2001; Reedy et al., 2001). Thus, isof BARD1 leads to an increase of p53 protein, which is
not accompanied by detectable elevations of p53 the p53-dependent proapoptotic activity of BARD1 an
obstacle toward malignant progression in cells withmRNA. Together with the direct protein-protein interac-
tion of the two molecules shown above, this suggests BRCA1 mutations, which has to be overcome through
p53 mutations?posttranslational stabilization of p53 by BARD1. To fur-
ther substantiate this point, we transfected p53-defi-
cient ES cells with vector sequence, p53 plus control Mechanisms of BARD1-Induced p53 Elevations
vector, or p53 plus BARD1. In this system, p53 (ex- Our results demonstrate that DNA damage leads to
pressed from the constitutive CMV promoter) cannot be upregulation of BARD1, presumably by altering RNA
controlled on a transcriptional level, but p53 protein levels (Figure 1E). Increase of BARD1 protein subse-
stabilization must result from interaction with BARD1. quently affects p53 protein stabilization through a mech-
Indeed, as shown in Figure 7E, markedly higher levels anism that most likely involves direct BARD1-p53 pro-
of p53 protein are observed in cells cotransfected with tein-protein interaction. What could be the precise
p53 and BARD1 than in cells transfected with p53 only. biochemical mechanisms of the BARD1-induced p53
upregulation? The most straightforward explanation
would be BARD1-induced changes of the p53 moleculeDiscussion
leading to protein stabilization. Alternatively, however, it
might be due to an interference of BARD1 with ubiquitin-Our results demonstrate a function of BARD1 in signaling
between genotoxic stress and induction of apoptosis: dependent p53 degradation. Indeed, p53 turnover is
controlled by the cellular protein degradation machineryBARD1 levels increase in response to genotoxic stress
and are necessary and sufficient for p53 upregulation that involving ubiquitin ligases, such as E6-AP (Scheffner et
al., 1993; Rodriguez et al., 2000) and MDM-2 (Honda etresults in apoptotic response (Sionov and Haupt, 1999).
There are several interesting parallels between our re- al., 1997). Several observations point toward a role of
BARD1 in ubiquitination: BARD1 possesses an N-termi-sults and previously published observations. First, we
show decreased sensitivity to apoptosis-inducing drugs nal RING finger domain found in many proteins impli-
cated in ubiquitination (Freemont, 2000), and as recentlyin BARD1-repressed cells (Figures 5A–5D), reminiscent
of the aberrantly reduced expression levels of BARD1 shown, the BARD1/BRCA1 complex possesses ubiqui-
tin ligase activity (Scully and Livingston, 2000; Hashi-reported in spontaneous breast tumors (Yoshikawa et
al., 2000). Second, we show elevations of BARD1 during zume et al., 2001). Our data do not exclude that BARD1
alters p53 ubiquitination; however, as BARD1 inductionapoptosis, reminiscent of BARD1 found in apoptotic
tumor cells (Gautier et al., 2000). Third, we show that of apoptosis is BRCA1 independent, ubiquitination
would have to occur through mechanisms other thanthe BARD1Q564H mutant has a decreased proapoptotic
activity (Figure 3B), matching with its association with those described (Hashizume et al., 2001). Also, it is very
unlikely that the recently described function of BARD1breast and endometrium cancer (Thai et al., 1998).
in inhibition of mRNA 3	 end processing (Kleiman and
Manley, 2001) is linked to the BARD1-induced apoptosisRelationship between BRCA1 and BARD1-
pathway described here, since it involves the formationInduced Apoptosis
of a BARD1/BRCA1/CstF-50 complex.Hitherto described BARD1 functions depend on its as-
sociation with BRCA1, and a function of BRCA1 in apo-
ptosis induction was proposed previously (Harkin et al., Dual Mode Hypothesis of BARD1 Function
Based on the BRCA1-dependent BARD1 functions de-1999). However, the function of BARD1 as apoptosis
inducer, described here, has to be attributed to BARD1 scribed previously and on the BRCA1-indepedent
BARD1 function described in this paper, we propose aindependently of its association with BRCA1, because
(1) only BARD1 but not BRCA1 increased after stroke; “dual mode of action” model of BARD1 function (Figure
7F). In the survival mode, BARD1 acts in a heterodimeric(2) the cotransfection of BRCA1 did not enhance
BARD1-induced apoptosis; and (3) BARD1 induced apo- complex with BRCA1 and is involved in DNA repair and
cell survival. In the death mode, BARD1 acts indepen-ptosis in BRCA1-deficient cells. Thus, BRCA1 is not
required for apoptosis induction by BARD1. Our results dently of BRCA1 and induces apoptosis. Thus, ac-
cording to this model, the ratio of BRCA1 and BARD1even indicate that the interaction of BRCA1 with BARD1
reduces apoptosis induction, as BARD1-induced apo- expressed in a given cell would determine cell fate; a
high BRCA1/BARD1 ratio would lead to DNA repair andptosis is diminished by cotransfection of BRCA1 but
enhanced in BRCA1-deficient cells. survival, while a low ratio would lead to cell death. This
model would be compatible with the observed expres-The BRCA1-dependent decrease of BARD1-induced
apoptosis raises some intriguing questions concerning sion of BARD1 but not BRCA1 under conditions where
cell death occurs, e.g., stroke (see above) and the estrusrecently published results. Brca1-deficient mice are em-
bryonic lethals (reviewed in Hakem et al., 1998) but can phase of the uterine cycle (Irminger-Finger et al., 1998).
It would also be compatible with the observed develop-be rescued through elimination of p53 (Ludwig et al.,
1997). Similarly, Brca1 delta11/delta11 mice are rescued ment of a premalignant phenotype in vitro (Irminger-
Finger et al., 1998) and tumorigenesis (Yoshikawa et al.,from lethality by elimination of one p53 allele (Xu et al.,
2001). Thus, does the proapoptotic activity of BARD1 2000) under conditions of reduced BARD1 levels.
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Experimental Procedures primers were designed to amplify region 1840 through 2360 of the
BARD1 cDNA, and p53 primers were designed to amplify region
118 through 310 of the p53 cDNA sequence. The p53 coding se-Cerebral Ischemia
Cerebral ischemia was induced in the right brain hemisphere of quence was cloned by RT-PCR from TAC-2 cells (GenBank acces-
sion number AY044188).C57BL/6 mice by medium cerebral artery occlusion (MCAO) as de-
scribed (Martinou et al., 1994). Mice were sacrificed at 1, 3, 7, and
14 days after MCAO, and their brains were prepared for immunohis- Quantification of Apoptosis
tochemistry and Western blots. Protein extracts from brain tissue Apoptosis was monitored by several criteria, including changes in
of the right and left hemisphere were prepared separately. cellular morphology observed by light microscopy and nuclear mor-
phology observed after DAPI staining; DNA laddering was performed
with Quick Apoptotic DNA Laddering Kit (Biosource International),Western Blotting and Immunoprecipitation
annexin V staining and TUNEL assays were performed with kits fromFor Western blots, protein extracts from tissues or cell cultures were
Molecular Probes, and analyses were carried out on DAKO Galaxyprepared in standard lysis buffer (150 mM NaCl, 0.1% SDS, 50 mM
pro flow cytometer. Caspase-3 activity tests were performed withTris [pH 8.0], and 2 mM EDTA [pH 8.0]) and analyzed by Western
kits from Molecular Probes and analyzed on a multilabel counterblotting using anti-p53 (Santa Cruz FL-393), anti-BARD1 PVC (Ir-
Victor from Perkin Elmer (Switzerland).minger-Finger et al., 1998), N-19, and C-20 (Santa-Cruz sc-7373),
or anti--tubulin (Beohringer) antibodies. Immunoprecipitation was
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2. Nuclear-cytoplasmic translocation of BARD1 is linked to its apoptotic 
activity 
Jefford CE, Feki A, Harb J, Krause KH, Irminger-Finger I. Oncogene. 2004 Apr 29; 
23(20):3509-20. 
The work performed in this report is a continuation of the previous paper in that it 
defines the region necessary for induction of apoptosis. According to our previous 
results, we know that BARD1 can induce apoptosis in transient transfection 
experiments. In order to identify the BARD1 protein domain or region responsible for 
triggering the apoptotic response, we constructed a series of deletion mutants of 
BARD1. We then analysed their capacity to induce apoptosis by TUNEL assay, DNA 
laddering assays and morphometric measurements and assessed their nuclear 
localization by immunohistochemistry, by epi-fluorescence microscopy of GFP-
tagged BARD1 deletion recombinants. We demonstrated in particular that the 
minimal region required for inducing apoptosis maps to a region that does not 
contain a functional domain, which lies in between the ankyrin repeats and the 
BRCT domain. Surprisingly, this region, comprising the amino acids 510-604, 
coincides with 2 presumed cancer predisposition mutations C557S and Q564H and 
correlates with the tumour suppressor function of BARD1. In contrast with previous 
reports which stipulated an exclusive localization of BARD1, we showed that BARD1 
localizes to the cytoplasm in vitro and in vivo. Furthermore, we showed by using a 
BARD1-EGFP fusion and BARD1-EGFP deletion proteins that BARD1 localizes to 
the cytoplasm in spite of several predicted nuclear localizing signal sequences 
(NLSs). Finally, we showed that apoptosis is concomitant with enhanced 
cytoplasmic localization of BARD1, as well as the appearance of a p67 cleavage 
product. The electron microscopy (EM) images were obtained by Jean Harb, and the 
western blot and the immunohistochemistry performed by Anis Feki.  
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The tumor suppressor protein BARD1 plays a dual role in
response to genotoxic stress: DNA repair as a BARD1–
BRCA1 heterodimer and induction of apoptosis in a
BRCA1-independent manner. We have constructed a
series of BARD1 deletion mutants and analysed their
cellular distribution and capacity to induce apoptosis. As
opposed to previous studies suggesting an exclusively
nuclear localization of BARD1, we found, both in tissues
and cell cultures, nuclear and cytoplasmic localization of
BARD1. Enhanced cytoplasmic localization of BARD1,
as well as appearance of a 67 kDa C-terminal proteolytic
cleavage product, coincided with apoptosis. BARD1
translocates to the nucleus independently of BRCA1.
For recruitment to nuclear dots, however, the BRCA1-
interacting RING ﬁnger domain is required but not
sufﬁcient. Protein levels of N-terminal RING ﬁnger
deletion mutants were much higher than those of full-
length BARD1, despite comparable mRNA levels, sug-
gesting that the N-terminal region comprising the RING
ﬁnger is important for BARD1 degradation. Sequences
required for apoptosis induction were mapped between the
ankyrin repeats and the BRCT domains coinciding with
two known cancer-associated missense mutations. We
suggest that nuclear and cytoplasmic localization of
BARD1 reﬂect its dual function and that the increased
cytoplasmic localization of BARD1 is associated with
apoptosis.
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Introduction
A function of BARD1 in a pathway of stress-induced
signaling towards apoptosis was discovered previously
(Irminger-Finger et al., 2001). Overexpression of
BARD1 inducing apoptosis in a number of cell lines,
and genotoxic stress triggering apoptosis is accompanied
by upregulation of BARD1. Thus, BARD1 serves as a
mediator between proapoptotic stress signals and p53-
dependent apoptosis. In line with its tumor suppressor
function, depletion of BARD1 protein in vitro through
antisense BARD1 mRNA or ribozyme expression,
annihilates p53 upregulation and apoptotic response to
stress and leads to genomic instability and a premalig-
nant phenotype (Irminger-Finger et al., 1998, 2001;
Soriano et al., 2000). BARD1 is implicated in a number
of other functions most of them dependent on its
interaction with the tumor suppressor protein BRCA1,
of which it is the major binding partner in a yeast two-
hybrid screen (Wu et al., 1996).
BRCA1 and BARD1 heterodimerize through their
respective N-terminal RING ﬁnger domains (Meza et al.,
1999). Association of the C64G mutation within the N-
terminal RING ﬁnger of BRCA1 with familial breast
and ovarian cancer (Wu et al., 1996; Ruffner et al., 2001)
suggests a relevant function for the BRCA1–BARD1
interaction in tumor suppression. Structural analysis of
the BARD1–BRCA1 heterodimeric complex by NMR
(Brzovic et al., 2001b) and mutational analysis demon-
strated that abolishing heterodimer formation (Morris
et al., 2002) results in genomic instability, uncontrolled
cell proliferation and tumorigenesis (Baer, 2001; Parvin,
2001).
Evidence for BARD1/BRCA1 heterodimer formation
in vivo comes from the observation that BARD1
colocalizes with BRCA1 and the repair protein Rad51
in nuclear dots during S phase (Jin et al., 1997) and to
nuclear foci in response to DNA damage (Scully et al.,
1997b). Mutations in the RING ﬁnger of BRCA1,
disrupting BRCA1/BARD1 interactions, annihilate the
formation of nuclear foci (Chiba and Parvin, 2002;
Fabbro et al., 2002), which suggests that the interaction
with BARD1 is required for this localization.
A recent report shows that BARD1 plays a role as
chaperone for the correct translocation of BRCA1 into
the nucleus (Fabbro et al., 2002). Deletion of the
BRCA1-RING domain leads to exclusion of BRCA1
from the nucleus, and a BRCA1 mutant lacking NLS,
but retaining the RING domain structure, is translo-
cated to the nucleus by BARD1 overexpression. Most
importantly, the binding of BARD1 inhibits the nuclear
export of BRCA1 by masking its nuclear export signal
(NES) (Brzovic et al., 2001a; Fabbro et al., 2002). Since
more than 75% of all BRCA1 is complexed with
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BARD1 (Baer and Ludwig, 2002), BARD1 plays an
important role in trapping BRCA1 within the nucleus.
Whether BARD1 itself depends on other proteins for
entering and exiting the nucleus has not been
determined.
The BRCA1/BARD1 heterodimer exhibits ubiquitin
ligase activity, which is abolished by mutations within
the RING ﬁnger domain of BRCA1 (Hashizume et al.,
2001; Chen et al., 2002). BARD1 supports the associa-
tion of BRCA1 with Polymerase II holoenzyme, a
suspected target of BARD1/BRCA1 ubiquitylation,
which is abrogated by a deletion of the BRCA1-RING
ﬁnger domain (Chiba and Parvin, 2002). Furthermore,
the stability of BARD1 and BRCA1 proteins themselves
might be controlled by ubiquitylation (Mallery et al.,
2002; Xia et al., 2003). Besides degradation, ubiquityla-
tion can act as a regulator of nuclear–cytoplasmic
shuttling, as described for the nuclear export of p53 (Gu
et al., 2001; Lohrum et al., 2001). A similar mechanism
might exist in the case of BARD1 and BRCA1, in
particular since BARD1 and BRCA1 become ubiquiti-
nylated upon association (Chen et al., 2002). It was
suggested that nuclear–cytoplasmic shuttling has func-
tional implications since BARD1 and BRCA1 are less
prone for degradation when bound together but their
dissociation after ubiquitylation could lead to nuclear
export and degradation (Fabbro and Henderson, 2003).
In addition to its interaction with BRCA1, BARD1
associates with a number of other proteins involved in
different functions (Irminger-Finger and Leung, 2002),
all of which imply a nuclear localization such as mRNA
polyadenylation factor CstF50 (Kleiman and Manley,
1999; Kleiman and Manley, 2001), the NFK-B regulator
oncoprotein Bcl-3 (Dechend et al., 1999), the complex
containing BRCA1 and CtIP (Yu and Baer, 2000), and
the Ewing’s sarcoma protein EWS (Spahn et al., 2002).
BARD1 structurally relates to BRCA1, as it contains
N-terminal RING ﬁnger and C-terminal BRCT do-
mains (Wu et al., 1996; Ayi et al., 1998); however, novel
functions of BARD1 might relate to its ankyrin repeats,
which are found in proteins with very diverse functions,
and to regions without known protein motifs. Here, we
report that BARD1 is found in the nucleus and the
cytoplasm and that its apoptotic function is associated
with its cytoplasmic localization. Furthermore, by
mapping the regions responsible for intracellular loca-
lization or required for its apoptotic function, using an
enhanced green ﬂuorescent protein (EGFP), tagged to
the C-terminal end of full-length BARD1 or various
deletion variants, we demonstrate their respective
dynamic intracellular localization and the correlation
of cytoplasmic localization and apoptotic activity.
Results
Cytoplasmic localization of BARD1
The tissues with the highest expression of BARD1 and
BRCA1 mRNAs are spleen and testis (Wu et al., 1996;
Ayi et al., 1998; Irminger-Finger et al., 1998). In the
spleen, a BRCA1-associated function of BARD1 could
be expected, as well as a function in apoptosis. We
applied immunohistochemistry to detect the BARD1
protein in the spleen. BARD1 staining was observed in
the red pulp and the white pulp, both regions known for
the high turnover of lymphocytes (Figure 1a). The
intracellular localization of BARD1 was both nuclear
and cytoplasmic and in some cells exclusively
cytoplasmic (Figure 1a).
It was interesting to determine the intracellular
localization of BARD1 in tissues where BARD1 is
upregulated in response to cellular stress. In the brain,
no BARD1 expression can be found normally but
maximum BARD1 expression is observed in the regions
adjacent to the stroke induced by ischemia (Irminger-
Finger et al., 2001), in the penumbra, where apoptosis
has been described (Ferrer and Planas, 2003). Immuno-
histochemisty on mouse brain sections after ischemia
demonstrates that the intracellular localization of
BARD1 is rather cytoplasmic than nuclear (Figure 1b).
Figure 1 In vivo localization of BARD1. (a) BARD1 staining on
sections of mouse spleen using anti BARD1 N-19 and PVC
antibodies. BARD1 can be localized to the red pulp and white pulp
(magniﬁcation  10). Intracellular localization is observed with
both antibodies. Bar 100mm. (b) BARD1 staining (anti-BARD1 N-
19) is shown in a mouse brain after ischemia. Penumbra region is
shown in overview in ( 4.5). BARD1 staining is cytoplasmic in
most cases, as exempliﬁed by arrows in higher magniﬁcations in
( 40). Bar 100mm
Nuclear–cytoplasmic translocation of BARD1
CE Jefford et al
3510
Oncogene
Strong evidence for cytoplasmic localization of BARD1
protein is the observed staining of protrusions of
neuronal cells (Figure 1b). Control staining without
primary antibody or in the presence of antigenic peptide
did not produce staining (not shown). Antibodies
against the N-terminal and the C-terminal portion of
the protein present the same distribution. These data
suggest that in vivo, apoptosis, occurring physiologically
or induced upon stress, is accompanied by a cytoplasmic
localization of BARD1, and that the apoptotic function
of BARD1 might be conﬁned to the cytoplasm.
Subcellular distribution of BARD1 in vitro
Previous reports stipulate that BARD1 is found in
nuclear extracts and localizes to BRCA1 foci in the
nucleus during the S phase (Jin et al., 1997; Scully et al.,
1997a) and to distinct intranuclear foci upon genotoxic
stress (Scully et al., 1997a). To explore the dynamics of
BARD1 localization at various stages of the cell cycle
and apoptosis, immunoﬂuorescent staining and electron
microscopy (EM) were performed on NIH 3T3 cells
(Figure 2). Immunoreactivity with anti-BARD1 anti-
bodies results in a punctuate staining in the nucleus of
interphase cells but diffuse staining in the cytoplasm as
well (Figure 2a). Similar results were obtained when
BARD1 protein localization was assayed in other cell
lines (TAC2, HEK 293T, HeLa) and when other
antibodies (N-19, C-20, H300) were used (Figure 2b).
Enhanced staining of BARD1 in nuclear dots is
obtained by confocal microscopy. By EM, immunor-
eactive dots of BARD1 were identiﬁed in the nucleus
and with similar frequency in the cytoplasm (Figure 2c)
corroborating the data obtained by immunoﬂuores-
cence. Interestingly, we also observed that cells progres-
sing through mitosis accumulate higher levels of
BARD1 than G1 or S-phase cells. BARD1 is excluded
from the condensed chromatin during metaphase–
anaphase stages of mitosis (Figure 2a). This localization
of BARD1 contrasts with the reported binding of
BRCA1 to the centrosomes during mitosis (Hsu and
White, 1998; Deng, 2002; Lotti et al., 2002). Our data
suggest that BARD1 might have a speciﬁc function in
the cytoplasm, and that BARD1 is not engaged in
functions associated with the centrosomal location of
BRCA1.
Intracellular localization of BARD1-EGFP and BARD1-
EGFP deletion mutants
Mouse BARD1 has three putative NLS sequences
located close to or within each functional domain
(Figure 3a): NLS1 -RKKNSIKMWFSPRSKKV- start-
ing at position 130, NLS2 -PARKRNH- at 408 and
NLS3 -RKPK- at 693. When applying Reinhardt’s
method (http://psort.nibb.ac.jp/) for the prediction of
nuclear localization with a reliability coefﬁcient of
94.1%, the prediction for intracellular localization for
mouse BARD1 has a 52.2% score for the nucleus,
30.4% for the mitochondria, 13% for the cytoplasm and
a 4.3% for the cytoskeleton. Together the cytosolic
fraction values add up to 47.8% implying a possible role
for BARD1 within the cytoplasm. Human BARD1 has
six putative NLS sequences and a higher prediction
score for the nucleus of 82.6%.
In order to ascertain BARD1’s intracellular localiza-
tion and to determine which domains of BARD1 or
which NLS are necessary for nuclear import, we
generated either EGFP-tagged full-length mouse
BARD1 or deletion mutants (Figure 3a). Constitutive
expression of EGFP-BARD1 fusion proteins was
obtained under the transcriptional control of the CMV
promoter. To determine the localization of BARD1-
EGFP or deletion mutants, we transfected the BARD1-
EGFP plasmids in various cell lines and monitored their
localization by ﬂuorescent microscopy at different time
points (12–30 h) after transfection. The intracellular
Figure 2 Cytoplasmic and nuclear localization of BARD1 in vitro.
(a) Indirect immunoﬂuorescent staining of BARD1 protein in
NIH3T3 cells using anti-BARD antibody (PVC). Interphase cells
show immunoreactive dots in the nucleus and the diffuse staining in
the cytoplasm. In mitotic cells, BARD1 is excluded from the
chromatin. Nuclear staining with DAPI of identical ﬁeld is shown.
Bar 10 mm. (b) Immunoﬂuorescent staining of HeLa cells with
various anti-BARD1 antibodies (PVC, C-20, N-19, H-300) show
nuclear dots and cytoplasmic staining. (c) EM photomicrograph of
an interphase cell. BARD1 reactive dots are evenly dispersed in the
cytoplasm and the nucleus. EM image of an early mitotic cell shows
that BARD1 reactive dots are excluded from the condensed
chromatin
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distribution of all BARD1-EGFP fusion proteins
differed greatly from the nuclear and cytoplasmic
localization of EGFP alone (Figure 3b). The analysis
of a number of 8–12 microscopic ﬁelds from at least
three independent transfection experiments at 24 h after
transfection (Figure 3c), showed that full-length
BARD1-EGFP locates to the nucleus more frequently
(76%) than to the cytoplasm (24% of the cases).
Surprisingly, the D-RING-EGFP and D-HIND-EGFP,
which lack the ﬁrst NLS at position 130, but also lack
the BRCA1-interacting RING ﬁnger domain, exhibited
a most pronounced preference for the nucleus. Interest-
ingly, D-RING-EGFP, which localized exclusively to
the nucleus, never aggregates within nuclear dots during
the S phase. The RING domain by itself when fused to
EGFP localizes evenly to the cytoplasm and nucleus, as
did ANK-EGFP (Figure 3b). Both constructs have only
a single NLS. Most interestingly, the C-terminal
deletion, D-BRCT-EGFP, localized almost exclusively
to the nucleus and formed distinct speckles within the
nucleus, as did the full-length BARD1-EGFP. These
data indicate that the nuclear localization of BARD1 is
independent of BRCA1, since the BARD1 deletion
constructs lacking the RING ﬁnger have even increased
nuclear localization. However, the aggregation within
nuclear dots might depend on BRCA1, since neither D-
RING-EGFP nor D-HIND-EGFP, or ANK-EGFP
concentrate on nuclear dots. The N-terminal region
containing the BRCA1 interaction domain might be
required but not sufﬁcient for BARD1 localization to
nuclear dots.
Mapping of apoptotic function of BARD1
While the function of the conserved RING ﬁnger
domain is well described, less contributions have been
made to elucidate the functional signiﬁcance of the
ankyrin repeats, the BRCT domains, or the intervening
sequences. To determine the proapoptotic region of
BARD1 and to investigate whether any of the conserved
sequence motifs was involved, we analysed the induction
of apoptosis by BARD1 deletion mutants missing either
RING ﬁnger, ankyrin, or BRCT domain (Figure 4).
Maximal induction of apoptosis, as tested by DNA
laddering (Figure 4a) and TUNEL staining (Figure 4b),
was observed only with the full-length BARD1 con-
struct. Efﬁcient induction of apoptosis was observed
with a variety of deletion mutants (Figure 4c), namely
deletion of the BARD1 C-terminal BRCT domains (D-
BRCT), of the region comprising the ankyrin repeats (D-
ANK), of the N-terminal domain comprising the RING
ﬁnger (D-RING), or the deletion of N-terminal and the
C-terminal regions (ANK2). One mutant was devoid of
apoptosis-inducing activity, namely of the construct
expressing the BARD1 N-terminus, RING. From these
experiments, it can be concluded that the region
sufﬁcient for apoptosis induction includes sequences
from amino acid 316 through 604 and that a minimal
region required for apoptosis induction comprises
sequences from amino acid 510 through 604.
Figure 3 Subcellular localization of EGFP-tagged BARD1
deletion mutants. (a) Schematic representation of mouse BARD1
and BARD1-EGFP fusion proteins. Relative positions of mouse
BARD1 functional domains (RING, green, ANKYRIN, blue, and
BRCT, red), and three NLS (blue) are indicated. Schematic
diagram of the various deletion mutants of BARD1 fused to the
EGFP. (b) Merge of DNA stain DAPI and epiﬂuorescent images of
HEK-293T shows subcellular localization of transfected BARD1-
deletion mutants tagged with EGFP 30h post transfection. (c)
Intracellular localization of BARD1 and deletion mutants. 293-T
cells were transfected with BARD1-EGFP mutants and ﬁxed in
PFA 2%. Histograms show distribution of cells displaying either
nuclear (N), nuclearþ cytoplasmic (NC), or cytoplasmic localiza-
tion. Statistics of localization of EGFP ﬂuorescence was performed
on eight different randomized ﬁelds under ﬂuorescent microscope.
Results from at least three different experiments were pooled to
give signiﬁcant numbers of transfected cells
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To demonstrate that apoptosis induction was directly
due to the expression of BARD1, we determined the
apoptosis inducing capacity of BARD1-EGFP and
BARD1 deletion mutants fused to EGFP in transient
transfection assays in TAC-2 cells. With comparable
transfection efﬁciencies, the overexpression of the
exogenous BARD1-EGFP proteins induces morpholo-
gic changes and nuclear fragmentation, which is not
observed with cells transfected with control plasmid
EGFP only or in nontransfected cells. All constructs
comprising the minimal apoptotic region led to apop-
tosis induction after transient transfection. Staining with
DNA dye DAPI demonstrates that apoptotic cells,
recognized by their nuclear fragmentation, are clearly
correlated with cells expressing EGFP fusion proteins in
the case of BARD1-EGFP, D-RING-EGFP, D-BRCT-
EGFP, and ANK-EGFP, while expression of EGFP, or
RING-EGFP was not correlated with apoptosis
(Figure 5). Inspection of random ﬁelds showed that at
early time points after transfection (24–48 h) the
frequency of apoptosis was lower for D-RING-EGFP,
D-HIND-EGFP, and D-BRCT-EGFP than for other
deletion mutants or for BARD1-EGFP, and at all times
insigniﬁcantly low for EGFP and RING-EGFP.
Cytoplasmic localization of BARD1 during apoptosis
Since endogenous and exogenous expression of BARD1
is found in both the nucleus and cytoplasm, it was
speculated that the apoptotic function of BARD1 was
correlated with its cytoplasmic localization as observed
for other gene products of the apoptotic pathway
(Conus et al., 2000). When individual cells were
monitored after transient transfection with BARD1-
EGFP, it was observed that the EGFP-tagged BARD1,
or truncated BARD1, D-RING-EGFP, was translo-
cated from the nucleus to the cytoplasm during
apoptosis (Figure 6a). This was speciﬁcally pronounced
Figure 4 Mapping of the apoptotic domain of BARD1. Apoptosis induction, as observed 48 h post transfection in TAC2 cells, was
monitored of BARD1 and deletion mutants. (a) BARD1 and BARD1-deletion mutants induce DNA laddering and apoptosis, except
deletion mutant RING lacking aa 316–777 (excluding the ANKYRIN and BRCT domains). (b) Apoptotic cells were quantiﬁed by
TUNEL assay. FITC-positive cells were counted by ﬂow cytometry. (c) Schematic presentation of BARD1 and regions expressed on
deletion constructs is presented. Red bracket indicates minimal required region for apoptosis induction. Position of cancer associated
missense mutations are indicated (Thai et al., 1998; Ghimenti et al., 2002)
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in cells transfected with D-RING-EGFP that after
transfection is located exclusively to the nucleus. To
demonstrate that exogenous BARD1 D-RING-EGFP
and endogenous BARD1 were both translocated from
the nucleus to the cytoplasm during apoptosis, immuno-
ﬂuorescence microscopy was performed on cells trans-
fected transiently with D-RING-EGFP. Staining with
anti-BARD1 antibodies (PVC) directed against the
RING domain (Irminger-Finger et al., 1998) demon-
strates that D-RING-EGFP, not recognized by anti-
BARD1-PVC, ﬁrst localized to the nucleus, then at later
stages of apoptosis is translocated to the cytoplasm,
while endogenous BARD1, detected with anti-BARD1
antibody PVC, is still localized to nuclear dots. At late
stages of apoptosis, both exogenous and endogenous
BARD1 are found mostly excluded from the nucleus
(Figure 6b). This observation is consistent with the
hypothesis that excess of BARD1 over BRCA1 could
lead to cytoplasmic localization of BARD1 and initiation
of the apoptotic pathway (Irminger-Finger et al., 2001).
To further address the apoptosis-related translocation
of BARD1, its distribution between nucleus and
cytoplasm was assayed after treatment with the apop-
tosis inducing drug doxorubicin, both by immunoﬂuor-
escence microscopy and Western blotting. MCF7 cells
were analysed with or without doxorubicin treatment. In
untreated cells, BARD1 protein levels are very low but
higher in the nucleus than in the cytoplasm; upon
apoptosis, overall BARD1 levels are increased, but the
distribution of BARD1 between the nucleus and
cytoplasm is inversed (Figure 7a). Interestingly, BRCA1
remains localized to nuclear dots after doxorubicin
treatment, as observed by staining with anti-BRCA1
antibodies (Figure 7a).
Figure 5 Apoptosis induction by EGFP-tagged BARD1 and BARD1-deletion mutants. (a) Epiﬂuorescence images, merged with
DNA stain DAPI, of TAC-2 cells transfected with the full-length or the various deletion-bearing BARD1-EGFP plasmids. Cells were
ﬁxed and stained with DAPI 48 h after transfection. Constructs used for transfection were as described in Figure 3. Nuclear
fragmentation in EGFP positive cells is observed for all BARD1 EGFP fusion constructs except for RING-EGFP. Apoptosis
progression of EGFP-positive cells was correlated with intensity of EGFP stain. (b) Percentage of GFP-positive apoptotic cells in
transcient transfection assays. Six microscopic ﬁelds of two to three independent transfection assays were analysed. GFP-positive
apoptotic cells were determined based on nuclear morphology. Percentages of apoptotic cells are presented
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To investigate BARD1 translocation after doxorubi-
cin treatment biochemically, protein extracts from cells
treated with doxorubicin were prepared and nuclear and
cytoplasmic fractions were analysed on Western blots
(Figure 7b). To follow the translocation of BARD1 to
the cytoplasm after BARD1-induced apoptosis, we
monitored BARD1 expression in cytoplasmic and
nuclear fractions at different time points after treatment.
Using antibodies against different regions of BARD1,
we observed that full-length 97 kDa BARD1 concentra-
tions were increased at early time points after treatment
with doxorubicin, and decreased at later time points.
Analysis of nuclear and cytoplasmic extracts demon-
strates that the concentration of BARD1 in the nucleus
is increased during 6 h of doxorubicin treatment and
then decreased. In the cytoplasm, however, BARD1 of
97 kDa is slightly increased and a protein of 67 kDa is
massively increased after 5 h of treatment. These data
could be explained with the following hypothesis:
BARD1 levels increase after apoptosis induction, but
excess BARD1 translocates to the cytoplasm and is
cleaved and gives rise to the stable C-terminal 67 kDa
fragment. The appearance of a C-terminal 67 kDa
BARD1 cleavage product is consistent with the previous
report that a truncated 67 kDa product of BARD1
accumulates during apoptosis due to cleavage by the
caspase-dependent kinase calpain (Gautier et al., 2000).
Apoptotic function of BARD1 regulated through protein
stability
It was observed that BARD1-EGFP and EGFP-tagged
deletion constructs did not give rise to identical protein
expression levels of the fusion products after transfec-
tion. To investigate whether the differences observed
were due to differences in transcriptional activity, the
regulation of translation, or protein stability, we
monitored the expression of BARD1-EGFP and of
BARD1 deletion mutants on the level of mRNA and
protein expression (Figure 8a–c). RT–PCR was per-
formed using primers directed against EGFP and
Figure 6 BARD1-EGFP translocates to the cytoplasm during
apoptosis. (a) NIH3T3 cells transfected with D-RING-EGFP are
monitored at different time points after transfection. FITC
ﬂuorescence is extruded from the nucleus. (b) Comparison of
endogenous and exogenous EGFP-tagged BARD1 location, D-
RING-EGFP mutant is presented. Endogenous BARD1 was
detected with anti-BARD1 antibody PVC reacting with the
BARD1 N-terminal region (Irminger-Finger et al., 1998), which
is omitted in D-RING-EGFP. Merge of EGFP signal (FITC) and
anti-BARD1 signal (rhodamin) images shows that both the
exogenous and the endogenous BARD1 are translocated from
the nucleus to the cytoplasm in cells that are undergoing apoptosis.
An early (arrow) and a late (arrow head) apoptotic cell are shown
Figure 7 Endogenous BARD1 translocates to the cytoplasm
during apoptosis. (a) BARD1 staining is shown in MCF-7 cells.
BARD1 is localized primarily to the nucleus in untreated cells and
translocates to the cytoplasm after UV exposure. Note that low
levels of BARD1 in untreated cells were visualized by overexposure
of the image. UV exposure was as described previously (Irminger-
Finger et al., 2001). BRCA1 staining was performed with anti-
BRCA1 antibody 5-MO. (b) Western blot analysis of nuclear versus
cytoplasmic extracts in NIH3T3 cells following exposure to
doxorubicin in a time-dependent manner shows increased expres-
sion of BARD1 during apoptosis and demonstrates the appearance
of a different truncated form of BARD1 found in the cytoplasm.
Antibodies used were C-20 (Santa Cruz) recognizing a C-term
epitope (** represents the 97 kDa isoform and * the 67 kDa.)
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against BARD1. The mRNA expression levels of full-
length BARD1-EGFP and of the diverse BARD1-
EGFP deletion mutants were compared by using
primers either covering different regions of the mouse
BARD1 coding sequence or directed against the GFP
portion of the fusion proteins. The mRNA levels were
similar in all observed cases (Figure 8a), indicating that
mRNA expression levels were directly correlated to the
concentration of plasmid DNA transfected.
To test protein translation potential of the various
constructs, in vitro transcription/translation was per-
formed to monitor protein stability in vitro. Full-length
BARD1 and deletion mutants were transcribed and
translated into protein with similar efﬁciency, although
slightly elevated levels of protein were obtained with the
D-RING construct (Figure 8b). However, protein
expression levels after transfection of EGFP-tagged
constructs appeared to vary. Western blots were probed
with antibodies against GFP in cell extract collected 24 h
after transfection. Probing of protein extracts after
transfection of the various BARD1 expression con-
structs exhibited signiﬁcant differences in expression
levels. Highest expression was observed for D-RING-
EGFP, less for D-HIND-EGFP and ANK-EGFP, very
little for full-length BARD1-EGFP, which was compen-
sated by increasing the protein concentration for
BARD1-EGFP loaded on the gel (Figure 8c). Repeat-
edly, a C-terminal cleavage product could be detected
more readily with anti-GFP antibodies than full-length
BARD1-EGFP, suggesting that BARD1 and BARD1
deletion mutants that comprise the N-terminal region of
BARD1 are prone for degradation.
Discussion
Nuclear–cytoplasmic distribution of BARD1
The general idea that BARD1 is a nuclear protein is
based exclusively on in vitro studies. We have investi-
gated the localization of BARD1 in tissues. In parti-
cular, we were interested to determine the intracellular
localization of BARD1 in tissues where apoptosis
occurs, either physiologically or induced. Our results
demonstrate that BARD1 is localized to both the
nucleus and the cytoplasm in vivo. We further explored
the localization of BARD1 in a variety of cell lines
in vitro. Both immunoﬂuorescence and electromicro-
scopy revealed that endogenous BARD1 resides in the
nucleus and the cytoplasm. Using EGFP-tagged
BARD1 and BARD1 deletion mutants, we conﬁrmed
that all BARD1 deletion proteins were translocated to
the nucleus, but a variable proportion of the proteins
was also detected in the cytoplasm. These data contrast
with previous reports showing that BARD1 is localized
exclusively to the nucleus colocalizing with BRCA1 in
discreet dots during the S phase (Scully et al., 1997a). It
is possible that in human cells with human BARD1,
which has six NLS, the propensity of nuclear localiza-
tion is higher than that for mouse BARD1, which has
only three putative NLS. All BARD1-EGFP fusion
proteins, described here, are translocated to the nucleus,
indicating that a single NLS sequence is sufﬁcient for the
correct addressing of BARD1 to the nucleus. The
differential intracellular localization of the EGFP-
tagged constructs may be correlated with the number
of NLS present within each speciﬁc construct. Interest-
ingly, the BARD1-RING ﬁnger motif is not required for
nuclear localization, and nuclear localization of BARD1
is therefore independent of BRCA1. In fact, it has been
shown that on the contrary BRCA1 requires BARD1
for entering and remaining in the nucleus, and this is
dependent on the BRCA1-RING domain (Fabbro et al.,
2002). Furthermore, we demonstrate that the BRCT-
deletion mutant of BARD1 localizes to speciﬁc nuclear
dots, as does full-length BARD1, but not the RING
domain by itself, suggesting that RING is not sufﬁcient
for localization of BARD1 in nuclear dots.
Figure 8 Differential stability of BARD1 and BARD1 deletion
proteins. (a) RT–PCR analysis of cell extracts after transfection
with plasmids as indicated. Primers were against two different
regions of BARD1 or against EGFP. Similar amounts of mRNA
were ampliﬁed from cells transfected with the various transcripts.
The RING-EGFP construct can only be detected with the EGFP
primers. To visualize loading differences, two different volumes
were loaded. (b) In vitro transcription and translation of BARD1
and deletion bearing constructs. Plasmids were transcribed and
translated (with S-35 labeled methionine) in vitro, and analysed by
PAGE. All constructs gave rise to comparable amounts of protein.
(c) Western blot analysis of whole-cell extracts of cells transfected
with the aforementioned BARD1-EGFP-fusion plasmids and
probed with an anti-EGFP (TP-401) antibody. Expression of full
length was reduced compared to N-terminal deletion mutants and
was loading was ﬁvefold increased. Full-length BARD1-EGFP and
D-RING-EGFP give rise to a degradation product that comigrates
with D-HIND-EGFP. Triangles indicate proteins with expected
size for each fusion protein on the left (for EGFP and ANK-
EGFP) and on the right side (for D-HIND-EGFP, BARD1-EGFP,
and D-RING-EGFP)
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An alternative localization of BARD1 occurs during
apoptosis. BARD1 and a truncated form of BARD1,
p67 BARD1, appears in the cytoplasm during apopto-
sis. This isoform of BARD1 represents the C-terminal
portion of the protein, recognized by antibodies directed
against 50 C-terminal amino acids. A 67 kDa C-terminal
truncated form of BARD1 was reported previously to
be generated during apoptosis in various cell lines
through cleavage by the caspase-dependent protease
calpain (Gautier et al., 2000). The p67 protein observed
in the cytoplasmic fraction is consistent with the
accumulation of the p67 BARD1 cleavage product in
apoptotic tumor cells (Gautier et al., 2000).
Apoptosis is triggered by overexpression of a minimal
required region of BARD1
Overexpression of all forms of BARD1-EGFP and
deletion mutants, with the exception of the RING-
EGFP construct, induced apoptosis, based on TUNEL
and DNA fragmentation assays, and visualized by the
condensed and fragmented nuclear morphology as
compared to the EGFP control. Furthermore, using
deletion mutants of BARD1, a minimal region required
for triggering apoptosis could be determined. As
observed with the overexpression of full-length BARD1,
cells transfected with BARD1-EGFP, or BARD1-
deletion mutants cannot be cultured over time due to
the apoptotic effect of the fusion proteins. The minimal
region required for the apoptotic function comprises the
sequence between the end of the ankyrin repeats and the
beginning of the BRCT domain. Interestingly, this
region harbors two point mutations (C557S and
Q564H) associated with tumors of the breast, ovary,
and uterus (Thai et al., 1998; Ghimenti et al., 2002). In
line with these ﬁndings, we have previously reported
that the mutant Q564H when used in transient
transfections is less efﬁcient in apoptosis induction than
full-length BARD1 (Irminger-Finger et al., 2001). Taken
together, these data suggest that the primary tumor
suppressor function of BARD1 is linked to its BRCA1-
independent function in inducing apoptosis.
Protein stability is increased in the absence of the RING
domain
When expression of BARD1-EGFP or the tagged fusion
proteins was monitored on Western blots, the protein
levels varied according to the speciﬁc plasmid construct
and despite identical transfection conditions and iden-
tical plasmid DNA concentrations used. Interestingly,
BARD1-EGFP, RING-EGFP and D-BRCT-EGFP
constructs showed increased susceptibility for degrada-
tion. However, BARD1 protein stability appears to be
increased in the absence of the RING domain.
Consistent with this observation, all BARD1-EGFP
deletion-mutants that bear the RING ﬁnger domain
have lower expression levels than the mutants lacking
the RING domain. One possible explanation for the
degradation of these fusion proteins is the reported
ubiquitylation activity of the RING domain (Chen et al.,
2002). Possibly, the BARD1-RING domain is a target
for protein degradation by the ubiquitin pathway, as
speculated for BRCA1 (Fabbro and Henderson, 2003),
and BARD1–BRCA1 may target excess BARD1 for
degradation, but BARD1–BRCA1 dimer formation pro-
tects from degradation. Furthermore, it was also hypo-
thesized that ubiquitylation could act as nuclear export
signal, as it is the case for p53 (Gu et al., 2001; Lohrum
et al., 2001), and that BARD1 inﬂuences the nuclear
export of BRCA1, which is controlled by ubiquitylation
(Fabbro and Henderson, 2003). The observation of
BARD1 translocation to the cytoplasm, together with
its described degradation, suggests that BARD1 trans-
location could be based on the ubiquitylation, speciﬁ-
cally since BARD1 does not have an NES on its own.
The model derived from these observations
It was suggested that the BRCA1/BARD1/Polymerase
II holoenzyme complex is the sensor for double-
stranded DNA breaks while arresting the cell in S phase
for repair mechanisms to occur (Parvin, 2001). Accord-
ing to our model (Figure 9), BARD1 may be the key
molecule that could trigger the cell-cycle block as a
BARD1–BRCA1 complex and apoptosis through an
increase of BARD1. Initiation of apoptosis is accom-
panied by BARD1 cleavage and accumulation of a
stable C-terminal cleavage product, which might repre-
sent an irreversible decision for apoptosis. BRCA1 may
recruit BARD1 to activate ubiquitylation of the Poly-
merase II holoenzyme, and provoking its degradation
through the proteasome pathway. BRCA1 was sug-
gested to be liberated from BARD1 at later stages
(Fabbro and Henderson, 2003), although it is not clear
what triggers the separation of BARD1 and BRCA1. In
case of a high ratio of BARD1/BRCA1, the excess
Figure 9 Model of BARD1 cytoplasmic translocation. BARD1
enables BRCA1 to be transported to the nucleus. Excess BARD1 is
translocating to the cytoplasm more readily. However, full-length
BARD1 might be exported and degraded. BARD1 degradation
depends on the presence of the RING structure. A C-terminal
fragment, p67 BARD1, presumably due to proteolytic cleavage, is
stable and found in the cytoplasm. p67 BARD1 is no binding
partner for BRCA1 but has apoptotic activity
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BARD1 is found in the cytoplasm and might be
degraded, but the cleavage mechanism that eliminates
the N-terminal sequences including the RING domain
produces a stable C-terminal portion of BARD1. This
p67 cleavage product of BARD1 is mimicked by the
deletion mutant D-RING. Since D-RING retains
apoptotic activity, it is likely that the cleaved form of
BARD1 has an apoptotic function. Most importantly,
both the BARD1 cleavage product p67 and D-RING are
devoid of the RING ﬁnger and seem more resistant
against degradation. Therefore the cleavage of BARD1
during apoptosis could provide a positive regulatory
feedback loop upon apoptosis induction.
In conclusion, BARD1 has at least ﬁve different
functions in binding to BRCA1, all of which are
disrupted by mutations that effect the interaction of
BRCA1with BARD1: (1) tumor suppression and genetic
instability (Wu et al., 1996; Ruffner et al., 2001), (2)
colocalization in nuclear dots upon genotoxic stress
(Scully et al., 1997a, b), (3) nuclear translocation of
BRCA1 (Fabbro et al., 2002), (4) ubiquitin ligase
activity of the BARD1/BRCA1 heterodimer (Hashi-
zume et al., 2001; Chen et al., 2002), (5) recruiting of
Polymerase II holoenzyme (Chiba and Parvin, 2002).
The localization of BARD1 in nuclear dots requires
RING domain, but also the additional domains that
might promote binding of other proteins than BRCA1,
since the BARD1-RING domain by itself does not
localize to nuclear dots. It could be concluded, that full-
length BARD1 might be required for BRCA1-depen-
dent functions associated with nuclear localization, but
a C-terminal portion of BARD1 is sufﬁcient for
apoptotic activity, associated with cytoplasmic localiza-
tion (Figure 9).
Materials and methods
Cell cultures
TAC-2 cells is a clonal subpopulation derived from the
NMuMG normal murine mammary gland epithelial cell line
(CRL 1636; American Type Culture Collection, Rockville,
MD, USA). They were cultured in collagen-coated tissue
culture dishes in high-glucose DMEM supplemented with 10%
fetal calf serum (FCS), penicillin (110mg/ml) and streptomycin
(110mg/ml). The Human Embryonic Kidney HEK 293T cell
line, as well as HeLa cell lines, were obtained from the
American Tissue Type Culture Collection. NIH-3T3 and
MCF-7 cell lines were purchased from the NIH (Bethesda,
MD, USA). All cell lines were cultured in 10 cm plastic tissue
culture dishes (NUNC, Roskilde, Denmark) and incubated at
371C in humidiﬁed air containing 5% CO2. Adherent
subcultures were detached from culture dishes using a solution
of Trypsin/EDTA in HBSS without Ca2þ or Mg2þ . Subcon-
ﬂuent cell cultures were passaged regularly at 1 : 10 dilution
twice a week. All cell culture media, solutions, buffers and
antibiotics were purchased from GIBCO (Invitrogen AG,
Basel, Switzerland).
Plasmid constructions
Two sets of deletion mutants were generated with and without
the EGFP fusion tag. The full-length mouse cBARD1
(Irminger-Finger et al., 1998) was used to generate the
following constructs in pcDNA3 behind a CMV promoter:
(1) full-length BARD1 (aa 1–765); (2) DRING (aa 137–765)
using the EcoRI(396) restriction site; (3) DBRCT (aa 1–604)
ScaI(1812); (4) DANK (aa 1–316/510–765) Stu/Hpa; (5)ANK2
(aa 316–604) StuI/ScaI; (6) RING (aa 1–266) EcoRI. The
plasmid pEGFP-N1 (Enhanced Green Fluorescent Protein)
was purchased from Clontech and was used to generate either
the full-length BARD1-EGFP or BARD1 deletion bearing
mutants fused in frame with the EGFP tag. The following
inserts were ligated in frame with the EGFP: (1); (2); (3); (6)
and (7) DHIND (aa 394–765); (8) ANK (aa 316–604).
Transfection and whole-cell extract preparation
Cells were seeded in 10 cm Petri dishes and transfected with
2mg of DNA using the Effectene reagents by Qiagen. Cells
were harvested at 18, 24 and 48 h post-transfection. They were
centrifuged and washed once in PBS, resuspended in 0.3ml of
ice-cold radio immunoprecipitation assay (RIPA) buffer
(150mM NaCl, 1% Nonidet P-40, 0.5% NaDOC, 0.1%
SDS, 50mM Tris, pH 8.0, 2mM EDTA, pH 8.0) and
supplemented with protease inhibitors (1mM PMSF, 3 mg/ml
aprotinin, 10 mg/ml leupeptin)). Cells were incubated on ice for
30min. The extracts were centrifuged at 13 000 g in a
microcentrifuge for 15min at 41C in order to remove cell
debris and clear the cell lysate.
Nuclear and cytoplasmic fractions
For separation of cytosolic fraction, cells were incubated in
Lysis Buffer (Triton X-100 (1%), HEPES pH 7.6. (50mM),
NaCl (150mM), NaF (100mM), Na-pyrophosphate (50mM),
EDTA (4mM), Na3VO4 (10mM)) supplemented with protease
inhibitors (as above) and rotated at 41C for 30min. Super-
natant was separated from nuclear fractions by centrifugation
at 13 000 r.p.m. for 15min. The pellet was washed in the Wash
Buffer (Lysis Buffer þ 25% glycerol) and centrifuged once
more as above. The supernatant wash was added to cytosolic
fraction. Nuclear fraction was lysed in the nuclear lysis buffer
(NLB) (Wash Buffer with 330mM NaCl), sonicated, incubated
on ice for 30min and centrifuged as above to separate cell
debris from nuclear fraction.
Western blots
In vitro transcription/translation products were obtained using
a kit from Promega. Equal concentrations of all in vitro
transcription/translation, whole-cell extracts as well as cyto-
solic and nuclear fractions per gel were loaded onto SDS–PAA
gels according to Laemmli’s protocol and were transferred to
polyvinylidene ﬂuoride (PVDF) membranes. All primary
antibodies were incubated at room temparature (RT) at
indicated dilutions for 1 h in TBS/5% nonfat dry milk and
washed ﬁve times 3min in TBS/0.1% Tween 20. Secondary
HRP-conjugated antibodies were incubated at a 1 : 2000
dilution (Santa Cruz) at RT for 1 h, and bands were revealed
using the Enhanced Chemiluminescence (ECL) system by
Boehringer.
Antibodies
The anti-BARD1 (N-19, C-20, H-300), and anti-p53 (FL-393)
antibodies were purchased from Santa Cruz. Anti-BRCA1 (5-
MO) was a generous gift from Dr A Vincent and G Lenoir.
Anti-GFP (TP-401) was purchased from Chemokine (Torrey
Pines Biolabs, Houston, TX, USA)). PVC is a previously
described anti-BARD1 antibody (Irminger-Finger et al., 1998).
Nuclear–cytoplasmic translocation of BARD1
CE Jefford et al
3518
Oncogene
Secondary conjugated antibodies to horseradish peroxidase
(HRP) were purchased from Santa Cruz and were compatible
with Cruz Molecular Weight Markers (Santa Cruz, CA, USA).
Assessment of apoptosis
Cells were harvested 48 h post transfection. Trypsinized cells
were centrifuged and washed once with PBS prior assay.
Quantiﬁcation of apoptosis was measured by performing
TUNEL assay, using the APO-DIRECT kit (Pharmingen).
At least 10 000 events were measured on a ﬂow cytometer from
DAKO corporation and analysed using the software package
FlowMax from PARTEC. Assessment of DNA fragmentation
was performed with Suicide-Track DNA isolation kit (Onco-
gene) and DNA ladders were stained with ethidium bromide
on 1% agarose gels.
Fluorescence microscopy
Cells were seeded on glass coverslips in 6-well culture dishes or
plated on an 8-well coverslide and transfected or not with the
aforementioned plasmids. Cells were washed in HBSS, and
either ﬁxed 2% paraformaldehyde (PFA) in Hank’s balanced
salt solution (HBSS) 15min at RT or in methanol for 6min at
201C and rinsed in acetone for 30 s. Coverslides were
mounted and observed under a Nikon epi-ﬂuorescence
microscope and images captured with a 3.3 mega-pixel CCD
camera and processed with MetaMorph software (Visitron).
Tissue preparation for immunohistochemistry
Two adult male mice Balb/c were used in this part of the study.
This study was conducted according to the rules written by the
Swiss veterinary ofﬁce (Bern). The animals were killed by
cervical dislocation. After the animals were killed, the thoracic
aorta was cannulated and the vasculature ﬂushed with sodium
chloride solution (0.9 g/l). The ﬁxation was performed by
perfusion with 2% glutaraldehyde and 2% paraformaldehyde
in 0.05M phosphate buffer, pH 7.4.
Immunohistochemistry
The immersion-ﬁxed mouse brain and spleen were embedded
in parafﬁn. Consecutive orthogonal 5 mm sections were
mounted on polylysine-coated slides. Sections were counter-
stained with hematoxylin/eosin (HM). The ﬁrst section of each
set of sections was stained HM and used to determine tubule
stages. The remaining sections were further processed for
immunocytochemical staining. The endogenous peroxidase
was quenched by 15-min incubation in 2% hydrogen peroxide
in PBS. Unmasking of the epitopes was carried out by boiling
the deparafﬁnized rehydrated sections for 10min (two times,
5min each) in 10mM citrate buffer, pH 6.0, using a microwave
oven at 5000W power output. Primary antibodies were used in
a 1 : 50 dilution.
Immunogold labeling and silver enhancement for EM
Cells were ﬁxed with 3% freshly depolymerized paraformalde-
hyde and 0.15%. glutaraldehyde in 0.1M phosphate buffer
(PB) pH 7.2 for 1 h at room temperature. They were then
permeabilized with PB containing 0.1% Triton X-100. The
immunostaining was then performed using ultrasmall gold
conjugates and R-Gent SE-EM silver enhancement reagent
using the Aurion Kit (Biovalley, Marne-la-Valle´e, France) as
indicated by the manufacturer. Primary antibody used was C-
20 diluted at 1/100. After immunostaining, the cells were
postﬁxed for 1 h at 41C with osmium tetraoxide buffered at pH
7.2 with symmetric collidin. After two washes in the same
buffer, the preparations were dehydrated through a series of
graded ethanol and propylene oxide, and the pellets embedded
in Epon 812 medium. Ordinary thin sections were then cut
with a Reichert ultramicrotome, stained with uranyl acetate
and lead citrate, or left unstained. All sections were then
examined and photographed under a JEM electron
microscope.
Note added in proof
Coincidentally, our results are corroborated by similar ﬁndings
(Rodriguez et al., 2003) published recently in this journal as
our article was undergoing ﬁnal revision.
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3.  BARD1 expression during spermatogenesis is associated with 
apoptosis and hormonally regulated 
Feki A, Jefford CE, Durand P, Harb J, Lucas H, Krause KH, Irminger-Finger I. Biol 
Reprod. 2004 Nov; 71(5):1614-24. 
Since we know that BARD1 expression is high and necessary during embryogenesis 
and in testis, we investigated the expression pattern of BARD1 at the mRNA and 
protein levels during spermatogenesis in rat testis. In this study, we showed that 
BARD1 is expressed at all stages of spermatogenesis. This fact contrasts with 
BRCA1 which is only expressed in meiotic spermatocytes and early round 
spermatids. While spermatogonia expressed full-length BARD1 mRNA, later stage 
spermatocyte precursors express predominantly a novel, shorter splice variant 
BARD1β. This BARD1β form lacks the RING finger domain, which abrogates its 
interaction with BRCA1, but conserves its apoptosis-inducing capabilities. 
Furthermore, it is well known that apoptosis is necessary to regulate the 
overproduction of early germ cells in testis. Therefore, in order to assess the role of 
BARD1 and apoptosis in testis, we monitored the expression pattern of BARD1 with 
that of apoptotic markers such as BAX, active caspase-3, and DNA fragmentation on 
histological sections of rat testis. We found that BARD1 expression correlates with 
apoptosis as indicated by BAX and active caspase-3 coincidental spatial and 
temporal expression. Furthermore, we tested and showed the ability of BARD1β 
splice variant to trigger apoptosis in vitro by transient over-expression. Finally, we 
show that elevated BARD1 protein expression correlates with testis pathologies 
such as obstructive azoospermia, cryptorchidy and Sertoli cell syndromes. My 
contribution consisted in providing the BARD1-EGFP constructs, performing the 
transfections, some of the western blot as well as some technical help on apoptosis 
assays are shown in Figures 3 and 5.  
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BARD1 Expression During Spermatogenesis Is Associated with Apoptosis
and Hormonally Regulated1
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and Irmgard Irminger-Finger2,3
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ABSTRACT
The BRCA1-binding RING-finger domain protein BARD1 may
act conjointly with BRCA1 in DNA repair and in ubiquitination,
but it may also induce apoptosis in a BRCA1-independent man-
ner. In this study, we have investigated BARD1 expression during
spermatogenesis. In contrast with BRCA1, which is expressed
only in meiotic spermatocytes and early round spermatids,
BARD1 is expressed during all stages of spermatogenesis. How-
ever, while spermatogonia expressed full-length BARD1 mRNA,
later stages of spermatocyte precursors express predominantly
a novel, shorter splice form BARD1b. BARD1b lacks the
BRCA1-interacting RING finger but maintains its proapoptotic
activity. Consistently, BRCA1 can counteract the proapoptotic
activity of full-length BARD1 but not of BARD1b. Several lines
of evidence suggest that BARD1 is involved in proapoptotic sig-
naling in testis: i) both BARD1 isoforms are mostly found in cells
that stain positive for TUNEL, Bax, and activated caspase 3; ii)
BARD1b, capable of inducing apoptosis even in the presence of
BRCA1, is specifically expressed in BRCA1-positive later stages
of spermatogenesis; iii) antiapoptotic hormonal stimulation
leads to BARD1 downregulation; and iv) BARD1 expression is
associated with human pathologies causing sterility due to in-
creased germ cell death. Our data suggest that full-length
BARD1 might be involved in apoptotic control in spermatogonia
and primary spermatocytes, while a switch to the BRCA1-inde-
pendent BARD1b might be necessary to induce apoptosis in
BRCA1-expressing meiotic spermatocytes and early round sper-
matids.
apoptosis, BARD1, BRCA1, FSH, infertility, meiosis, spermato-
genesis, splicing, steroid hormones, testosterone
INTRODUCTION
Spermatogenesis entails a complex series of events in
which germ cells proceed through successive rounds of mi-
tosis, meiosis, and cellular differentiation and become ma-
ture spermatozoa. Maturation of germ cells is closely linked
to Sertoli cells; however, their nourishing and protective
function is limited, and the overproduction of early germ
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cells is balanced by selective apoptosis [1, 2]. In the adult
rat, A2–4 spermatogonia and spermatocytes undergo apo-
ptosis [2, 3], thus maintaining a constant number of cells
entering meiosis. Spontaneous germ cell apoptosis can be
enhanced after various insults, including testicular injuries,
withdrawal of hormonal support [4, 5], radiation [6], toxi-
cant [7, 8] and heat exposure [9]. Hence, whether male
germ cells survive or die is determined by a complex net-
work of signals. These include paracrine signals such as
stem cell factor (SCF), leukemia inhibitory factor (LIF),
and desert hedgehog (Dhh), as well as endocrine signals
such as pituitary gonadotrophs and testosterone [10]. Like
other cell types, male germ cells respond to external signals
and their internal milieu by activating intracellular signaling
pathways that ultimately determine their fate [10].
In the adult rat, the rate of spontaneous apoptosis extends
to 75% and occurs mostly in spermatogonia [11–13]. Ap-
optotic signaling pathways lead to caspase 3 activation and
involve Bax and Apaf1 or the FasL/Fas and FADD [14].
Expression of p53 was also reported in spermatogonia and
early meiotic prophase cells associated with DNase I ex-
pression and commitment for apoptosis [15]. The upregu-
lation of p53 might either lead to the repair of DNA by
inducing cell cycle arrest or apoptosis by activating the
proapoptotic gene Bax, a pathway well described in sper-
matogenesis [16].
BARD1, a protein that interacts with p53 in vitro [17],
originally identified as binding partner for BRCA1 [18], is
also implicated in the apoptotic pathway involving p53
[17]. The expression of BARD1 is highly elevated in testis
[19, 20], suggesting a role of BARD1 in spermatogenesis.
The mRNAs of BRCA1 and BARD1 are quite abundant
in preparations from whole testis [19, 20], and an additional
2 kilobase (kb) smaller BARD1 transcript of 2 kb is found
in testis, but not in other tissues, by Northern blotting. Mea-
surements of BRCA1 mRNA levels in purified somatic
cells of the testis and in staged germ cells showed that high-
level BRCA1 mRNA expression is limited to the germ cell.
Within the germ cell lineage, the high expression was de-
tected in meiotic cells, specifically pachytene spermatocytes
and in postmeiotic round spermatids. In contrast, little or
no BRCA1 mRNA was found in premeiotic germ cells
[21]. In situ hybridization localized BRCA1 mRNA to early
meiotic prophase spermatocytes [22]. A partial understand-
ing of BRCA1 function in meiosis comes from studies on
meiotic chromosomes where BRCA1 localizes to recom-
bination nodules [23] and the finding that Brca1 2/2 mice
lack crossover during the pachytene stage and fail to enter
diplotene [24].
1615BARD1 IN SPERMATOGENESIS
Although exhaustive studies on the localization and
function of BARD1 and BRCA1 proteins during spermato-
genesis are not available, portions of the BRCA1 and
BARD1 proteins localize to the XIST RNA on the inactive
X-chromosome during the pachytene stage [25] and suggest
a function in the maintenance of its repressed state. In this
present study, we intend to elucidate the function of
BARD1 in spermatogenesis, including its potential role in
apoptosis suggested by earlier studies on BARD1 and
BRCA1.
MATERIALS AND METHODS
Tissue Preparation
Two adult male Wistar rats were used in each part of the study. Ani-
mals were anesthetized, the tunica albuginea of the right testis was incised
from the proximal to the distal pole, and the parenchyma was immersion
fixed with 10% formaldehyde in 0.1 M phosphate buffer, pH 7.4. The
thoracic aorta was then cannulated and the vasculature flushed with buf-
fered sodium chloride before perfusion fixation of the left and the right
testes with 2% glutaraldehyde and 2% paraformaldehyde in 0.05 M phos-
phate buffer, pH 7.4. Procedures relating to the care and use of animals
were approved by the Swiss cantonal veterinary office.
Immunohistochemistry
The immersion-fixed right and left testes were processed for paraffin
embedding. Consecutive orthogonal sections (5 mm) across the seminif-
erous tubules were mounted on polylysine-coated slides. The first section
of each set of sections was stained with hematoxylin eosin and used to
determine tubule stages. The remaining sections were further processed
for immunocytochemical staining. The endogenous peroxidase was
quenched by 15 min of incubation in 2% hydrogen peroxide in PBS.
Unmasking of the epitope was carried out by boiling deparaffinized re-
hydrated sections (twice for 5 min) in 10 mM citrate buffer, pH 6.0, using
a microwave oven at 5000 W power output. Primary antibodies were as
follows: anti-BARD1 N19 polyclonal antibody (1:20) directed to N-ter-
minus of BARD1 (Santa Cruz); anti-BARD1 C20 polyclonal antibody (1:
20), directed to carboxyl-terminus of BARD1 (Santa Cruz); anti-BARD1
JH3 polyclonal antibody (1:20), directed to the amino acids 527–540; anti-
BRCA1 D16 (1:50), epitope corresponding to the amino-terminus; anti-
BRCA1 M20 (1:20), directed to the carboxyl terminus; anti-p53 (1:20)
(Santa Cruz), epitope corresponding to amino acids 1–393. Secondary an-
tibodies were peroxidase coupled and negative controls were processed in
an identical manner except that the primary antibody was replaced by PBS.
Generation of Polyclonal Anti-BARD1 Antibody JH-3
Peptides were generated corresponding to the region including amino
acids 527–540 and polyclonal antibodies JH-3 were generated in rabbits.
Whole sera were used for Western blotting and immunohistochemistry.
Reverse Transcription-Polymerase Chain Reaction
Total RNA was purified from physically isolated rat germ cells of
different stages using Qiagen reagent. RNA was reverse transcribed using
oligo-dT and superscript II (Life Technologies). BARD1 primers used
were: 56 forward (ccatggaaccagctaccg) and 2307 reverse (tcagctgtcaagag-
gaagca). GAPDH primers were 176 forward (CTACCCACGGCA-
AGTTCAAT) and 557 reverse (ACTGTGGTCATGAGCCCTTC). Re-
verse transcription (RT) products were subjected to PCR analysis using
specific primers for rat BARD1 cDNA (covering BARD1 coding regions).
PCR cycles were: 948C 15 min, 948C 1 min, 568C 1 min, 728C 2 min 30
(35 3), then 728C 10 min. Equal volumes of PCR products were analyzed
on 1% agarose gel.
Western Blot
BARD1 expression was monitored by Western blot analysis. Germ
cells harvested by elutriation were lysed in SDS loading buffer (4% SDS,
10% glycerol, 4% 2-mercaptoethanol, 0.125 M Tris base, and 0.02% brom-
ophenol blue, pH 6.8) containing protease inhibitors. Protein concentra-
tions were determined using Bio-Rad protein analysis solution (Bio-Rad,
Hercules, CA). Protein samples (40 mg) were size separated on 10% dis-
continuous polyacrylamide gels and transferred overnight to polyvinyli-
dene fluoride membranes. Filters were blocked for 1 h with 5% nonfat
milk and then incubated for 2 h with polyclonal BARD1 antibodies (C20:
1:200; JH3:1:1000). N-19, which was used in immunohistochemistry, did
not work on Western blots. After washing, membranes were incubated
with horseradish-peroxidase-conjugated anti-rabbit antibodies for JH3 con-
jugated anti-goat antibodies for C20 (1:1000), and the resulting complexes
were visualized by enhanced chemiluminescence autoradiography.
Preparation of Sertoli Cell Conditioned Media
Sertoli cells were plated in tissue culture flasks at a density of 2 3 105
cells/cm2 and were cultured for 3 days in HEPES-buffered F12/DMEM
supplemented with insulin (10 mg/ml), transferrin (10 mg/ml), vitamin C
(1024 M), vitamin E (10 mg/ml), retinoic acid (3.3 3 1027 M), retinol (3.3
3 10–7 M), pyruvate (1 mM) (all products from Sigma, La Verpillie`re,
France), 0.2% fetal calf serum (Life Technologies, Cergy-Pontoise, France)
in the absence or presence of 1027 M testosterone (Sigma) and/or 1 ng/
ml bovine NIH FSH-20 obtained through NIDDK (lot no. AFP-7028D).
On Day 3, media were replaced by serum-free media supplemented or not
with hormones. On Day 5, culture media were recovered, centrifuged to
eliminate cell debris, and conserved at 2208C until used. Four Sertoli cell
conditioned media (SCCM) were prepared: control (no FSH, no testoster-
one [F2/T2]), FSH (1 ng/ml) (F1/T2), testosterone 1027 M (F2/T1),
and a combination of both hormones (F1/T1).
Isolation of Rat Sertoli Cells, Pachytene Spermatocytes,
Round Spermatids, and Spermatogonia/Preleptotene
Spermatocyte Fractions
Sertoli cells from 20-day-old rats and pachytene spermatocytes and
round spermatids from 90- to 120-day-old rats were isolated as described
previously [26]; the purity of these different fractions was assessed by
flow cytometry. In Sertoli cell fractions, 77% 6 1% of the isolated cells
were 2C cells, 5.5% 6 1% were 4C cells; in pachytene spermatocyte
fractions, 94% 6 3% of cells were 4C cells, 3% 6 2% were 2C cells, and
1% 6 0.5% were 1C cells; in round spermatid fractions, 67.2% 6 5.2%
were 1C cells, 10.6% 6 6.6% were 4C cells, and 9.1% 6 1.6% were 2C
cells. Procedures relating to the care and use of animals were approved
by the French Ministry of Agriculture according to the French regulations
for animal experimentation.
Spermatogonia/preleptotene spermatocytes were prepared by centrifu-
gal elutriation of germ cells isolated from 21- to 23-day-old rats, which
do not yet produce round spermatids in their testes. These spermatogonia/
preleptotene spermatocytes eluted in the fraction of elutriation in which
round spermatids from mature rats are recovered. In this fraction, 64.8%
6 7.3% of cells were 2C cells, 29.1% 6 5.4% were 4C cells, and 5.3%
6 2.8% were 1C cells.
Incubation of Germ Cells in Sertoli Cells Conditioned
Media
Pachytene spermatocytes, round spermatids, spermatogonia/prelepto-
tene spermatocytes were incubated for 24 h in the different conditioned
media. At the end of the incubation period, the cells were centrifuged and
recovered for RNA extraction.
Generation of BARD1b Expression Clone
BARD1b expression clone was produced by cloning the sequence of
BARD1b PCR product cDNA into pcDNA3-EGFP in frame with EGFP.
Transfections were performed reproducibly with Effecten (Qiagen).
One to 4 mg of DNA was transfected per well of mouse embryonic stem
cells, CGR8 [17]. Transfection efficiency was between 20% and 30% as
assayed by parallel transfection of GFP cloned into pcDNA3 and analyzed
by flow cytometry and fluorescent microscopy. Thirty-six hours after
transfection, cells were harvested and apoptosis was monitored by 7-AAD
viability probe (BD Pharmingen) and TUNEL assay (Molecular Probes)
by flow cytometry (DAKO galaxy pro).
RESULTS
BARD1 expression is most abundant in testis, as is the
case for BRCA1 [19, 20]. While the function of BRCA1
had been related to meiotic recombination, based on colo-
calization of BRCA1 with RAD51 to recombination nod-
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FIG. 1. Immunohistology of BARD1 and
BRCA1 expression in adult rat testis. A)
Seminiferous tubes showing BARD1 stain-
ing. BARD1 is present in spermatogonia
(a) and preleptotene spermatocytes and
pachytene spermatocytes (b). BARD1 anti-
bodies also stain material in Sertoli cell. B)
Seminiferous tubes showing BRCA1 stain-
ing. BRCA1 expression is predominant at
the meiotic pachytene stage (c) and less
frequent at the preleptotene stage (d). C)
Background staining with omission of pri-
mary antibody is shown.
ules [23], the function of BARD1 in spermatogenesis re-
mains to be elucidated.
BARD1 Expression Is Not Correlated with BRCA1
Expression
To determine the cell type and stage-specific expression
of BARD1, we performed immunohistochemistry on sec-
tions of testis from adult rats. Interestingly, in the testis of
young adult rats (23 days) BARD1 protein is expressed in
many, but not all, spermatogonia and preleptotene sper-
matocytes, and it is less abundant during later stages of
spermatogenesis (Fig. 1A). Staining was also observed in
some cells at later stages of meiosis and in round sperma-
tids (Fig. 1A). During early stages, BARD1 staining is lo-
calized to the nucleus, but it is also found in the cytoplas-
mic prolongations of Sertoli cells. The same staining could
be observed when different antibodies against the N-ter-
minal region of BARD1 were used. No staining was ob-
served when the primary BARD1-specific antibody was
omitted (Fig. 1C). However, when JH-3, an antibody di-
rected against the middle region of BARD1 was used, sper-
matogonia showed strong staining but also later stage germ
cells were stained.
Because it could be expected that BARD1 and BRCA1
act in concert during spermatogenesis, we determined the
specific stages at which the BRCA1 protein is expressed
by immunohistochemistry with anti-BRCA1 antibodies.
Consistent with previous observations of BRCA1 mRNA
expression, the BRCA1 protein was predominantly detected
at the pachytene stage and rarely in preleptotene spermato-
cytes or spermatogonia (Fig. 1B). These data demonstrate
that BRCA1 expression is mostly limited to the pachytene
stage, while BARD1 expression is found in spermatogonia
and preleptotene spermatocytes. The elevated expression of
BARD1 but not BRCA1 in spermatogonia and primary
spermatocytes is indicative of a BRCA1-independent func-
tion of BARD1 in spermatogenesis.
Stage-Specific Isoforms of BARD1
To characterize the expression pattern of BARD1 further,
isolated cells from different stages of spermatogenesis were
analyzed on Western blots. Two forms of BARD1, corre-
sponding to a molecular mass of 97 and 74 kDa, were
found on Western blots probed with different antibodies
(Fig. 2A). Spermatogonia were prepared from 9-day-old
rats, at which age spermatogenesis is not induced [27], and
spermatogonia but not primary spermatocytes are present.
While in spermatogonia from very young rats (9 days), the
97-kDa BARD1 was expressed, it was less abundant in
preleptotene spermatocytes from young rats (23 days). The
74-kDa protein was found in pachytene spermatocytes of
young (23 days) and adult rats (3 mo), as well as in round
spermatids. Depending on which antibody was used for de-
tection, the 97-kDa and 74-kDa proteins could be detected
at the preleptotene stage. This protein expression pattern
suggests that a shorter isoform of BARD1 is expressed at
all stages with the exception of spermatogonia. The 97-kDa
BARD1 was also found in Sertoli cell preparations but
might be derived from BARD1 staining of residual bodies
phagocytosed by the Sertoli cells (data not shown). Simi-
larly, p53 and Bax immunohistochemical staining on
phagocytosed residual apoptotic bodies has been reported
previously [15, 28].
Stage-Specific BARD1 mRNA Expression
To determine whether stage-specific isoforms of BARD1
were generated at the protein or the mRNA level, we in-
vestigated BARD1 mRNA expression at different stages of
spermatogenesis. For this purpose, rat testes were dissected
and differentially-staged germ cells were fractionated [26].
Total RNA was prepared from each of the isolated cell
types and RT-PCR was performed to monitor BARD1
mRNA expression profiles. Primers were designed for am-
plification of the entire BARD1 coding region. While con-
trol RT-PCR of the GAPDH shows similar expression lev-
els in all cell types tested, BARD1 mRNA was found in
spermatogonia and less abundantly in primary spermato-
cytes and round spermatids. Interestingly, RT-PCR pro-
duced two products of slightly different size (Fig. 2B). The
primers corresponding to regions of the translation initia-
tion and stop codon were expected to amplify a 2251-base
pair (bp) fragment, corresponding to the coding region of
wild-type BARD1. This was only found in spermatogonia
and was less pronounced in preleptotene stages. A fragment
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FIG. 2. Stage-specific expression of BARD1. A) Western blots performed
on cell extracts from purified stages of germ cells: spermatogonia from 9-
day-old rats (G), preleptotene spermatocytes from 23-day-old rats (PL),
pachytene spermatocytes of 23-day-old rats (Pjr), pachytene spermato-
cytes of 3-mo-old rats (P), and round spermatids from 3-mo-old rats (RS).
Two proteins of 97 and 74 kDa can be detected with antibodies JH-3 and
C-20, corresponding to the full-length BARD1 protein, 97 kDa, and the
calculated molecular mass of the testis-specific BARD1b, which is about
74 kDa. B) The mRNA expression in different stages of spermatogenesis.
RT-PCR was performed in isolated germ cells as described in (A). Expected
length of 2251 bp was amplified in G; two bands, 2251 bp and 1964 bp,
were amplified in samples from PL stage, and 1964 bp in all other stages.
Control primers were directed against the coding region of housekeeping
gene GAPDH.
of approximately 2000 bp was amplified in preleptotene
and pachytene spermatocytes as well as in round spermatids
(Fig. 2B). As observed on the protein level, on the tran-
script level, two different mRNAs are transcribed in a
stage-specific fashion, full-length BARD1 in spermatogonia
and a shorter form in all stages except spermatogonia. In
preleptotene stages, both BARD1 mRNAs and both pro-
teins of 97 and 74 kDa are expressed. This might reflect
the purification procedure, which does not permit the sep-
aration of spermatogonia and preleptotene spermatocytes.
A Testis-Specific Isoform of BARD1 Is Generated
by Differential Splicing
We cloned and sequenced the RT-PCR fragments cor-
responding to the 2.2-kb and the approximately 2000-bp
fragments. The 2.2-kb fragment was identified as 2251 bp
of full-length rat BARD1 cDNA [29]. The 2000-bp frag-
ment encoded a 1964-bp sequence identical to the known
rat BARD1 sequence but missing the regions including nu-
cleotides 143–348 and nucleotides 1287–1367. The deleted
sequences are homologous to exons 2 and 3, and 5, re-
spectively, of the corresponding human BARD1 sequence
(Fig. 3A). To determine whether the equivalent testis-spe-
cific isoform, called BARD1b hereafter, is unique to the
rat, RT-PCR was confirmed on RNA isolated from mouse
testis. Cloning and sequencing RT-PCR products showed
that a similar splice variant exists in the mouse. The abun-
dance of mouse BARD1b when cloned from total RNA
from mouse testis was fourfold lower that full-length
BARD1 cDNA. Our data suggest that intron-exon bound-
aries are conserved between mouse and human sequences
and that the same intron-exon boundaries are used in hu-
man, mouse, and rat.
The missing BARD1 exons 2 and 3 encode part of the
RING-finger structure, and exon 5 encodes one of the an-
kyrin repeats. However, deletion of nucleotides 143–348
leads to a frame shift that would result in translation of 46
amino acid peptide before ending with a stop codon (Fig.
3A). Alternatively, ATG at position 389, 42 nucleotides
downstream of the deletion, could serve as translation ini-
tiation codon. Translation initiation at nucleotide 389 would
result in a protein of approximately 70 kDa, which is con-
sistent with the observed 74-kDa protein detected in pre-
leptotene and pachytene spermatocytes and round sperma-
tids. We used a deletion construct D-RING-EGFP (nucle-
otides 1–340), designed to be translated from the ATG at
position 389 and producing a truncated BARD1-GFP fu-
sion protein [30] and compared its expression with
BARD1b fused to GFP. Both constructs expressed a trun-
cated BARD1-EGFP fusion protein of approximately 97
kDa, which can be detected with antibodies directed against
GFP (Fig. 3B), indicating that ATG at position 389 is a
functional translation initiation codon in vitro. This sup-
ports the assumption that wild-type BARD1 is expressed in
spermatogonia and the protein product of the splice variant
BARD1b, schematically presented in Figure 3C, corre-
sponds to the 74-kDa protein expressed in pachytene sper-
matocytes and round spermatids.
BARD1 Expression Is Correlated with Apoptosis
The stage-specific pattern of BARD1 expression during
spermatogenesis was reminiscent of the reported occur-
rence of apoptosis [14]. To confirm this correlation, we per-
formed TUNEL experiments and BARD1 staining on serial
sections from testes of a young adult rat. TUNEL assays
primarily produced positive staining in spermatogonia and
preleptotene spermatocytes coinciding specifically with
anti-BARD1 staining when using antibody N-19 (Fig. 4A).
TUNEL staining was also observed at later stages of sper-
matogenesis, in round spermatids, coinciding with BARD1
staining. Only a few TUNEL positive cells could be de-
tected at the pachytene stage. Therefore, the spatial and
developmental distribution of BARD1 staining coincides
with apoptosis at all stages of spermatogenesis.
To further demonstrate the correlation between BARD1
expression and apoptosis induction, we also tested the coex-
pression of BARD1 with other proteins involved in apo-
ptosis pathways, such as increased p53, Bax, and activated
caspase 3. Staining with BARD1 antibodies against the
amino-terminus colocalized with cells positive for activated
caspase 3, tested on adjacent sections, mostly in spermato-
gonia (Fig. 4B), while expression of activated caspase 3
was also observed at later stages. When using an antibody
against the middle region of BARD1, JH-3, staining was
observed in spermatogonia and later stages of spermato-
genesis (Fig. 4B). Similar staining was observed for the
proapoptotic protein Bax. At these stages, the expression
of BARD1 was primarily cytoplasmic, which is consistent
with an apoptotic function, as reported recently [30, 31].
The increase of a C-terminal but not N-terminal epitope at
the pachytene stage and postmeiotic stages is consistent
with the expression of a new splice form BARD1b at those
stages and suggests that BARD1 and BARD1b expression
is associated with apoptotic events at all stages of sper-
matogenesis.
BARD1b, a Potent Apoptosis Inducer
To test whether BARD1b is capable of apoptosis induc-
tion, the BARD1b sequence was cloned into pcDNA and
was transiently transfected into mouse embryonic stem
cells, which were previously reported to readily induce ap-
optosis in response to exogenous expression of BARD1
[17]. The testis-specific splice variant BARD1b induced ap-
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FIG. 3. Differentially-spliced testis-specific BARD1. A) Alignment of deduced protein sequence of BARD1b (testis) with human, mouse, and rat BARD1
cDNAs. RING-finger and ankyrin motifs are boxed. Regions deleted in BARD1b are indicated. Potential translation of nucleotides 1–142 would end in
a stop (*) and produce a protein of 46 amino acids. An alternative ATG initiation codon at position 389 is indicated in blue (M). In-frame deletion of
exon 5 is presented within the ankyrin repeats. B) Transient expression of BARD1-EGFP (124 kDa), DRING-EGFP (97 kDa), and BARD1b-EGFP (97
kDa) and analysis on Western blots probed with anti-GFP. Protein of identical size is detected after transfection of delta-RING-EGFP, and BARD1b-
EGFP. C) Schematic presentation of BARD1 and presumed BARD1b protein. BARD1 is presented with RING finger (green), ankyrin repeats (blue), and
BRCT repeats (red), as well as approximate location of BARD1 antibodies. BARD1b is presented with presumed location of introns (triangles), translated
region (filled heavy line), transcribed region (thin line), and deleted regions (dotted lines). Epitopes recognized by particular antibodies (l) are indicated.
optosis in vitro as well as the full-length BARD1 sequence,
pcBARD1. Apoptosis was quantified by vital staining of
living cells with 79AAD and analyzed by flow cytometry
(Fig. 5A). Interestingly, the RING-finger deficient splice
form BARD1b is as efficient in apoptosis induction as
BARD1. This apoptotic capacity could be due to the lack
of the RING finger, thus liberating BARD1 from apoptosis-
competing binding to BRCA1, which was found previously
[17]. Indeed, cotransfection of BARD1b with BRCA1 did
not lead to a reduction of apoptosis induction, while co-
transfection of BRCA1 with BARD1 decreased apoptotic
capacity of BARD1 (Fig. 5, A and B). Apoptosis induction
by BARD1b could be due to increased protein stability of
BARD1b, as compared with full-length BARD1, because
an N-terminal deletion renders BARD1 more stable [30].
Apoptosis induction by BARD1 is dependent on a func-
tional p53 [17]; we therefore tested whether BARD1b ex-
pression affected p53 stability. Indeed, p53 is upregulated
in cells that are transfected with BARD1 and even more so
in cells that are transfected with BARD1b (Fig. 5C). From
these data, we concluded that BARD1b, like BARD1, in-
duces apoptosis when overexpressed in vitro, through sta-
bilization of p53. It is likely that BARD1b might have a
similar function in vivo.
BARD1 Expression Is Implicated in Pathologies
of Defective Spermatogenesis
Several pathologies are known that result in infertility
due to abortive spermatogenesis, such as obstructive azo-
ospermia, Sertoli cell syndrome, and cryptorchidy. Those
diseases are marked by increased levels of apoptosis of
germ cells at different stages of spermatogenesis. We have
analyzed the expression of BARD1 in sections of human
testis samples of those pathologies. An upregulation of
BARD1 expression is found in round spermatids and in
apoptotic germ cells phagocytosed by the Sertoli cells on
sections from patients suffering from azoospermia (Fig.
6A). The expression of BARD1 clearly coincides with ap-
optosis, as can be determined by the formation of apoptotic
bodies. Cryptorchidism in humans is known to prevent all
spermatogenesis in the undescended testis and germ cell
development is inhibited. We investigated the expression of
BARD1 in the cryptorchid testis and the contralateral de-
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FIG. 4. BARD1 expression is correlated with apoptosis. A) BARD1 staining, as observed with antibody N-19, colocalizes with TUNEL staining on
adjacent section (a and b). Bar 10 5 mm. B) BARD1 staining colocalizes with staining against activated caspase 3. Regions where activated caspase 3
staining was observed (a), correspond to staining pattern with N-19 (b). Magnification in insets (a) and (b) was fourfold. C) Bax staining was observed
at all stages. Note that BARD1 staining with antibody JH3 is cytoplasmic in most cells. Bar 5 10 mm.
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FIG. 5. Apoptosis induction by testis-spe-
cific BARD1b. Transient transfection assays
were performed in ES cells CGR8. A) The
extent of apoptosis induction was mea-
sured by vital staining and monitored by
flow cytometry. Proportion of vital cells
(R2), apoptotic cells (R3), and necrotic
cells (R4) were measured in CGR8, CGR8
plus doxorubicin (doxo), CGR8 plus
BARD1b, CGR8 plus full-length BARD1,
CGR8 plus BARD1b plus BRCA1, CGR8
plus full-length BARD1 plus BRCA1. B)
Histogram presenting percentage of cell
death, as determined in three different
transfection experiments. C) Increased p53
protein expression after transfection with
BARD1b. Western blot of cell extracts af-
ter transfection experiments or doxorubicin
treatment demonstrates p53 increase after
BARD1b, BARD1, and BARD1b plus
BRCA1 transfection, but not after transfec-
tion of BARD1 plus BRCA1. Ponseau stain-
ing of the membrane was applied to con-
firm loading of equal amounts of protein.
scended testis of the same individual (Fig. 6B). Within the
descended testis, heavy BARD1 staining could be ob-
served, and increased apoptosis and BARD1 expression
was clearly associated with apoptotic cells and phagocy-
tosed apoptotic bodies within the Sertoli cells. This is con-
sistent with the reported reduced fertility of individuals
with cryptorchidy. In the cryptorchid testis, which contains
only Sertoli cells, no BARD1 staining could be detected
(Fig. 6, B, a and b), indicating that BARD1 is not expressed
in Sertoli cells per se. These data are consistent with our
finding that BARD1 mRNA is not expressed in Sertoli cells
and supports our interpretation that BARD1 antibody stain-
ing in Sertoli cells is derived from the incorporation of
apoptotic germ cells.
BARD1 expression therefore is clearly associated with
germ cell apoptosis in vivo and with apoptosis in pathol-
ogies marked by reduced spermatogenesis.
Regulation of BARD1 Transcription
Since BARD1 is associated with developmental and
pathological events of apoptosis, it was interesting to in-
vestigate the conditions that drive BARD1 expression. We
have observed that BARD1 is expressed at all stages of
spermatogenesis, although to a different extent. We hy-
pothesized that BARD1 expression is linked to the presence
or absence of hormones driving sexual maturation [32]. In
particular, FSH and testosterone have been described suf-
ficient for triggering spermatogenesis in vitro [33, 34]. This
implies that BARD1 expression is induced in spermatogo-
nia and primary spermatocytes through the paracrine sig-
naling of the Sertoli cells. To test this hypothesis, we cul-
tured isolated germ cells, specifically spermatogonia/pre-
leptotene stage, pachytene, and round spermatids, either in
normal culture medium, as defined previously [26], or in
conditioned culture medium, obtained from Sertoli cells
that were preincubated with hormones, to mimic in vivo
paracrine signaling and maturation. FSH and testosterone
were added to the culture medium. The response of BARD1
to hormone exposure, FSH or testosterone or both, was
monitored on the mRNA level. RT-PCR was performed to
detect BARD1 mRNA expression in RNA isolated from the
different cultures (Fig. 7).
Interestingly, in spermatogonia/preleptotene germ cells,
no reduction of expression was observed with the addition
of testosterone. FSH, however, led to a complete repression
of BARD1, but the combination of FSH and testosterone
had no effect, suggesting that testosterone compensated the
effect of FSH. In all conditions, two forms of BARD1
mRNA were detected that can be correlated with the wild-
type full-length BARD1 and with BARD1b, respectively,
when primers amplifying regions including nucleotides 56–
2307 were used (Fig. 7A). At the pachytene stage, the ad-
dition of hormones did not result in a variation of the ex-
pression level of BARD1. At the round spermatid stage,
addition of hormones produced a similar repression pattern,
as observed at the spermatogonia/preleptotene stage, but
testosterone had no inhibitory effect on FSH-induced re-
pression of BARD1. Both forms of BARD1, full length and
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FIG. 6. BARD1 expression in human pa-
thologies. A) BARD1 staining shown on
cross-section of seminiferous tubes. The
syndrome of azoospermia is characterized
by abortive spermatogenesis and increased
formation of apoptotic bodies, which show
BARD1 staining (arrow heads) at stages
corresponding to round spermatids. Few
germ cells are developed in Sertoli cell
syndrome. Germ cells phagocytosed by
the Sertoli cells are stained positively for
BARD1 (arrows). B) Human cryptorchidy.
Hematoxylin and eosin staining shows
suppression of germ cell development and
presence of only a few Sertoli cells (a),
and BARD1 staining is negative (b) in the
intra-abdominal testis. In the contralateral
descended testis, hematoxylin staining
shows a large number of condensed, apo-
ptotic nuclei (c). BARD1 staining (d) is lo-
calized to cells of different stages, presum-
ably spermatogonia (arrow 1), preleptotene
(arrow 2), and pachytene (arrow 3). In-
creased number of apoptotic cells and ap-
optotic bodies are observed in association
with BARD1 staining. A and B) Original
magnification 340.
BARD1b, were obtained, although BARD1b was increased
proportionally. These results indicate that FSH acts as a
transcriptional repressor of BARD1 in spermatogonia/pri-
mary spermatocytes and round spermatids but has no effect
on pachytene stage spermatocytes. Interestingly, however,
testosterone, by itself, does not have any influence on
BARD1 mRNA expression at any of the stages tested, but
in combination with FSH, it annihilates the repressive effect
of FSH.
In contrast, when cells were grown in preconditioned
medium, medium from Sertoli cells that had been exposed
to the hormones, the addition of FSH and FSH plus testos-
terone, but not testosterone alone, resulted in suppression
of BARD1 expression in spermatogonia/preleptotene sper-
matocytes and in round spermatids. No effect of either hor-
mone was observed under these conditions in pachytene
spermatocytes (Fig. 7A). Interestingly, testosterone alone,
when applied through Sertoli cell-conditioned media, led to
BARD1 repression in round spermatids. Furthermore, tes-
tosterone had no compensatory effect on BARD1 repres-
sion by FSH, but even a repressive effect by itself in round
spermatids. These data indicate that FSH, when applied to
Sertoli cells, could act as a messenger for BARD1 repres-
sion at the spermatogonia/preleptotene stage and in round
spermatids.
To test whether other genes, the products of which pre-
sumably interact with BARD1, were also hormonally reg-
ulated in this in vitro system, we monitored the expression
of p53 mRNAs (Fig. 7B). The expression of p53 showed
only minor, insignificant changes under conditions of FSH
and/or testosterone addition. No changes were observed for
the control gene b-tubulin, which remained unchanged in
the various conditions.
In summary, our data suggest that, at the preleptotene
and round spermatid stages, BARD1 is directly or indirectly
repressed by FSH through paracrine signaling of the Sertoli
cells. The same treatment affects only mild repression of
BRCA1 and only in preleptotene cells (data not shown).
DISCUSSION
Two mechanisms seem to be of crucial importance dur-
ing spermatogenesis: meiotic recombination and apoptosis.
BARD1 and BRCA1 were reported to have maximal ex-
pression in testis. BRCA1 is mainly expressed during mei-
osis [21–24], where, most likely, it is involved in meiotic
repair. BARD1, however, is mainly expressed in spermato-
gonia and primary spermatocytes and to a lesser extent dur-
ing and after meiosis. BARD1 expression rather correlates
with apoptosis, which is known to occur at several stages
of spermatogenesis, including spermatogonia [14]. BARD1
specifically colocalized with TUNEL staining (Fig. 4A) and
with proteins implicated in apoptotic pathways, such as ac-
tivated caspase 3, p53, and Bax (Fig. 4B). However, there
are more cells expressing BARD1 than apoptosis effector
genes, such as Bax. This could reflect the fact that BARD1
acts upstream of the apoptosis pathway and that other ad-
ditional signals are required to activate apoptosis. These
data are consistent with a role of BARD1 in a caspase-
dependent apoptotic pathway, as reported previously [17].
Other functions cannot be ruled out, however, such as the
binding of BARD1 together with BRCA1 to XIST RNA
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FIG. 7. Hormonal regulation of BARD1 expression during spermatogen-
esis. Purified germ cells, spermatogonia/preleptotene (GPL), pachytene
(P), or round spermatids (RS) were cultured. A) BARD1 expression after
direct addition of FSH (F) and/or testosterone (T) or after incubation with
Sertoli cell-conditioned medium (SCCM), was monitored by RT-PCR.
SCCM was prepared as described in the Materials and Methods. Both
forms of BARD1 (2.2 kb and 2.0 kb) are coexpressed. A third and much
less abundant band can be observed and represents a form without de-
letion of exon 5 but not exon 2 and 3. Control RT-PCR was performed
with primers directed against b-tubulin. B) The p53 or b-tubulin (b-tub)
expression of cultured germ cells was monitored after incubation with
SCCM medium. Sertoli cells were cultured with FSH and/or testosterone
for 1 day and culture medium was added to germ cell cultures. RT-PCR
was performed to compare the expression profiles of BARD1, p53, and
the housekeeping gene b-tubulin.
on the inactive X chromosome [25]. BARD1 interaction
with BRCA1 might compete for binding to other proteins
and inhibit its apoptotic activity [17]. Consequently, the
expression of BARD1 in the absence of BRCA1 could lead
to increased apoptotic capacity.
BARD1 knockouts have been generated but are lethal
during the early stages of embryogenesis and thus cannot
shed light on the function of BARD1 during spermatogen-
esis. We therefore performed experiments to further dissect
the specific local and temporal expression pattern of
BARD1 on the mRNA and the protein level. We found that
a novel isoform of BARD1, generated by differential splic-
ing, was expressed in the testis in addition to wild-type
BARD1. The testis-specific new splice variant, BARD1b,
shows a deletion of exons 2, 3, and 5. The translation of
BARD1b results in a frame shift after excision of exons 2
and 3 and would end with a stop codon (Fig. 3A). However,
downstream of the splice acceptor site, an ATG at position
389 could act as an alternative translation initiation site.
Western blot analysis is consistent with this site of trans-
lation initiation because the proteins detected with anti-
BARD1 antibodies correspond to the expected size for the
presumed translation product of BARD1b. Expression of a
deletion construct, missing regions 1–380, results in a pro-
tein of similar size as translation of BARD1b. It is therefore
likely that the 74-kDa protein, expressed at all stages of
spermatogenesis with the exception of spermatogonia and
detected with antibodies against the C-terminal portion of
BARD1, is a translation product of the differentially spliced
form BARD1b.
The temporal expression patterns of BARD1 mRNAs
and BARD1 proteins isoforms show a similar distribution,
a 97-kDa protein corresponds to full-length BARD1 and is
expressed in spermatogonia, as is the full-length BARD1
transcript. BARD1b mRNA is expressed at all stages ex-
cept in spermatogonia, as is a 74-kDa protein, which is
recognized by C-terminal antibodies, suggesting that the
74-kDa is derived from differential splicing rather than
from posttranslational modification of BARD1. Interesting-
ly, the presumed protein product of BARD1b lacks the
RING-finger domain, required for the interaction of
BARD1 with BRCA1 [18, 35], but retains regions sufficient
for its apoptotic function [30].
Expression of BARD1b in vitro resulted in similar levels
of apoptosis as BARD1. However, the in vivo apoptosis
induced by BARD1b could be more efficient due to in-
creased stability of BARD1b compared with full-length
BARD1, as determined on Western blot analysis using an-
tibodies against different regions of BARD1 (data not
shown) and due to the lack of BRCA1 interaction domain.
BRCA1 could act as an inhibitor of BARD1-induced apo-
ptosis [17]; therefore, we demonstrate that BRCA1 reduces
BARD1-induced apoptosis but has no affect on the apo-
ptotic capacity of BARD1b (Fig. 5, A and B). BARD1b
not only induces apoptosis but also shows p53 stabilization,
as does wild-type BARD1 (Fig. 5C). Therefore, BARD1b
acts in a p53-dependent apoptosis pathway. It could be
speculated that BARD1b acts as apoptosis inducer in stages
where BRCA1 and BARD1 are coexpressed.
This hypothesis stipulates that, during premeiotic stages,
in the absence of BRCA1, full-length BARD1 proteins are
expressed and presumably are involved in apoptotic func-
tions. To ensure apoptosis induction by BARD1 in the pres-
ence of the competitor BRCA1 [17], the testis-specific
splice variant BARD1b is expressed.
Besides the importance of apoptosis in normal sper-
matogenesis, the loss of germ cell homeostasis, or dereg-
ulated apoptosis, can result in infertility. In line with these
thoughts, BARD1 is associated with pathologies of reduced
germ cell maturation due to increased apoptosis. Loss or
reduction of apoptosis, on the other hand, can lead to un-
controlled proliferation and it could be speculated that
BARD1 plays a role as tumor suppressor in germ cell can-
cers.
Male germ cell apoptosis and development is regulated
by different growth-promoting or -repressing signals, one
of the regulators being hormones. Testosterone deprivation
leads to germ cell apoptosis [5] and estradiol increases
germ cell survival [36, 37]. We speculated that BARD1
expression was hormonally regulated because BARD1 mu-
tations are implicated in female gynecological cancers [38,
39] and its expression pattern in ovary and uterine tissue
reflected a hormonal modulation [19]. Here we report hor-
monally regulated transcriptional activation or repression of
BARD1. Interestingly, BARD1 transcription is repressed by
the addition of FSH or FSH and testosterone to isolated
germ cells, but not testosterone alone (Fig. 7A). But either
FSH or testosterone are capable of transcriptional repres-
sion of BARD1 when added in the presence of Sertoli cells.
Sertoli cells can convert testosterone to estradiol in the
presence of FSH, and estradiol is required for progression
of spermatogenesis [40]. Our data therefore suggest that the
repressive effect on BARD1 transcription is due to estradiol
rather than testosterone.
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In pachytene spermatocytes, no effect is observed by
either hormones added, neither directly nor as conditioned
medium of Sertoli cells. In round spermatids, however, a
similar response is observed as in spermatogonia/prelepto-
tene spermatocytes. It is important to emphasize that the
pattern of expression of the two BARD1 splice forms is
influenced by additional factors in vivo (Fig. 2), which are
not reproduced in vitro (Fig. 7). Interestingly, BRCA1 ex-
pression parallels the expression of BARD1. This could be
due to similar transcriptional repression of BRCA1 or to
BARD1 mRNA or protein affecting BRCA1 transcription,
although the latter possibility is unlikely, considering ex-
periments performed with xBARD1 and xBRCA1 [41]. As
expected, the expression of p53 mRNA was only slightly,
if at all, modulated. Our data are consistent with a model
that predicts that BARD1 is repressed by FSH and/or es-
tradiol produced in Sertoli cells but not by testosterone.
BARD1 acts as mediator between paracrine signals and ap-
optosis by transcriptional response to hormone levels, as
increased transcript and protein levels of BARD1 lead to
increased p53 levels and apoptosis [17]. A pathway of
FSH-induced apoptosis to caspase activation and apoptosis
induction has been described previously [34]. This would
mean that cells in contact with Sertoli cells are more prone
to be exposed to the suppressive effect of FSH even in the
presence of testosterone, consistent with survival rather
than apoptosis and consistent with a limited support func-
tion of Sertoli cells.
Although the correlation of BARD1 expression and ap-
optosis in spermatogenesis is intriguing, it remains to be
considered that components of the apoptotic machinery in
male germ cells are required for and activated during sper-
matogenesis without completion of apoptosis, as demon-
strated for Drosophila [28]. Whether similar mechanisms
exist in mammals remains to be determined.
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damage response kinase 
Feki A, Jefford CE, Berardi P, Wu JY, Cartier L, Krause KH, Irminger-Finger I. 
Oncogene. 2005 Mar 14. (In press). 
It was previously shown that BARD1 plays a role in mediating apoptosis, 
independently of BRCA1, but it requires p53 for signalling towards apoptosis. This 
was later confirmed because BARD1-repressed cells exhibit resistance in signalling 
apoptosis. Furthermore, p53 stability and activation requires its phosphorylation on 
serine 15. In order to investigate further the interactions between BARD1 and p53, 
and map the region imputable to this binding ability, we performed co-
immunoprecipitation assays and western blots. In this study we reveal that BARD1 
over-expression may be sufficient to activate p53 phosphorylation on serine 15. We 
identify the region of BARD1 which binds to p53 through a series of co-
immunoprecipitations of deletion mutants fused to EGFP. We can see that even the 
deletion mutants lacking the RING functional domain, which normally binds BARD1 
to BRCA1, are capable of co-immunoprecipitating p53. This results rules out the 
preconception that p53 was co-immunoprecipitated through interaction with BRCA1. 
We show also that BARD1 binds to Ku-70 in co-immunoprecipitation experiments as 
well as phosphorylated p53. These result further points to a role for Ku-70 in 
phosphorylating p53. My involvement consisted in furnishing the various plasmids 
coding for the BARD1-EGFP fusion proteins, immunocytochemistry, co-
immunoprecipitation and western blots appearing in Figures 2 and 3. I also furnished 
some of the data shown in Figure 4 by repeating the experiments in order to confirm 
validity of our results. 
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BARD1 induces apoptosis by catalysing phosphorylation of p53 by
DNA-damage response kinase
Anis Feki1,2, Charles Edward Jefford1, Philip Berardi1,3, Jian-Yu Wu1, Laetitia Cartier1,
Karl-Heinz Krause1 and Irmgard Irminger-Finger*,1
1Biology of Aging Laboratory, Department of Geriatrics, University of Geneva, Chemin de Petit Bel Air 2, CH-1225
Geneva/Cheˆne-Bourg, Switzerland; 2Department of Gynecology and Obstetrics, University Hospital of Geneva, Geneva,
Switzerland; 3Biochemistry and Molecular Biology and Oncology, University of Calgary, Calgary, Canada
The BRCA1-associated RING domain protein BARD1
acts with BRCA1 in double-strand break repair and
ubiquitination. BARD1 plays a role as mediator of apop-
tosis by binding to and stabilizing p53, and BARD1-
repressed cells are resistant to apoptosis. We therefore
investigated the mechanism by which BARD1 induces p53
stability and apoptosis. The apoptotic activity of p53 is
regulated by phosphorylation. We demonstrate that
BARD1 binds to unphosphorylated and serine-15 phos-
phorylated forms of p53 in several cell types and that the
region required for binding comprises the region sufﬁcient
for apoptosis induction. In addition, BARD1 binds to Ku-
70, the regulatory subunit of DNA-PK, suggesting that
the mechanism of p53-induced apoptosis requires BARD1
for the phosphorylation of p53. Upregulation of BARD1
alone is sufﬁcient for stabilization of p53 and phosphor-
ylation on serine-15, as shown in nonmalignant epithelial
cells and ovarian cancer cells, NuTu-19, which are
defective in apoptosis induction and express aberrant
splice variants of BARD1. Stabilization and phosphoryla-
tion of p53 in NuTu-19 cells, as well as apoptosis, can be
induced by the exogenous expression of wild-type
BARD1, suggesting that BARD1, by binding to the
kinase and its substrate, catalyses p53 phosphorylation.
Oncogene advance online publication, 14 March 2005;
doi:10.1038/sj.onc.1208491
Keywords: apoptosis; BARD1; DNA-PK; Ku-70; p53;
phosphorylation
Introduction
Apoptosis is an important means of eliminating
dangerously damaged cells. Cancer cells have developed
strategies to escape apoptosis and consequently become
resistant to apoptosis inducing treatments. Along this
line, the tumor suppressor p53, a key element in the
apoptosis response pathway, is mutated in more than
50% of tumors. Several signaling pathways converge on
the activation of p53, which leads either to cell cycle
arrest and DNA repair or senescence, or apoptosis
(Levine, 1997). P53 activation and stabilization depend
on its phosphorylation at multiple sites, by a number of
kinases (Meek, 1994; Milczarek et al., 1997). Phosphor-
ylation at serines 6 and 9 by casein kinase 1-delta and
casein kinase 1-epsilon occurs both in vitro and in
vivo (Knippschild et al., 1997; Kohn, 1999), the
checkpoint kinases Chk1 and Chk2 phosphorylation at
serine 20 enhances its tetramerization, stability, and
activity (Shieh et al., 1999; Hirao et al., 2000).
Phosphorylation of p53 at serine-392 is observed in
vitro by CDK-activating kinase (CAK) (Lu et al., 1997)
and in vivo (Hao et al., 1996; Lu et al., 1997), but is
altered in human tumors. Serine-392 phosphorylation
has been reported to inﬂuence the growth suppressor
function, DNA binding, and transcription activation of
p53 (Hao et al., 1996; Lohrum and Scheidtmann, 1996;
Lu et al., 1997; Kohn, 1999). Phosphorylation of p53 at
serine-46 is important for regulating its ability to induce
apoptosis (Oda et al., 2000). However, the rapid
response to DNA damage is induced by phosphoryla-
tion of p53 at serines 15, 20, and 37 and leads to reduced
interaction of p53 with its negative regulator, oncopro-
tein MDM2 (Shieh et al., 1997).
Known kinases for the DNA damage response are
ATM, ATR, and DNA-PK, which can phosphorylate
p53 at serines 15 and 37 (Shieh et al., 1997; Tibbetts
et al., 1999). These phosphorylation events impair the
ability of MDM2 to bind p53, promoting both the
accumulation and functional activation of p53 in
response to DNA damage (Shieh et al., 1997; Tibbetts
et al., 1999). MDM2 acts as inhibitor of p53 function by
targeting it for ubiquitination and proteasomal degra-
dation (Honda et al., 1997; Chehab et al., 1999).
The tumor suppressor BRCA1 Associated Ring
Domain protein (BARD1) can act as a mediator
between genotoxic stress and apoptosis by binding to
and stabilizing p53 (Irminger-Finger et al., 2001;
Irminger-Finger and Leung, 2002). BARD1 is the major
protein-binding partner of BRCA1 (Wu et al., 1996)
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and the BARD1/BRCA1 heterodimer has functions in
DNA repair (Jin et al., 1997; Scully et al., 1997) and
ubiquitination (Baer and Ludwig, 2002). Both proteins
are homologous within their RING domains and two
BRCT domains. The BRCT domains of BRCA1 have
recently been characterized as modules for kinase and
target interaction (Manke et al., 2003; Yu et al., 2003)
and a role of BARD1–BRCA1 complexes in signaling
from DNA damage to p53 phosphorylation has been
described recently (Fabbro et al., 2004).
The repression of BARD1 expression in vitro results
in genomic instability and cellular changes suggestive
of a premalignant phenotype (Irminger-Finger et al.,
1998) and resistance to apoptosis (Irminger-Finger et al.,
2001). Similarly, BARD1, as well as BRCA1, knockout
cells exhibit high levels of genomic instability (Joukov
et al., 2001; Ludwig et al., 2001; McCarthy et al., 2003).
However, excess of BARD1 over BRCA1 results in
apoptosis independently of BRCA1 (Irminger-Finger
et al., 2001). Interestingly, the expression of BARD1,
but not BRCA1, is hormonally controlled in uterine
tissue (Irminger-Finger et al., 1998), suggesting a role
in tissue homeostasis. Further evidence for a role of
BARD1 in tumor suppression is presented by BARD1
mutations found in breast, ovarian, and most intrigu-
ingly in endometrial tumors (Thai et al., 1998; Hashi-
zume et al., 2001; Ghimenti et al., 2002; Ishitobi et al.,
2003). In contrast, BRCA1 mutations have not been
found in uterine cancers, supporting a BRCA1-
independent role of BARD1 in tumor suppression
by apoptosis induction (Irminger-Finger and Leung,
2002).
To further elucidate the mechanism by which BARD1
induces apoptosis, we investigated its possible function
in the regulation of p53 phosphorylation required for
apoptosis (Lakin and Jackson, 1999).
Here we report that BARD1 is involved in p53ser15
phosphorylation and BARD1 overexpression is sufﬁ-
cient for this phosphorylation. We identiﬁed a cancer cell
line which is resistant to apoptosis and deﬁcient in
p53ser15 phosphorylation in response to genotoxic stress.
Indeed, BARD1 is mutated and deleted in this cell line
and exogenous expression can restore p53ser15 phosphory-
lation and apoptosis.
Results
Given the role of BARD1 in p53 stabilization, we
investigated its expression in relation to p53 in various
cell types. In nonmalignant mammary gland cells, TAC-
2, treatment with the apoptosis-inducing drug doxo-
rubicin resulted in the upregulation of BARD1 and
accumulation of the p53 protein, as shown previously
(Irminger-Finger et al., 2001). Simultaneously to the
increase of BARD1 and p53 protein levels upon
genotoxic stress, the accumulation of phosphorylated
p53ser15 was observed when phospho-epitope-speciﬁc
antibodies against phospho-p53ser15 were used on Wes-
tern blots (Figure 1a). This is consistent with the
reported stabilization of p53 by phosphorylation upon
stress induction (Shieh et al., 1997). Phosphorylation of
serines 15, 20, and 37 is essential for p53 function during
apoptosis (Shieh et al., 1997; Tibbetts et al., 1999). Since
serine 15, but not serines 20 and 37, is conserved
between human, mouse, and rat p53, we determined
whether this site was implicated in the resistance to
apoptosis in cancer cells.
Figure 1 p53 and phospho-p53 expression correlated with
BARD1 expression. (a) Doxorubicin treatment of TAC-2 cells
induces BARD1, p53 and phospho-p53 (p-p53). Western blots were
performed with respective antibodies on cell extracts treated with
doxorubicin for various intervals. (b) BARD1 is expressed in TAC-
2 but not NuTu-19 cells after treatment with doxorubicin.
Correlated expression of p53 and phospho-p53 is shown. (c)
Exogenous expression of BARD1 restores p53 expression and
phosphorylation. HEK 293T cells with constitutive expression of
p53 and NuTu-19 cells were transduced with lentiviral vector
expressing BARD1. The membranes were probed with anti-actin as
loading control
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We ﬁrst compared the effect of doxorubicin treatment
applied to TAC-2 cells and to highly malignant rat
ovarian cancer cells, NuTu-19 (Rose et al., 1996).
NuTu-19 lack the full-length BARD1 protein and
showed only a slight upregulation of p53, as compared
to TAC-2 cells (Figure 1b). Most importantly, no trace
of phospho-p53 could be detected in doxorubicin-
treated NuTu-19 cells, while phospho-p53 was readily
detectable in TAC-2 cells.
Since overexpression of BARD1 by itself can lead to
p53 stabilization and apoptosis (Irminger-Finger et al.,
2001), we tested the effect of BARD1 expression on
p53 phosphorylation. HEK 293T cells were used and
compared to malignant NuTu-19 cells, since both cell
types showed similar transduction efﬁciency with
lentiviral vectors. Transduction of HEK 293T and
NuTu-19 cells with wild-type BARD1, under the control
of the EF1-alpha promotor, resulted in increased
expression of BARD1 in HEK 293T cells and expression
of exogenous BARD1 in NuTu-19 cells. An increase of
total p53 in HEK 293T cells, and less pronounced in
NuTu-19 cells, was observed. Phosphorylation of p53
p53ser15 was observed in HEK 293T cells and NuTu-19
cells after exogenous expression of BARD1 (Figure 1c).
These data indicate that upregulation of BARD1
protein is sufﬁcient for p53 upregulation and phosphory-
lation, suggesting that the function of BARD1 in p53
stabilization involves phosphorylation of p53 at the key
residue serine-15 and that increased BARD1 protein
levels can induce this post-translational modiﬁcation.
To investigate whether BARD1 and p53 or phospho-
p53 physically interact, we used HEK 293T cells trans-
fected with a cDNA expression vector of a BARD1–
EGFP fusion construct expressed from the CMV
promoter (Jefford et al., 2004). Immunoﬂuorescence
microscopy was performed to visualize BARD1–EGFP,
p53, and phospho-p53ser15 with speciﬁc antibodies. When
antibodies recognizing total p53 were used, we observed
that all cells expressed p53 independently of BARD1–
EGFP expression, whereas some accumulation of p53 in
nuclear dots was correlated with BARD1–EGFP
expression (Figure 2a). Using p53 antibodies speciﬁc
for phospho-serine-15, no staining was observed in
untransfected HEK 293T cells, while phospho-p53 was
expressed in BARD1–EGFP-positive cells, and
BARD1–EGFP and phospho-p53ser15 co-localized in
nuclear dots (Figure 2a). Comparison of p53 and
phospho-p53ser15 in nontransfected cells and in
Figure 2 BARD1 co-localizes with phospho-p53. (a) HEK293T cells nontransfected or transfected with BARD1–EGFP expression
vector were used for immunoﬂuorescence microscopy. DAPI staining, BARD1–EGFP ﬂuorescence, anti-p53, and anti-phospho-p53
staining are shown. Arrowheads mark cells with high BARD1–EGFP content, arrows mark those with moderated BARD1–EGFP
expression. Merge shows colocalization (arrow) of BARD1–EGFP and phospho-p53. (b) The histogram demonstrates BARD1, p53,
and phospho-p53 expression in nontransduced and BARD1-transduced cells, derived from three independent transduction
experiments
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BARD1–EGFP-expressing cells clearly shows that
phospho-p53 is only present in BARD1–EGFP expres-
sing cells, and the amount of phospho-p53 labeling is
correlated with the level of BARD1–EGFP expression.
The quantitative analysis of BARD1–EGFP and phos-
pho-p53ser15 expression shows similar percentage of
BARD1- and phospho-p53ser15-positive cells (Figure 2b).
These results are consistent with the observation that
overexpression of BARD1 can induce p53 phosphoryla-
tion (Figure 1c).
We have previously shown that BARD1 binds to p53
in co-immunoprecipitation assays (Irminger-Finger
et al., 2001). To test BARD1 binding to phospho-p53,
immunoprecipitation experiments were performed with
cell extracts from HEK 293T, TAC-2, and NuTu-19
cells, using a C-terminal BARD1 antibody (Figure 3a).
To obtain increased protein levels of BARD1 and
p53, HEK 293T and NuTu-19 cells were transduced
with BARD1-expressing lentiviral vector, and TAC-2
cells were treated with doxorubicin. To quantify the
transduction efﬁciency, control transductions were
performed using a GFP-expressing lentiviral vector. As
shown previously (Irminger-Finger et al., 2001), the
increase of BARD1 was associated with the increase of
p53 expression as compared to control transduction.
Moreover, p53 and phospho p53ser-15 levels were elevated
in doxorubicin-treated TAC-2 cells and in BARD1-
transduced HEK 293T and NuTu-19 cells. BARD1
antibodies co-immunoprecipitated p53 and phospho
p53ser-15 in all cell types. Phospho-p53ser-15 was co-
Figure 3 BARD1 interacts with p53 and with phospho-p53. (a) Co-immunoprecipitations were performed with HEK 293T, NuTu-19,
and TAC-2 cells, using anti-BARD1 antibody C-20. TAC-2 cells, with or without doxorubicin treatment, and HEK293T and NuTu-
19, nontransduced or transduced with BARD1 expression vector, were compared. Western blots were probed with anti-p53 antibodies
or anti-phospho epitope serine-15 antibodies. The left panel shows control immunoprecipitation supernatants, the right panel shows
pellets. (b) BARD1 stabilizes wild-type (wt) and triple mutant 33-81-315 (tri), but not p53 mutants of ser15 or ser37. Prostate cancer
cells PC3, deﬁcient of p53 (Honda et al., 2002), were transfected (þ ) or not transfected () with BARD1 and cotransfected with p53 or
p53 mutants. Western blots of cell extracts were probed with anti-p53 antibodies. (c) Region sufﬁcient for p53 binding includes ANK
and the region between ANK and BRCT. EGFP-tagged BARD1 and deletion constructs, and EGFP alone, were transiently
transfected. Immunoprecipitation was performed with anti-p53 antibodies and Western blots were probed with anti-GFP antibodies.
The supernatant (S) and pellet (P) fractions show the fractions of the respective fusion proteins. (d) Schematic diagram of BARD1
protein sequence and deletion-bearing fusion constructs is presented. Percentage of p53 binding, determined by gel intensity scan, and
capacity of apoptosis induction reported previously, (Jefford et al., 2004), are indicated. Arrows above the protein scheme indicate
relative positions of tumor-associated mutations (Thai et al., 1998; Ghimenti et al., 2002; Karppinen et al., 2004)
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immunoprecipitated with BARD1 as efﬁciently as p53,
albeit the amounts of p53 and phospho-p53ser-15 were
reduced in NuTu-19 as compared to TAC-2 and HEK
293T cells. These results indicate that BARD1 interacts
with p53 and with phospho-p53ser-15 in different cell
types and cells from different species.
To further investigate the speciﬁcity of BARD1-
dependent p53ser15 phosphorylation, we tested the
mutated forms of p53. Cotransfection assays were per-
formed in p53-deﬁcient human prostate cancer cells PC3
(Honda et al., 2002). No p53 can be detected in PC3 cells
without exogenous p53 expression, also ser15 and ser37
mutants do not express detectable amounts of protein
after transfection. Triple mutant 33-81-315, however, is
stable (Zacchi et al., 2002). BARD1 cotransfection leads
to an increase of wild-type p53 and of the triple mutant,
but had no effect on p53 mutated at ser15 and ser37
(Figure 3b).
The interaction of BARD1 and p53 was also tested
with BARD1–EGFP fusion constructs, using antibodies
against p53 to co-immunoprecipitate BARD1–EGFP,
which was assayed with anti-EGFP antibodies on
Western blots (Figure 3c). To determine the speciﬁc
region of BARD1 required for this interaction, BARD1-
EGFP deletion constructs were used in transfection
assays followed by immunprecipitations with anti-p53
antibodies. Interestingly, all deletion constructs co-
immunoprecipitated with anti-p53 except RING-EGFP,
which represents the amino-terminal 89 amino acids of
BARD1 (Figure 3c, d). The minimal region required for
binding to p53 was deletion construct ANK-EGFP,
which was previously identiﬁed as the minimal region
sufﬁcient for apoptosis induction (Jefford et al., 2004).
This ﬁnding suggests that the molecular pathway of
BARD1 signaling towards apoptosis is based on its role
in p53 stabilization by phosphorylation.
Since p53 phosphorylation on serine 15 can be
induced by overexpression of BARD1, it was tempting
to speculate that BARD1 might act as a mediator
between p53 and its speciﬁc kinase. Phosphorylation of
p53ser-15 and p53ser-37 is required for p53 stabilization and
for p53-dependent response to genotoxic stress (Shieh
et al., 1997; Tibbetts et al., 1999; Jack et al., 2004).
A role of BARD1–BRCA1 complexes in phosphoryla-
tion of p53ser-15 in an ATM/ATR pathway has been
described recently (Fabbro et al., 2004). We suspected
that DNA-PK kinase might be responsible for p53ser-15
phosphorylation in a BARD1-dependent pathway, since
DNA-PK can phosphorylate p53ser-15 upon genotoxic
stress (Woo et al., 1998, 2002) and DNA-PK and
Ku-70, the active subunit of DNA-PK, are upregulated
in ATM/ATR-dependent stress response (Brown et al.,
2000; Shangary et al., 2000). Most recently, it was found
that Ku-70 mutation partially suppresses the homo-
logous-repair defects of BARD1 disruption (Stark et al.,
2004), suggesting that both act in a common pathway.
We performed co-immunoprecipitation assays with
anti-p53 antibodies, anti-Ku-70, the active subunit of
DNA-PK, or anti-BARD1 antibodies to investigate the
interactions between DNA-PK, p53, and BARD1
(Figure 4a). Immunoprecipitation assays, when per-
formed on lysates from HEK 293T cells, or HEK 293T
cells transduced with BARD1–EGFP, revealed that
BARD1 and p53 were co-immunoprecipitated with Ku-
70. When anti-p53 antibodies were used to precipitate
p53 or interacting proteins, p53 immunoprecipitation
was nearly 100%, as was BARD1 co-immunoprecipita-
tion with anti-Ku-70 antibodies (Figure 4a).
We were interested whether NuTu-19 cells expressed
Ku-70 and immunoprecipitation experiments were
performed with untransfected and BARD1-transfected
NuTu-19 cells (Figure 4b). Only exogenous BARD1
could accumulate detectable amounts of Ku-70 in im-
munoprecipitation. No precipitation was observed when
BARD1 antibodies were omitted.
As further evidence for the implication of DNA-PK, a
member of the phosphoinositide 3-kinase related kinase
(PIKK) family, in phosphorylation of p53 and inter-
action with BARD1, we treated cells with caffeine and
doxorubicin. Caffeine is a well-known inhibitor of
PIKK kinase activity and as a result can effectively
inhibit the phosphorylation of p53ser-15. Doxorubicin on
the other hand induces genotoxic stress on cells,
consequently resulting in phosphorylation of p53 on
the same residues inhibited by caffeine. After treatment
of HEK 293T cells with 50mM caffeine alone, we
observed a slight elevation in p53 levels as compared to
untreated cells; however, there was no change in the
phospho-p53 levels (Figure 4c). Doxorubicin treatment
induces the expression of both p53 and BARD1, as
described previously (Irminger-Finger et al., 2001;
Jefford et al., 2004). Since HEK 293T cells have
constitutive p53 expression, no signiﬁcant changes in
p53 levels with or without genotoxic stress were
observed. We did not observe substantial increase in
phospho-p53 protein levels co-immunoprecipitating
with BARD1 when treated with caffeine, but when
treated with doxorubicin. The combined treatment with
caffeine and doxorubicin resulted in decreased phospho-
p53 levels in both the supernatant and pellet fractions of
the BARD1 immunocomplexes (Figure 4c). This result
provides further evidence that p53 is phosphorylated by
a PIKK family member and that this reaction might be
catalysed by the presence of BARD1, since BARD1
immunocomplexes contain both phosphorylated and
unphosphorylated species of p53. The same immuno-
precipitation extracts were probed with anti-ATM
antibodies and no binding of ATM to BARD1 could
be observed (Figure 4c), thus supporting that DNA-PK
rather than ATM is responsible for BARD1-dependent
p53ser-15 phosphorylation.
While p53 phosphorylation was induced in several cell
types by exogenous expression of BARD1, this effect
was most striking in malignant ovarian cancer cells
NuTu-19. NuTu-19 cells were generated by continuous
in vitro culture of ovarian epithelial cells leading to
spontaneous malignant transformation (Rose et al.,
1996). These cells lack full-length BARD1 protein
(Figure 1b, c). Cloning and sequencing of the BARD1
mRNAs expressed in NuTu-19 cells revealed that none
of the cDNAs encoded a full-length BARD1 gene
(Figure 5a, c, d). The cDNA corresponding to the 2.2 kb
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wild-type BARD1 transcript contained point mutations
leading to a premature translation stop at position 1786
between the ankyrin repeats (ANK) and the BRCT
domains (Figure 5a). A smaller 2 kb fragment was due
to deletion of exons 2 and 3. This mRNA species, herein
designated BARD1g, was similar to the testis-speciﬁc
mRNA BARD1b (Feki et al., 2004). This ﬁnding was
corroborated by Western blots performed with three
different previously characterized anti-BARD1 antibo-
dies (Feki et al., 2004), which showed that full-length
BARD1 protein is absent in NuTu-19 cells (Figure 5b).
HEK 293T expressed a 94-kDa protein, detectable with
N-terminal antibodies H-300 and PVC, directed against
the region adjacent to the RING ﬁnger, and JH3,
directed against the regions between ANK and BRCT.
None of the antibodies tested recognized a protein
fragment corresponding to the molecular weight of full-
length BARD1 in NuTu-19 cell extracts. Consistently,
the most abundant transcript of BARD1 in NuTu-19
cells was an 800 bp RT–PCR product, a novel splice
variant, hitherto named BARD1d. BARD1d lacks exons
2–7, which include regions coding for the RING ﬁnger
and the ankyrin repeats (Figure 5c, d). Therefore,
NuTu-19 cells do not express full-length BARD1
molecules and none of the BARD1 transcripts encode
ANK repeats and the region between ANK and BRCT.
Interestingly, nucleotides 1618–1641 represent an
inverted repeat of region 804–826, which could act as
antisense to abrogate the translation of BARD1, but not
BARD1d transcripts. Mutations and deletions in the
BARD1 coding region were in strong contrast to the
status of p53. Cloning and sequencing of the p53 cDNA
from NuTu-19 cells revealed two polymorphisms, S66P
and L192F, within the less conserved domains of p53,
but no mutations that predict structural changes of the
encoded protein.
We had evaluated the apoptotic activity of NuTu-19
cells after treatment with UV or doxorubicin. NuTu-19
cells show little response to apoptosis-inducing drugs
as measured by FACS and TUNEL assays. Doxorubi-
cin treatment resulted in no signiﬁcant increase of
apoptotic cells as observed after TUNEL or 7AAD
staining and ﬂow cytometry analysis (Figure 6a). How-
ever, when we overexpressed wild-type BARD1 by
Figure 4 BARD1 interaction with p53 and DNA-PK subunit Ku-70. (a) HEK293T (293T) nontransduced or transduced with
BARD1 were used for immunoprecipitation assays with Ku-70, p53, and BARD1 antibodies. Supernatants (S) and pellet (P) fractions
are shown. (b) NuTu-19 cells nontransduced or transduced with BARD1 were used to demonstrate BARD1–Ku-70 interaction. Little
co-precipitation is observed in the absence of exogenous BARD1. Control experiment without antibodies shows no precipitation
(beads). (c) P53 phosphorylation is induced (doxo) or inhibited (caffeine). Immunoprecipitation performed with BARD1 antibody C-
20 to show interaction between BARD1, phospho-p53, p53, and ATM. Supernatants (S) and pellet (P) fractions are shown
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transient transfection, apoptosis was induced to a
similar extent in NuTu-19 cells as in nonmalignant
control cells, TAC-2. We also transduced NuTu-19 cells
with wild-type BARD1 cloned into a lentiviral vector
under the transcriptional control of a tetracycline-
inducible promoter. Induction of BARD1 by increasing
Figure 5 NuTu-19 cells lack full-length BARD1. (a) RT–PCR of p53 and BARD1 transcripts from NuTu-19 and control RT–PCR
from TAC-2 cells. (b) Western blot of HEK 293T and NuTu-19 cells probed with anti-BARD1 antibodies H-300, PVC, and JH-3.
Expression of full-length 97 kDa BARD1 is observed in HEK 293T but not in NuTu-19 cells. (c) Schematic presentation of BARD1
protein with conserved regions RING, ankyrin (ANK) and BRCT, and epitopes for antibodies H-300, PVC, and JH-3 (l signs),
aligned with RT–PCR products BARD1g and BARD1d. Triangles above indicate position of introns. Small arrows on BARD1g and
BARD1d indicate position of inverted repeats. (d) Comparison of the deduced protein sequence of rat BARD1 with isoforms
BARD1a, BARD1g, and BARD1d. Positions of point mutations leading to translation stop in BARD1a are indicated by asterisks,
polymorphisms are in black. Boxed sequences indicate RING ﬁnger, ANK, and BRCT, respectively
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doxycyclin levels clearly resulted in apoptosis in a dose-
dependent manner (Figure 6b). However, BARD1
expression and apoptosis in response to doxorubicin in
nontransduced NuTu-19 cells was comparable to back-
ground levels of apoptosis induction in BARD1-
transduced cells without induction of gene expression
by doxycyclin.
Similarly, we tested p53-phosphorylation on p53ser15
as dose response to BARD1 expression levels in NuTu-
19 cells. Nontransduced cells and cells transduced with
increasing amounts of BARD1 expression vectors were
compared on Western blots. Phospho-p53ser15 increase
was observed in a dose-dependent manner on Western
blots probed with antibodies against phospho-p53ser15
(Figure 6c).
This experiment proved that expression of wild-type
BARD1 could reverse apoptosis resistance in cells
lacking full-length BARD1. In nonmalignant cells with
endogenous wild-type BARD1, overexpression of exo-
genous BARD1 is sufﬁcient to stabilize p53 and to
induce p53ser-15 phosphorylation. In BARD1-deﬁcient
NuTu-19 cells, phosphorylation of p53 cannot be
induced by apoptosis-inducing drugs, but by the
exogenous expression of wild BARD1, without other
stress signals, suggesting that BARD1 facilitates the
phosphorylation of p53 by binding to p53 and Ku-70,
the subunit of DNA-PK, and that this is sufﬁcient and
required for apoptosis induction.
Discussion
In the present study we demonstrate that BARD1 plays
a critical role in phosphorylation of p53, which is
required for its apoptotic function. Several kinases
Figure 6 Expression of BARD1 reverses apoptosis resistance in NuTu-19 cells. (a) TUNEL assay on NuTu-19 ovarian cancer cells or
nonmalignant TAC-2 cells with or without treatment with doxorubicin (doxo) or transfection of BARD1. Percentage of TUNEL-
positive cells was quantiﬁed by ﬂow cytometry. (b) NuTu-19 cells and NuTu-19 transduced with lentiviral vector containing BARD1
were monitored for apoptosis. Cells were incubated with or without doxycyclin to induce BARD1 expression, or with doxorubicin
(doxo). (c) Dose response of BARD1-induced phosphorylation is observed after transduction of NuTu-19 cells with BARD1.
Nontransduced (0), transduced (1 ), or transduced with threefold (3 ) concentration of BARD1 expression viral vector, cells were
probed on Western blot with anti-phospho-ser15 p53-speciﬁc antibody
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involved in p53 activation have been reported (Lu et al.,
1997; Shieh et al., 1997, 1999; Tibbetts et al., 1999;
Hirao et al., 2000) and ATM/ATR-dependent phos-
phorylation of p53ser-15, implicating BRCA1–BARD1
complexes, has been described very recently (Fabbro
et al., 2004).
It was shown before that BRCT domains, a protein
motif also present in BARD1 and BRCA1, have
phospho-epitope-binding capacities (Rodriguez et al.,
2003). A phospho-epitope-binding function was re-
ported speciﬁcally for BRCT domains of BRCA1.
BRCT domains are present in many other repair
proteins and seem to facilitate physical interactions
among proteins involved in the cellular response to
DNA damage check point control and DNA repair
(Bork et al., 1997; Callebaut and Mornon, 1997). It is
speculated that BRCT domains are important modules
for tumor suppressor functions, supported by cancer-
associated mutations within the BRCT domain of
BRCA1 (Williams et al., 2001).
BARD1 contains tandem BRCT motifs, it has tumor
suppressor functions (Irminger-Finger and Leung,
2002), and it binds and stabilizes p53 (Irminger-Finger
et al., 2001) which is suggestive of a role in a pathway of
p53 phosphorylation. Here we show that, indeed,
BARD1 binds to p53 and phospho-p53 and, secondly,
BARD1 interacts with the DNA-PK subunit, Ku-70,
but not ATM. The region sufﬁcient for p53 interaction
and apoptosis induction comprises ANK, the region
between ANK and BRCT, and part of the BRCT
domains. It is possible that the BRCT domains are
binding to the kinase and that its target is binding to the
adjacent region.
Ku-70 is abundantly expressed in HEK 293T cells, as
is p53, as compared to BARD1. Nevertheless, over-
expression of BARD1, without an additional stimulus
through DNA damage, causes p53 phosphorylation in
HEK 293T cells and NuTu-19 cells, suggesting that
BARD1 is an essential and limiting partner for the
formation of the p53–DNA–PK complex. Consistent
with this view, BARD1 co-localizes with phospho-p53 in
distinct nuclear dots (Figure 5b). Since overexpression
of BARD1 is sufﬁcient for p53ser15 phosphorylation,
binding of BARD1 to the kinase and its target catalyses
p53 phosphorylation.
Supporting this view, several cancer-associated mis-
sense mutations (Thai et al., 1998; Ghimenti et al., 2002;
Ishitobi et al., 2003), map to the region deﬁned sufﬁcient
for p53 binding and apoptosis induction, and it is
deleted or mutated in the NuTu-19 cells, described here.
It is likely that BARD1 deﬁciencies are frequent in
cancer cells that have wild-type p53 but are resistant to
apoptosis, and signiﬁcant changes in BARD1 expression
have been found associated with malignancies (Pomeroy
et al., 2002; Iyengar et al., 2003; Schafer et al., 2003;
Zuco et al., 2003). The NuTu-19 ovarian cancer cells,
to some extent, are a model of ovarian cancer, which
suggests that BARD1 is a key target for mutations
leading to carcinogenesis. NuTu-19 cells are derived
from a spontaneous transformation of continuously
cultured ovarian epithelial cells (Rose et al., 1996),
suggesting that few genetic modiﬁcations led to
the phenotype of resistance to undergo apoptosis.
This process mimics the in vivo situation, as it has
been hypothesized that proliferation associated with
ovarian repair contributes to the risk of ovarian cancer
in humans (Fathalla, 1972). We speculated and conﬁrmed
here that one of the critical mutations for malignant
transformation involves the tumor suppressor BARD1.
Indeed, rat ovarian cancer cells, NuTu-19, have
applied several strategies to eliminate the expression of
functional BARD1: mutations leading to a truncated
form of the protein, differential splicing leading to the
deletion of essential parts of the protein, and possibly
repression of the partially active forms of the protein by
expression of a short inverse repeat sequence that could
function as antisense RNA in transcriptional repression
of wild-type forms of BARD1. These mechanisms of
inhibition of BARD1 function are consistent with the
hypothesis that BARD1 is an essential tumor suppres-
sor, critical for apoptosis induction upon damage, by
stabilizing p53 (Irminger-Finger et al., 2001). BARD1
binding to p53 could also inﬂuence p53 stability by
inhibiting its ubiquitination and/or its binding to
MDM2 (Meek, 1994; Honda et al., 1997; Milczarek
et al., 1997).
Consistently, no phosphorylation of p53 is observed in
NuTu-19 cells in the absence of exogenous expression of
wild-type BARD1. Co-immunoprecipitation experiments
suggest that BARD1 binds both the kinase and its
respective target p53 and catalyses its phosphory-
lation. This could be explained mechanistically by a
higher afﬁnity between BARD1 and Ku-70 and between
BARD1 and p53 than between p53 and Ku-70. Our data
support this view, since co-immunoprecipitations of
BARD1 and p53 or BARD1 and Ku-70 are more
efﬁcient than co-immunoprecipitations of p53 and Ku-
70. In addition, BARD1 protein levels are considerably
lower in the cell than either p53 or Ku-70, therefore
BARD1 can be regarded as the critical and limiting
factor in the formation of the p53/Ku-70 complexes.
Furthermore, the overexpression of BARD1 alone with-
out induction of the DNA damage pathway is sufﬁcient
for p53 phosphorylation and supports the view that
BARD1 catalyses p53 phosphorylation by DNA-PK.
Materials and methods
Cell cultures
The HEK 293T cell line, as well as HeLa cells, were obtained
from the ATCC. NuTu-19 cells (Rose et al., 1996) were a
generous gift from Dr Attila Major, Geneva, PC3, human
prostate cancer cells, were obtained from Dr Timothy
MacDonnell, Houston. All cell lines were cultured in 10 cm
plastic tissue culture dishes (NUNC, Roskilde, Denmark) and
incubated at 371C in humidiﬁed air containing 5% CO2.
Adherent subcultures were detached from culture dishes using
a solution of Trypsin/EDTA in HBSS without Ca2þ or Mg2þ .
Subconﬂuent cell cultures were passaged regularly at 1 : 10
dilution approximately twice a week. All cell culture media,
solutions, buffers, and antibiotics were purchased from
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GIBCO (Invitrogen AG, Basel, Switzerland). HEK 293T cells
were pretreated for 1 h with 50mM caffeine, after which they
were either treated with doxorubicin (50 mg/ml) or left
untreated as described previously (Irminger-Finger et al.,
1998).
Western blotting
For Western blots, protein extracts from cell cultures were
prepared in standard lysis buffer (150mM NaCl, 0.1% SDS,
50mM Tris (pH 8.0)). Equal concentrations of all whole cell
extracts per gel were loaded onto SDS–PAA gels according to
Laemmli’s protocol and were transferred to polyvinylidene
ﬂuoride (PVDF) membranes. Filters were blocked for 1 h in
PBS containing 5% non-fat milk and then incubated at room
temperature for 2 h with a polyclonal BARD1 (Irminger-
Finger et al., 1998), p53 and P-p53 (Santa Cruz) antibodies.
After washing, membranes were incubated with horseradish
peroxidase-conjugated secondary antibody and the resulting
complexes were visualized by an enhanced chemiluminescence
(ECL) system (Boehringer).
Immunoprecipitation
Immunoprecipitation was performed by homogenizing cell
samples in 100 ml (100–150 mg total protein) RIPA buffer
(150mM NaCl, 1% NP-40, 0.5% NaDOC, 0.1 SDS, 50mM
Tris (pH 8.0), and 2mM EDTA (pH 8.0)). Cells extracts were
incubated with p53 antibody (FL-393 Santa Cruz), or GFP
antibody (Torrey Pines Biolabs, Inc) in a 1 : 200 dilution over
night, followed by incubation with sepharose-bound protein G
for 3 h. Extracts were centrifuged, and pellets were washed
twice with RIPA buffer and re-suspended in 100ml RIPA
buffer. In all, 25ml of supernatant and pellet fractions was
analysed by Western blotting. Total protein content in
supernatant and pellet fractions was compared by fast green
staining after protein transfer and was 90–10% at least.
Antibody reactive bands were visualized, scanned, and
quantiﬁed using Imagequant.
Antibodies
The anti-BARD1 (H300), anti-p53 (FL-393), and anti-
phospho p53 ser15 antibodies (Cell Signaling 5284) were
purchased from Santa Cruz. Anti-GFP (TP-401) was pur-
chased from Chemokine (Torrey Pines Biolabs, Houston, TX,
USA). WFS is a previously described anti-BARD1 antibody
(Gautier et al., 2000). Horseradish peroxidase (HRP)-con-
jugated secondary antibodies were purchased from Santa Cruz
and were compatible with Cruz Molecular Weight Markers
(Santa Cruz, CA, USA).
RT–PCR
Total RNA was puriﬁed from NuTu-19 cells using Qiagen
reagent. RNA was reverse transcribed using oligo-dT and
superscript II (Life Technologies). RT products were subjected
to PCR analysis using speciﬁc primers for rat BARD1 cDNA
(covering BARD1 coding regions) and rat p53 (covering p53
coding regions). PCR cycles were: 941C for 15min, 941C for
1min, 561C for 1min, 721C for 2min 30 s for BARD1 and
1min 30 s for p53 (35 ), then 721C for 10min. Equal volumes
of PCR products were analysed on 1% agarose gel.
Lentiviral vector production and transduction
The packaging constructs used in this study were the
pCMVDR8.92 and the pCMVDR8.93 plasmids described
previously (Dull et al., 1998). The vesicular stomatitis virus
G (VSV-G) envelop was the pM2DG plasmid (Zufferey et al.,
1997). The BARD1 coding sequence was cloned into the
carrier pLOXEW plasmid (Zufferey et al., 1997). The viral
particles were produced using the usual transient transfection
method (Zufferey et al., 1997). The 293T cells (2.8 106 cells in
10-cm tissue culture dishes) were co-transfected with either
10 mg of pLOXEW-BARD1 ires-GFP, 3.75mg of
pCMVDR8.92, 3.75 mg of pCMVDR8.93, and 2.5mg of
pM2DG, or 10mg of pHR0-CMV-BARD1, 3.75mg of
pCMVDR8.92, 3.75 mg of pCMVDR8.93, and 2.5mg of
pM2DG.
After an overnight incubation in the presence of the
precipitate, the culture medium (10ml) was changed. Two
days later, the supernatant was harvested, ﬁltered through
0.45-mm pore-sized polyethersulfone membrane and subse-
quently 1ml of each was added to NuTu-19 target cells in six-
well plates (104 cells/well). Vector particles were left on the cells
for 3 days. Transduction efﬁciency was monitored using a
GFP-expressing vector.
Plasmid constructions and transfection
Different BARD1 mutants fused with GFP, was described
previously, were used. Brieﬂy, the full-length mouse BARD1
cDNA (Irminger-Finger et al., 1998) was used to generate the
deletion constructs in pcDNA3 behind a CMV promoter. The
plasmid pEGFP-N1 (enhanced green ﬂuorescent protein) was
purchased from Clontech and was used to generate either the
full-length BARD1–EGFP or BARD1 deletion-bearing mu-
tants fused in-frame with the EGFP tag. The deletion-bearing
constructs were the same as described (Jefford et al., 2004).
HEK293T cells were seeded in 10 cm petri dishes and
transfected with 2 mg of DNA using the Effectene reagents
from Qiagen. Cells were harvested 48 h post-transfection.
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5.  BARD1 interacts with BRCA2 to regulate cytokinesis and maintain 
genomic stability 
Jefford CE, Delaval B, Ryser S, Birnbaum D, Irminger-Finger I. 
BRCA1, BRCA2 and BARD1 are caretaker proteins and bona fide tumour 
suppressors since mutation in either of these genes is sufficient for tumour initiation. 
Furthermore, a knockout of either of the aforementioned gene in mice induces early 
embryonic death due to proliferation defects and not to apoptosis. Tumour cells with 
mutated BRCA1, BRCA2 or BARD1 exhibit definite chromosomal instability; 
repression of either of these genes in cultured cells by knockdown experiments 
causes genomic instability, the hallmark of all tumour cells. In this study we 
investigate further the mechanisms that link BARD1-mediated tumour suppression 
and maintenance of genomic stability. It was shown by us and others that BARD1 
expression is not only augmented upon genotoxic stress, but is also regulated during 
cell cycle. Here, we show by antibody staining that BARD1 is highly expressed 
during mitosis in several cell lines and it co-localizes with microtubule spindle. We 
showed that this staining is specific since the polyclonal antibody used recognizes 
the BARD1-EGFP constructs with the N-terminal domain and not the RING deleted 
BARD1-EGFP recombinants. Knockdown of BARD1 expression by transducing a 
anti-BARD1 shRNA results in slower cell cycles, delayed cytokinesis, and 
incompletion of mitosis. Furthermore, this phenotype is often accompanied by failure 
of efficient chromosome segregation as indicated by the appearance of aberrant 
karyotypes. Finally, we showed that BARD1 co-immunoprecipitates with Aurora B, 
but not with Aurora A. For the first time we reveal an interaction of BARD1 with 
BRCA2 in the regulation of cytokinesis, since BARD1 co-immunoprecipitates with 
BRCA2 during the G2/M phase of the cell cycle. These data give us new evidence 
that BARD1 may regulate cell-cycle progression through the Aurora B kinase 
pathway for completion of cytokinesis. The mechanisms involved in cell-cycle 
regulation and cytokinesis are not fully understood, but could be controlled by the 
ubiquitin ligase activity of BARD1/BRCA1 dependant on AuroraB phosphorylation. 
Cytogenetic analysis was provided by Sarantis Gagos, while some of the IPs were 
done in collaboration with the Birenbaum laboratory. 
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Mutations in BARD1 (BRCA1 associated Ring protein1) are associated with breast and ovarian 
cancer2-5, and BARD1 repression leads to genomic instability6-8. Genomic instability is also the 
hallmark of cancers with in BRCA1 and BRCA2 mutations9. The BRCA1-BARD1 complex 
controls centrosome amplification through ubiquitin ligase activity10, and BRCA2 is involved in 
regulation of cytokinesis11, both mechanisms that are required for accurate chromosome 
segregation. Here we report that BARD1, overexpressed during mitosis12,13, is localized to the 
mitotic spindle and to the midbody at telophase and cytokinesis. In mitotic extracts BARD1 
interacts with TACC1, Aurora B, and BRCA2, proteins with similar location and repression 
phenotypes at cytokinesis11,14. siRNA depletion of BARD1 leads to Aurora B stabilization on the 
midbody and inhibition of abscission of inter-sister cell microtubule bridges, associated with 
numerical and structural chromosomal instability. These findings suggest that BARD1 is 
required for regulation of Aurora B displacement/stability in a complex of BARD1-AuroraB-
BRCA2 that controls progression through cytokinesis.  
A common feature of BRCA1, BRCA2, and BARD1 knock-out mice is embryonic lethality8, 15-
18, underscoring that these genes are vital for a variety of cellular events10, 19. During mitosis, 
BRCA2 localizes to the midbody where it is involved in cytokinesis, as demonstrated by siRNA 
depletion of BRCA2, which impedes cell separation11. In contrast to BRCA2, BRCA1 is 
localized to centrosomes at anaphase onset, where in association with BARD1, it acts as E3 
ubiquitin-ligase on γ-tubulin10. This is substantiated by the fact that abrogation of BRCA1 leads 
to excessive centrosome duplication, incurring genomic instability10, 20. BARD1 is the major 
protein binding partner of BRCA11 , and some of the functions of BARD1 are tightly linked to 
the ubiquitin ligase activity of the BARD1/BRCA1 heterodimer21. However, independently of 
BRCA1, BARD1 upregulation mediates apoptosis induction by catalyzing p53 
phosphorylation22, 23.  
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Upregulated expression of BARD1 is also observed in mitotic cells12, 13, suggestive of its 
implication in mitotic mechanisms. To further characterize BARD1 expression and function in 
mitosis, indirect immunofluorescence was performed on non-synchronized cell populations. 
Consistently BARD1 levels were increased in mitotic cells (Fig. 1A). BARD1 staining was 
accumulated around and along the mitotic spindle (Fig. 1B). This intracellular localization of 
BARD1 during mitosis was observed when using different anti-BARD1 antibodies in different 
cell lines and across species, such as in human HeLa, MCF-7 (data not shown), PC3, and mouse 
non-malignant mammary gland TAC-2 cells6. Omission of the primary antibody or competition 
with blocking peptides did not lead to significant staining. The specificity of BARD1 staining 
was further confirmed with anti-BARD1 antibody H-300, directed against the N-terminal 300 
amino acids, on cells expressing exogenous BARD1-EGFP fusion proteins or BARD1-EGFP 
deletion constructs (Support data Fig. 1A). Co-localization of anti-BARD1 staining and EGFP-
fluorescence was observed with full length BARD1 and ∆-RING-EGFP but not with ∆-HIND-
EGFP, a deletion of the N-terminal coding half, or EGFP alone. This demonstrates that BARD1 
antibodies specifically recognize epitopes in the amino terminus of BARD1 (Support data Fig. 
1B).   
To further ascertain the localization of BARD1 on mitotic microtubules (MT), we performed 
double-immuofluorescence staining with antibodies against BARD1 and against β-tubulin in 
three different cell lines. Clearly, BARD1 colocalizes with spindle MT, as demonstrated in 
metaphase cells (Fig. 1C). The localization to spindle MT is nearly exclusive in HeLa cells, but 
additional cytoplasmic staining is observed in PC3 and to some extent in TAC-2 cells. BARD1 
concentration on MT seems much higher than the tubulin concentration; or, anti-BARD1 staining 
might be competitive for anti-tubulin staining, since the tubulin stain is less intense when the 
anti-BARD1 stain is strong in double labeling experiments. The upregulation of BARD1 during 
mitosis might be controlled at the protein level by CDK2, which regulates its ubiquitin ligase 
function13. 
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We then investigated the association of BARD1 with MT at different stages of the cell cycle. 
BARD1 localizes to spindle MT at all stages of cell cycle (Fig. 2). While nuclear dots and some 
cytoplasmic staining could be observed in typical interphase cells (Fig. 2A, S-phase merge), most 
BARD1 was localized to MT emanating from the spindle poles at metaphase and anaphase. 
BARD1 and β-tubulin co-localization was observed as yellow staining, and BARD1 and DNA 
co-localization as pink staining (Fig. 2B), indicating that a fraction of BARD1 co-localized with 
MT and a small fraction with chromosomes. BARD1 and MT co-localization was specifically 
observed at anaphase (Fig. 2B). Excessive BARD1 staining was also observed at the spindle 
midzone and at cytokinesis at the midbody (Fig. 2A-B). While BARD1 staining was more 
abundant than tubulin staining from anaphase to telophase, similar intensities were observed at 
cytokinesis. During the furrowing of the cleavage plane, and until the end of cytokinesis, BARD1 
staining intensified along the spindle midzone and even more so at the midbody.  
These localizations of BARD1 at different stages of mitosis suggest that BARD1 migrates along 
MT from the spindle pole to the midzone and accumulates at the midbody. While at onset of 
anaphase, BARD1 could act with BRCA1 as ubiquitin ligase on γ-tubulin10, functions at later 
stages of mitosis could be suspected.   
Among the proteins that also localize to the midzone during anaphase and to the midbody during 
cytokinesis, are BRCA211 and transforming acidic coiled-coil-containing protein (TACC1)14. 
TACC proteins are involved in MT stabilization and abnormal centrosome formation, and have 
been implicated in cancer progression (reviewed in24). TACC1 colocalizes and forms a functional 
complex with the mitotic kinase Aurora B during cytokinesis14. Aurora B depletion by siRNA-
mediated interference prevents the formation of the midbody, consequently affects TACC1 
localization to the midbody, and leads to abnormal cell division and multinucleated cells, a 
phenotype resembling BARD1 antisense depletion6. Since BARD1 localizes to the spindle 
midzone at anaphase and at the midbody during telophase and cytokinesis, we asked whether 
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BARD1 interacted with TACC1 and Aurora B. TACC1 as a MT stabilizing protein could have 
an adaptor function for localization of BARD1 on MT.  
Co-immunoprecipitation experiments were performed with anti-TACC1 and anti-BARD1 
antibodies. When probing HeLa cell extracts, from non-synchronized cells or cells blocked at 
different stages of the cell cycle, BARD1 co-precipitated with TACC1 in cells blocked at the 
G1/S or at the G2/M border (Fig. 3A).  When co-immunoprecipitation experiments were 
performed with TACC1 antibodies and Western blots were probed with anti-BARD antibodies, 
BARD1 was co-immunoprecipitated with TACC1 mostly in mitotic cells (Fig. 3B). An increase 
of BARD1 was observed in mitotic cell extracts. BARD1 protein appeared as a double band of 
97 kD and slightly larger, which could represent the phosphorylated and unphosphorylated 
forms13. The fraction of BARD1 co-precipitating with TACC1 in mitotic cells corresponded to 
the lower, presumably unphosphorylated form. No co-immunoprecipitation of BARD1 was 
found in the control assay with beads only. The reverse experiment showed that anti-BARD1 
antibodies co-precipitated TACC1 (Fig. 3B).  In contrast to BARD1, TACC1 expression was not 
increased during mitosis and only a fraction of TACC1 was co-immunoprecipitated with 
BARD1, but the interaction was restricted to cells arrested in G2/M. As for BARD1, TACC1 
antibodies recognized an additional band with slightly higher molecular weight, which was 
increased in G2/M total lysates (Fig. 3A-B*). These results show that BARD1 and TACC1 
interact in G2/M phase of the cell cycle and suggest a role for both proteins in a common 
pathway.  
It was shown previously that TACC1 is coexpressed temporally and spatially with Aurora B, a 
mitotic kinase, critical for progression through mitosis25, 26. We therefore tested the BARD1-
Aurora B interaction. Western blots of anti-BARD1 immunoprecipitations were probed with 
antibodies against Aurora A and B (Fig. 3C). Both Aurora A and B levels were increased in G1/S 
and more in G2/M blocked cell extracts. However, co-immunoprecipitation with anti-BARD1 
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antibodies was only observed in G2/M cell extracts and only for Aurora B. This observation is 
consistent with the specific subcellular localization of TACC1 and Aurora B and their potential 
roles at the exit of mitosis14, in contrast to the localization of Aurora A, which acts with 
BRCA127 at the spindle poles in centrosome duplication. The BRCA2 protein had also been 
localized to the midbody11 and we therefore tested coimmuneprecipitation of BRCA2 with 
BARD1. BRCA2 was binding to BARD1, in mitotic extracts, while the bona fide binding partner 
BRCA1 was binding to BARD1 in cell extracts of cells blocked at G1/S and at G2/M. This data 
suggest that during mitosis BARD1 sequentially interacts with BRCA1 and BRCA2. The specific 
interaction of BARD1 and BRCA2 in mitotic extracts suggests that BARD1 acts in a pathway 
involving TACC1, Aurora B, and BRCA2.  
To assess the role of BARD1 during mitosis, we abrogated BARD1 expression in HeLa, MCF-7, 
PC-3, and TAC-2 cells with siRNA and monitored the resulting phenotype. Immunofluorescence 
microscopy was performed on cells transciently transfected with BARD1 siRNA expressed from 
a constitutive promoter, using anti-BARD1 and anti–tubulin antibodies. When harvesting cells 36 
hours after transfection, we observed a striking phenotype of cells cycle arrest in mitosis, 
specifically an accumulation of cells at late telophase (Fig. 4A). MT staining showed that 
separated sister cells at cytokinesis were connected by MT bridges, while exhibiting decondensed 
chromosomes. The number of cells connected by midbody bridges was ten fold increased in the 
siRNA treated cells, as compared to non-treated cells (Fig. 4B). Depletion of BARD1 was 
specific, since siRNA against mouse BARD1 had not effect, compared to mock or human 
siRNAs, as shown on Western blots (Fig. 4C).  Residual expression of BARD1 is not found on 
MT bridges when double labeling with anti-tubulin and anti-BARD1 antibodies was performed 
(Fig. 4D) as compared to wild type cells (Fig. 2B). Thus, the depletion of BARD1 by siRNA 
leads to a delay or arrest of cell cycle in cytokinesis and suggests that BARD1 might be required 
for proper abscission of inter-sister cells MT bridges.  
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We investigated the localization of TACC1, Aurora B and BRCA2 in BARD1 depleted cells and 
found striking differences in expression and localization for Aurora B (Fig. 4E), but not TACC1 
or BRCA2 (data not shown). Aurora B localizes to distinct dots on inter-sister cells MT bridges, 
bracketing the abscission point14. Unlike the specific and exclusive localization of Aurora B to 
MT bridges at cytokinesis in wild type cells, in BARD1 repressed cells Aurora B dots are larger 
and their location is less precise. Aurora B sustained on the cell membrane of daughter cells after 
cytokinesis (Fig. 4E), while in wild type cells Aurora B dislocates to interphase nuclei of sister 
cells. No differences were observed for Aurora B staining at other stages than cytokinesis. These 
findings suggest that BARD1 controls Aurora B stability at the exit of mitosis.  
Since the BARD1 depletion phenotype is reminiscent of the Aurora B depletion phenotype, 
which also causes aneuploidy, it is suggestive that the interaction of BARD1 with Aurora B is 
functionally significant. Malfunction of chromosome segregation due to a delayed and abnormal 
cell division, could be caused by a deficient Aurora B- BARD1 complex.  
The phenotype of BARD1 deficiency is also similar to the phenotype induced by siRNA 
inhibition of BRCA2, in particular the phenotype of the BRCA2 mutation Capan-111. Like the 
Capan-1 mutation, BARD1 siRNA inhibition leads to the accumulation of cells with elongated 
midbodies. BARD1 and BRCA2 localize to the same regions during the late stages of mitosis 
and it is likely that interaction of BARD1 with Aurora B and BRCA2 are required for completion 
of cytokinesis.  
The function of BARD1 in abscission of inter-sister cells MT bridges provides an explanation for 
the observed genomic instability in BARD1-deficient cells6-8. Inhibition or delay of cytokinesis 
could cause genomic instability due to improper chromosome segregation. To test this hypothesis 
we performed a profound cytogenetic analysis of BARD1 expressing and BARD1 depleted HeLa 
and MCF-7 cells.  
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Using alpha-satellite probes specific for chromosomes 7, 17, 18, and X, and locus specific probes 
for chromosomal positions 13q12 and 21q12, we found that BARD1 repression leads to 
increased rates of chromosomal losses and overall numerical deviation in MCF-7 or HeLa cells 
(Table 1). We also observed masked numerical chromosomal instability due to whole 
chromosome losses compensated by non-disjunctions in MCF-7 cells using dual color FISH 
specific for centromeres 7 and 17 (Fig. 5). The rates of numerical instability of centromeres 7 and 
17 were twice as pronounced in the BARD1 depleted MCF-7 cells than in BARD1 expressing 
cells. Taken together these results show that loss of BARD1 leads to numerical chromosomal 
instability, presumably due to the defective abscission of inter-sister cells MT bridges, which is 
reminiscent of defects in mitotic fidelity as a consequences of Aurora-B ablation14.  
The similarity of genomic instability phenotypes induced by the depletion of BARD1, BRCA1, 
or BRCA2 is only partially reflected in the specific functions that were attributed of each of these 
proteins. However, the sequential interaction of BARD1, first with BRCA1 at the centrosome as 
ubiquitin ligase on γ-tubulin, a mechanism of control of centrosome duplication, and secondly 
with BRCA2 at cytokinesis, provides an explanation for their overlapping functions resulting in 
similar phenotypes.  As negative regulator of centrosome amplification, an obvious cause of 
aneuploidy28, 29, BARD1 acts as tumor suppressor with BRCA1. In regulation of cytokinesis, 
BARD1 and BRCA2, together with Aurora B and TACC1, are required to ascertain proper cell 
division and chromosome segregation to avoid aneuploidy. Hence the dual role of BARD1 in 
mitosis, by interacting with BRCA1 and BRCA2, could explain the common phenotype of 
genomic instability induced by BARD1, BRCA1 or BRCA2 deficiencies.  
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Materials and Methods 
Cell Culture 
TAC-2 cells are a clonal sub-population derived from the NMuMG normal murine mammary 
gland epithelial cell line (CRL 1636; American Type Culture Collection, Rockville, MD) and 
were used previously 6. They were cultured in collagen-coated tissue culture dishes (Falcon, 
Becton Dickinson, San Jose, CA) in high glucose DMEM (GIBCO, Invitrogen corporation) 
supplemented with 10% fetal calf serum (FCS, GIBCO), penicillin (110 µg/ml) and streptomycin 
(110 µg/ml). The Human Embryonic Kidney HEK 293T cell line, as well as HeLa cell lines, 
were obtained from the American Tissue Type Culture Collection. The PC3 cell line was 
obtained from McDonnell. All cell lines were cultured in the aforementioned tissue culture 
medium (TCM) containing low glucose concentration, using 9 cm plastic tissue culture dishes 
and incubated at 37°C in humidified air containing 5% CO2. Adherent subcultures were detached 
from culture dishes using a solution of Trypsin/EDTA (Life Technologies, Inc.). Sub-confluent 
cell cultures were passaged regularly at 1:10 dilution twice a week. 
 
Transfections of siRNA constructs 
Cells were seeded in either 6 well plates or in 10 cm petri dishes and transfected with either 
0.4µg or 2µg of DNA using the Effectene reagents provided by Qiagen. Cells were harvested at 
24 and 48 hours post-transfection. They were centrifuged and washed once in PBS, resuspended 
in 0.3 ml of ice cold radio immuno-precipitation assay (RIPA) buffer [150mM NaCl, 1% Nonidet 
P-40, 0.5% NaDOC, 0.1% SDS, 50mM Tris, pH 8.0, 2mM EDTA, pH 8.0] and supplemented 
with protease inhibitors [1mM PMSF, 3µg/ml aprotinin, 10µg/ml leupeptin] and phosphatase 
inhibitors [2mM NaF, 25 mM activated Na3VO4]. Cells were lysed on ice for 30 minutes and 
vortexed at regular intervals. The extracts were centrifuged at 13'000 rpm in a microcentrifuge 
for 15 minutes at 4°C in order to remove cell debris and clear the cell lysate. The human BARD1 
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siRNA construct was generated by annealing the following complementary oligonucleotides and 
inserted into the pSuper vector as a BglII/HindIII fragment: forward, 5'-G ATC CCC CAT TCT 
GAG AGA GCC TGT GTT CAA GAG ACA CAG GCT CTC TCA GAA TGT TTT TGG 
AAA-3', and reverse, 5'-AG CTT TTC CAA AAA CAT TCT GAG AGA GCC TGT GTC TCT 
TGA ACA CAG GCT CTC TCA GAA TGG GG-3'. This construct was then transiently 
transfected in Hela cell as described. Mouse siRNAs were directed against the respective 
homologous regions.  
 
Antibodies 
The anti-BARD1 (H-300), anti-Aurora A and B, antis-BRCA1 and 2 antibodies were purchased 
from Santa Cruz. Anti-GFP (TP-401) was purchased from Chemokine (Torrey Pines Biolabs). 
PVC and WSF were described previously6. Anti-TACC1 antibody was purchased from Upstate 
Biotechnology Euromedex (Mundolsheim, France). 
Secondary conjugated antibodies to horseradish peroxidase (HRP) were purchased from Santa 
Cruz and were compatible with Cruz Molecular Weight Markers (Santa Cruz). Secondary 
immunoflurescent donkey anti-mouse, rabbit and goat conjugated to FITC or Alexa red 555 
fluorochromes were obtained from Molecular Probes. 
 
Immunofluorescence microscopy 
Cells were seeded on glass cover slips in 6 well culture dishes or plated on a 8 well coverslide 
and transfected or not with the aforementioned plasmids. Cells were washed in HBSS, and either 
fixed 2% paraformaldehyde (PFA) in Hank's Balanced Salt Solution (HBSS) 15 min at room 
temperature (R.T.) or in methanol for 6 minutes at -20c and rinsed in acetone for 30 seconds. 
PFA-fixed cells were permeabilized in 1% Triton/PBS for 15 minutes at R.T. and thereafter 
blocked for in 1% serum/PBS for 30 min. Coverslides were incubated with appropriate 
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antibodies for 1 hour at R.T. in 1%FCS/PBS, washed and stained with DAPIC for 3 min. Finally 
coverslides were mounted with fluorogard solution, observed under a Nikon epi-fluorescence 
microscope and images captured with a 3.3 mega-pixel CCD camera. Images were processed 
with Metamorph software (Visitron). 
 
Immunoprecipitation 
 
Protein lysates used for immunoprecipitation correspond to HeLa cells synchronized (G1/S), 
synchronized and released (G2/M) and not synchronized (NS) using a double thymidine block. 
24 h after plating, cells were arrested in S-phase using 2mM thymidine for 18 h, released from 
the arrest for 9 h, arrested a second time with thymidine, and released again to obtain a 
population enriched in mitotic cells. Proteins from lysates were precipitated with anti-TACC1 or 
anti-BARD1 antibodies, and bound proteins were detected with anti-BARD1, anti-TACC1, anti-
Aurora A or B, or anti-BRCA1 or 2 antibodies.  
 
Interphase dual color cytogenetic analysis 
 
To investigate numerical instability we applied dual-color interphase FISH, which is more 
accurate than conventional karyotype analysis, satellite probes specific for chromosomes 7, 17, 
18, and X were used. We also applied locus specific probes hybridizing to the Rb region of 
chromosome 13 and the region critical for Down syndrome on chromosome 21. Probes were 
either purchased from Vysis, or produced and tested in house, using an indirect labeling Nick 
Translation process (ROCHE) according to the manufacturer’s protocol. Cell cultures of high 
mitotic index were exposed to colcemid (0.1 µg/ml) (Gibco, BRL) for 1,5 h, at 37ºC and 
harvested according to routine cytogenetic protocols. FISH was based on pepsin pre-treatment, 
formamide target denaturation, over-night hybridization, and stringency post hybridization 
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washes. For each chromosome pair studied (i.e. chromosome a and chromosome b), a modal 
number (Ma, Mb) was calculated as the most representative number of spots per nucleus per 100 
cells/harvest. Chromosome loss was defined as Mn-1, chromosome gain as Mn+1. Overall 
deviation was calculated as the number of nuclei that do not show modal number of spots. 
 
Metaphase dual colour cytogenetic analysis 
 
Masked numerical chromosomal instability due to coupled chromosomal losses and non-
disjunctions was explored in the MCF-7 cells using the same dual-color technique as described 
above. For this cytogenetic approach we performed conventional and multicolor FISH Karyotype 
analysis to select a specific pair of chromosomes that showed at least two different recombinant 
chromosomes of unequal size that could be easily identified on chromosome spreads. For MCF-7 
cells centromeres 7 and 17 were a suitable pairs (Fig. 5). We deduced the stability of 
recombinant and intact chromosomes, by FISH and inverted DAPI, in 50 randomly selected 
compact metaphase spreads derived from BARD1 expressing or BARD1 depleted cells. 
Chromosomal losses compensated by non-disjunction of one of the remaining homologous 
centromeres, were recorded as two events of numerical instability/metaphase. 
Jefford et al.   
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 Figure legends 
 
Figure 1. BARD1 expression during mitosis. (A) BAR1 is upregulated during in mitotic cells 
(m).  (B) BARD1 immunostaining of three different cell lines, TAC-2, HeLa, and PC-3. Indirect 
immunofluorescence images show that BARD1 accumulates around mitotic spindles during 
mitosis in all cell lines examined. BARD1 protein was flagged with H-300 antibody. Nuclei were 
stained with DAPI.  (C) BARD1 co-localizes with beta-tubulin staining in various cell lines. (A) 
Mouse mammary gland TAC-2 and (B) prostate cancer PC3 cells were stained with anti-β-
tubulin labeled and anti-BARD1 (H-300) antibodies. Tubulin is labeled with FITC, BARD1 with 
Alexa red 555, and nuclei are stained with DAPI.  
 
Figure 2. Localization of BARD1 during stages of mitosis. (A) Immunostaining of an 
asynchronous population of PC-3 cells with anti-BARD1 (H-300) and anti-β-tubulin showing 
high immunoreactivity of BARD1 surrounding microtubule spindles at all stages of mitosis. 
Tubulin is colored green and BARD1 in red. At anaphase BARD1 is mostly localized to the 
spindle pole, only partial colocalization with tubulin. (B) At metaphase colocalization of BARD1 
and tubulin staining marked in yellow (short arrow) and abundant BARD1 staining at the spindle 
periphery (long arrow) can be observed. At telophase some of the colocalization with tubulin, 
marked yellow (short arrow) is observed, but abundant staining of BARD1 is localized to the 
midbody (long arrow), colocalization of BARD1 and DNA can be observed in pink (arrowhead). 
In cytokinesis the most prominent BARD1 staining is seen at the midbody, colocalized with 
tubulin (yellow).  
 
Figure 3. BARD1 interacts with TACC1 and Aurora B, but not Aurora A, and BRCA2 but not 
BRCA1 in mitotic extracts. The co-immunoprecipitation assay shows that TACC1 can pull down  
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full length BARD1 (C). Cells were either not enriched (--), enriched in S phase (S) with a double 
thymidine block or enriched in G2/M phase of the cell cycle (G2/M) released after double 
thymidine block. Western blot of total cell extract clearly shows that BARD1 is enriched during 
mitosis, as compared to the lower unrelated protein which serves as loading control. The reverse 
experiment shows that BARD1 can pull-down TACC1 (B), Aurora B, but not Aurora A (C), 
BRCA1 in G1/S and G2/M extracts and BRCA2 in G2/M extracts only (D).  
 
Figure 4. HeLa cells transiently transfected with BARD1 siRNA expressing plasmid. Cells were 
collected and stained 20 hours post transfection with anti-BARD1 (H-300) and anti-β-tubulin 
antibodies. Panel (A) demonstrates phenotype obtained with BARD1 repression, and percentage 
of cells, delayed or arrested at late cytokinesis, with abnormal abscission of midzone body is 
shown in (B). The fraction of cells with abnormal abscission is about 10 fold higher in BARD1 
depleted cells than in the control cells transfected with mock siRNA. Residual BARD1 staining 
is not localized to the midbody (D). Aberrant localization of Aurora B in BARD1 depleted cells 
(E). Arrow indicates persistent Aurora B staining in sister cells after mitosis.  
 
Figure 5. Numerical chromosomal instability in BARD1 depleted cells. Centromere specific 
staining with probes for chromosomes 7 (orange) and 17 (green) was applied on MCF-7 cells 
depleted of BARD1 by siRNA expression. Chromosomal losses are monitored by centromere 
staining of interphase nuclei (a). Embedded partial karyotypes, representing the modal (most 
representative) imbalances of chromosomes 7 and 17, were defined as chromosomal markers m1, 
m2, m3, and m4. m1 and m2 were clonaly retained recombinant chromosomes derivatives of 
chromosome 7. m3 and m4 were clonaly retained recombinant chromosomes derivatives of 
chromosome 17 (G-Banding/Inverted DAPI FISH; magnification x1000) (b). Staining of four 
spots per centromere of chromosomes 7 and 17 is representative for majority of metaphase 
spreads (c). Loss of m4 and a translocation involving m3 is shown in (d). A non-disjunction of 
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recombinant m3 leads to increased number of spots (five) for centromere 17 (e). Examples of 
masked numerical instability are shown in f-h: a loss of m4 is compensated by non-disjunction of 
recombinant m3 (f), non-disjunction of recombinant m1 coupled to loss of one of the two 
apparently intact chromosomes 7 (g), and loss of m1, coupled to non-disjunction of m2 (h). 
Arrows indicate chromosomal non-disjunctions. 
 
Support Figure 1. (A) Antibody control on cells transfected with various constructs. (B) 
Schematic view of constructs.   
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HeLa 
 
Chromosome 
Loss% 
Chromosome 
Gain% Overall deviation% 
BARD1 (+) (-) (+) (-) (+) (-) 
13 3 13 3 7 8 25 
18 12 35 29 15 52 63 
21 26 38 2 7 31 48 
X 15 8 6 17 23 35 
 
 
MCF-7 
 
Chromosome 
Loss% 
Chromosome 
Gain% Overall deviation% 
BARD1 (+) (-) (+) (-) (+) (-) 
7 10 19 1 2 12 22 
13 9 10 14 14 26 28 
17 20 33 2 6 23 44 
18 11 30 0 20 21 46 
21 23 17 14 3 46 45 
X 16 20 1 1 18 21 
 
Table 1: Percentages of chromosomal instability of BARD1 expressing (+) vs BARD1 depleted 
cells (-).
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Supplemental results and ongoing projects 
6.  Role of BARD1 in telomere maintenance and crisis 
Introduction 
The BARD1 and BRCA1 proteins are involved in several mechanisms that maintain 
genomic stability, because mutation or absence in either of these genes leads to 
chromosomal instability and pre-cancerous lesions. Most cancer cells are prone to 
genomic instability which is often correlated with a reactivated telomerase, whereas 
normal somatic cells bear a repressed telomerase. BARD1 and BRCA1 form nuclear 
dots during S-phase that are relocated upon DNA damage induced by hydroxyurea. 
Furthermore, it was shown that BARD1 and BRCA1 aggregate in PML bodies, in 
telomerase negative cell lines, and that the BRCA1-Mre11-Rad50-Nbs1 complex, 
which intervenes during DNA repair, is also present in telomeric complexes. 
Telomeres are ribonucleoprotein complexes poised on the end of chromosomes that 
maintain the stability of the chromosomes.  
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Figure 6.1. Co-localisation of telomeres and BARD1.  a) CHO cells stained with anti-TRF-2. b) Confocal 
image of HeLa cells stained with anti-BARD1 forming the characteristic nuclear foci. c) FISH of telomeric 
probe by using PNA probe (DAKO), red dots represent telomeres. d) PNA hybridisation in BARD1-/- mouse 
embryos. e) The four panels represent double staining with PNA in green and anti-BARD1 in red in four 
different cell lines. These are overlay images, therefore co-localisation is in yellow and is indicated with yellow 
arrows. f) and g) 293T cells transfected with full-length BARD1-EGFP and stained with anti-TRF-2 in f) and 
with anti-BARD1 as a positive control in g). Nuclei are stained with DAPI in blue.  
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The absence of telomeres or of proteins responsible for maintaining telomere 
maintenance results in chromosomal instability and inaccurate segregation of 
chromosomes that perpetrate breakage-fusion-bridge cycles. Telomeres and their 
associated proteins such as TRF-1 and TRF-2 (Telomere Repeat binding Factor 1 
and 2) form dot-like structures as seen by FISH (Fluorescent in Situ Hybridisation) 
experiments and by immunofluorescence respectively. In view of all the above 
evidence, we wanted to see if there was a link between BARD1, telomeres and 
chromosome instability. We investigated whether BARD1 repression would have an 
effect on telomere length or on telomerase activity and whether BARD1 can interact 
within telomeric complexes either by binding to telomeric DNA or to telomere 
proteins. 
 
Results and discussion 
Since BARD1 and telomeres form 
nuclear dots and that they share 
some of the same proteins in their 
complexes, we first investigated 
whether BARD1 and telomeres would 
be part of the same biochemical 
complex and would co-localize 
together in double immunofluorescent 
experiments. In order to observe this 
co-localisation, we performed indirect 
immunofluorescence on paraffin 
sections from mouse embryos and in 
cultured cells with anti-BARD1 
antibody combined with FISH using a 
telomere probe (PNA labelling system 
from DAKO). It is possible to observe 
some co-localization between BARD1 
and the PNA signal in certain places 
but it is not flagrant (Figure 6.1.e). 
Figure 6.2. Telomere Chromatin Immunoprecipitation 
assays (Telo-ChIP). The several anti-BARD1 antibodies 
(N19, C20, JH3, H300) are incapable of 
immunoprecipitating telomeric DNA, as compared to 
TRF-2 suggesting that there is no interaction between 
BARD1 and telomeric chromatin in either HeLa or 
TAC2 cells. 
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We also performed PNA telomere hybridisation on sections of BARD1-/- embryos in 
order to evaluate the state of the telomere structures. It appears that BARD1 
knockouts display a non-altered PNA stain compared to wild type mouse embryos 
(Figure 6.1.d). To further look at an interaction between BARD1 and telomeric DNA, 
we performed chromatin immunoprecipitation assays by using anti-BARD1 antibody 
and labelled telomeric DNA. The results are unfortunately not conclusive, since there 
is no strong signal indicating an attachment of BARD1 on the telomeric DNA (Figure 
6.2). Furthermore, to see if BARD1 interacts with components of the telomere 
Figure 6.3. Immunohistochemistry showing BARD1 expression. Paraffin embedded sections in the spleen 
and in the liver of wild type (G0) and 5th generation of mTR-/- knockout mice (G5) were immunostained 
with anti-BARD1 antibody. Left column represents sections from wild type tissue and show no reactivity. 
The two columns on the right side are from telomerase KO mice. Represented in brown the reactivity of 
N19 anti-BARD1 antibody secondary antibody is conjugated to HRP, DAB staining. Top two rows are 
taken from paraffin embedded liver sections and bottom row from spleen. Slides were counterstained with 
Hemalin. 
5x 
5x 20x 
60x 
5x 
G0 wild type G5 mTR -/- 
40x 5x 
5x 20x 
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complex, we performed double fluorescent immunohistochemistry using anti-TRF-2 
or hTERT and anti-BARD1 antibodies on cultured cells. Here again, only a few spots 
of co-localization can be observed, but these slides need to be visualized with a 
confocal microscope in order to get a more precise image. In order to assess the 
interaction between BARD1 and TRF-2 or hTERT, we immuno-stained cells that 
were expressing a BARD1-EGFP fusion protein with TRF-2 antibody (Figure 6.1.f).  
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Figure 6.4. Measurement of telomere length in normal and BARD1 repressed cells. Measurements were made 
by telomere-Flow-FISH and by southern blot of terminal restriction fragments (TRF) probed with a DIG 
labelled telomere probe. A) TAC2 and BARD1 repressed TAC2/ABI do not show significant differences. 
Cells with FITC labelled telomeres by in situ hybridisation are analysed by flow cytometry. FITC signal per 
cell is proportional to telomere length. Usually 10’000 events are counted. Signal is normally subtracted from 
non-labelled cells representing background signal. B) TAC2 and TAC2/ABI cells as well as control cells were 
assayed for telomere length by TRF southern. This assay displays physical length of cells. It is more direct 
than Flow-FISH. However, TAC2 and TAC2/ABI have marginally the same telomere length. Mouse 
telomeres are double the size of human telomeres. Human telomere length averages between 4 and 15 kb, 
whereas mouse telomeres are about 20-40kb long. C) U2OS and SAOS2 are telomerase negative cell lines that 
have very long telomeres compared to Jurkat, fibroblasts or even other ovarian cancer cells (SAR13). 
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We observed that TRF-2 anti-body co-localizes to some of the dots formed by the 
BARD1-EGFP fusion protein. These results show partial co-localization of TRF-2 and 
BARD1. In the future, we would like to use the BARD1-EGFP recombinant for 
biochemical experiments and for co-immunoprecipitation studies by using the various 
proteins involved in telomere metabolism. These proteins include TRF-1, Rap-1, 
hTERT, and so on. We also examined the expression of BARD1 in tissues from 
telomerase knockout mice (mTR-/-). It is worth noticing that BARD1 expression is 
increased in mTR-/- tissues, possibly because mTR-/- mouse tissues are more prone 
to apoptosis. These mice show premature aging and telomere attrition (Figure 6.3). 
 
In order to ascertain the effect of the absence of BARD1 on telomere length, we 
performed flow-FISH and TRF on BARD1 repressed cells (Figure 6.4.). Flow-FISH is 
an indirect labelling method to measure telomere length by fluorescent in situ 
hybridisation quantified by flow cytometry. TRF (terminal restriction fragment assay) 
utilizes southern blot method with a highly digested genomic DNA using a telomere 
probe to measure the physical length of telomeres. Since the BARD1 repressed cell 
lines did not give a clear result, we transfected primary cells and transformed cell 
lines with a siRNA of BARD1. We measured telomere length by using flow-FISH. Our 
preliminary results suggest that BARD1 repression could have an effect on telomere 
length, since telomere length appears to be diminished in siRNA transfected cells 
(Figure 6.5). These cells were assayed for telomerase activity by TRAP (telomere 
repeat amplification protocol); a very sensitive method which amplifies by PCR the 
telomere repeats added by telomerase elongation. However, no changes were 
observed on telomerase expression (Figure 6.6). Therefore, telomere attrition 
observed after BARD1 knock-down is not due to lack of telomerase activity. 
Furthermore, we transduced a short hairpin interfering BARD1 RNA (shRNA) by 
using a lentiviral system to obtain a constitutive and an inducible down regulation of 
BARD1. These cells have not been assayed yet for telomere length attrition. Several 
passages need to be created to observe an effect over time. Overall, our results do 
not allow to dress a complete picture of BARD1 interfering in telomere metabolism. 
However, these results do not exclude an indirect action of BARD1 on telomeres. 
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Figure 6.5. Telomere attrition in BARD1 knock-down cells. TAC2, HeLa and MCF-7 cells were 
transiently transfected with siRNA of BARD1 3 times over a course of 10 days. A) RT-PCR shows 
BARD1 mRNAlevels are decreased relatively efficiently. B) Shown in black the relative length of 
telomeres from the cell lines which were treated with siRNA BARD1. 
Figure 6.6. Measurement of telomerase activity by TRAP assay (Telomere Repeat Amplification 
Protocol). This PCR based assay amplifies telomeric repeats in presence of active telomerase. It appears 
that TAC2 cells are positive for telomerase at low passage (left panel). HeLa and MCF-7 cells 
transfected with siRNA BARD1 do not have repressed telomerase activity (middle and left panel).  
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7. Characterization of the BARD1 promoter 
It was established that BARD1 protein and mRNA are increased during genotoxic 
stress and during cell death. BARD1 is also expressed under hormonal control. 
Furthermore, it appears that BARD1 stabilizes BRCA1 and vice versa. This 
regulation is interdependent. In order to investigate the mechanisms regulating 
BARD1 expression under various physiological environments, such as hormonal 
treatment, inflammation, genotoxic insult, embryogenesis or cell death, we decided to 
isolate and characterize the BARD1 promoter region. The first step was to identify the 
5’UTR and the site of the initiation of transcription (cap site). To this purpose, we 
performed 5’RACE and a so called “steplike RT-PCR” with forward primers at various 
positions upstream of the BARD1 ATG site. We amplified the cDNA of BARD1 with 
primers positioned at –114 upstream of the ATG, but not at position –192, 
demonstrating that BARD1 initiation site is situated within this region. A position 
situated further upstream of what has been previously published (Figure 7.1).  
 
 
 
ATG = + 1
CAG
Exon 1
Initiation start site
Exon 2 Exon 3 Exon 4
CTGCTC
?   ?
- 28
position forward primers
- 73
- 280 - 114- 192 + 246+ 139
reverse primers
- 153 - 132
F 1=90 R 1=72F 2=91F 3=92F 4=93 R 2=94
Reverse primer R 1 (+139)
Reverse primer R 2 (+ 246)
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Gen DNA HeLa Lympho CTB 
HeLa Lympho CTB 
H2O
H2O
F1 F2 F3 F1 F2 F3 F1 F2 F3 
RT-PCR
- 864
F 5=41
Figure 7.1. Identification of 5’UTR of BARD1 in humans. A) This figure depicts the “steplike-RT-PCR” that 
amplifies, with upstream primers of ATG, the cDNA derived from the BARD1 messenger. B) and C) RT_PCR 
using the indicated primers showing a step formation. F3 and F4 do not amplify any product. 
B 
A 
C 
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We first isolated a primary region of 865 base pairs upstream. In a second step, we 
isolated a larger region of 2402 base pairs upstream of the BARD1 ATG by PCR on 
genomic DNA on two healthy young adults. We cloned these two regions into the 
pGL3 basic vector containing the luciferase reporter gene (Figure 7.2). This region 
was sequenced and analysed for candidate transcription factors (Figure 7.3). The 
luciferase gene is placed under the transcriptional control of the supposed BARD1 
promoter. The vector with the BARD1 promoter region was then assayed for 
luciferase activity by transfecting the pGL3b-BARD1-promoter plasmid into several 
human and mouse cell lines (Figure 7.4).  
 
HindIII
HindIII
A
B
-865 bp
-2402 bp
Figure 7.2. Cloning of putative BARD1 promoter region. Two fragments were cloned into pGL3 basic vector. 
BARD1 promoter of -865 and -2402 base pairs upstream from first ATG cloned in MCS of pGL3 basic. The 
promoter region of upstream of BARD1 was cloned from human lymphocytes from 2 different origins, male and 
female. They were inserted in-sense and anti-sense into pGL3 basic vector and sequenced. 
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After transfection in various cell lines, the BARD1 region of 865 base pairs appears to 
be sufficient for constitutive activity of BARD1 since there is a high signal in all cell 
lines. However, this region does not seem to have a regulatory potential since when 
the transfected cells were treated with doxorubicin to induce a genotoxic stress, no 
significant increase of the reporter luciferase was noticed (Figure 7.5). Furthermore, 
when transfected cells were treated with several hormones no change in signal was 
observed (Figure 7.6). In order to eliminate biological variation due to cell death or 
transfection discrepancies, these experiments were performed using a dual luciferase 
reporter system. The secondary Renilla luciferase serves as an internal control (pRL-
TK). It is transfected at the same moment as the reporter vector containing promoter 
and is constitutively expressed under a thymidin kinase (TK) promoter, whereas the 
reporter gene is a Firefly luciferase. The results are then normalized according to the 
internal expression for each sample. Furthermore, for accuracy, the transfections are 
performed in triplicate and measured at three points each. 
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Figure 7.3. Illustration of putative transcription factors within the upstream BARD1 5’UTR region.  
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After analysis of its sequence for possible transcription factors, we found several 
sites of interest inferring that the –2402 region could be the regulatory region. This 
stretch of DNA has to be evaluated in future studies. Unique NF-kB, p53 and p300 
binding sites were found as well as a repetitive sites for C/EBP. The promoter is a 
TATAless promoter region, rich in CpG and Sp-1 sites, which is characteristic of 
constitutive promoters. However, the NF-κB site could be important in the 
inflammation process and the regulation of BARD1 transcription. Further experiments 
should include foot-printing, band shift as well as super shift assays in order to 
determine the existence and the physical binding of the aforementioned transcription 
factors on this stretch of DNA. Furthermore, since it is known that BRCA1 over-
expression can up-regulate NF-κB in vitro, it would be interesting to see if this region 
can be activated by cytokines such as TNF-α or by BRCA1 transfection.  This would 
provide new insight on BARD1 regulation and the identification of its feedback loop. 
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Figure 7.4. Luciferase activity in 5 different cell lines. This histogram shows directional expression of –865 bp 
BARD1 minimal promoter region. Biological variation between different cell lines is probably due to 
transfection efficiency. Control is pGL3 control vector containing a firefly luciferase under a CMV promoter and 
an enhancer for optimal activity. (-)L5 is the 856 sequence from L5 and inserted negatively and serves as a 
mock. It demonstrates that orientation is primordial in this context despite several putative transcription factor 
sites placed in the opposite direction. Non specific DNA in pGL3 basic vector is immune to aberrant cryptic 
responsiveness. TAC-2 and NIH 3T3 are mouse cells the others are human. The human promoter region appears 
to show some conservation in mice. 
 134
Furthermore, we know that BARD1 may bind to the p50 sub-unit of NF-κB, through 
Bcl-3, and this could be the link in a possible regulated feedback loop for BARD1 
expression. 
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Figure 7.5. Dual luciferase assay after treatment with doxorubicin. No significant change in luciferase 
expression after treatment with 5 µg/ml for 6 hrs in any cell line used. 
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Figure 7.6. Response of luciferase reporter gene after hormonal treatment. Dual luciferase assay. 
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Conclusion 
This thesis is dispersed over several points but concentrate on the same theme: the 
role of BARD1 in tumour suppression and maintenance of genomic stability through 
cell cycle mechanisms. We wanted to investigate the role of BARD1 in tumour 
suppression and how it controls genetic integrity. We have shown that BARD1 often 
reflects the actions normally performed by BRCA1. Indeed BARD1 repression 
creates genomic instability, loss of regular or normal cell cycle progression, 
proliferation defects, and a tumour phenotype. Moreover, knockouts of BARD1, 
BRCA1 or BRCA2 are not viable, since embryos die early in gestation. In this thesis 
we have shown that BARD1 may have BRCA1-independent functions in addition of a 
BRCA1-dependent role, such as pro-apoptotic response to genotoxic stress which is 
dependent on p53. Furthermore, BARD1 is up-regulated upon genotoxic insult, 
hypoxia and cell death in vitro and in vivo. BARD1 pro-apoptotic function has been 
mapped to a region spanning amino acids 510 to 604. Moreover, this is confirmed by 
the fact that the mutant Q564H is inefficient in promoting cell death. We have shown 
that BARD1 is a dynamic protein with a function in the cytoplasm, expressed in G2/M 
and which is associated with apoptosis. Furthermore, we showed that BARD1 binds 
to p53 and Ku-70 in co-immunoprecipitation assays, independently from BRCA1. 
BARD1 has many roles and could be mediated through BRCA1/BARD1 E3 ubiquitin 
ligase activity. Lastly, it appears that BARD1 has several important roles in 
spermatogenesis, embryogenesis, cell cycle progression, mitosis, centrosome 
duplication and cytokinesis. It interacts with BRCA2 during G2/M and it also interacts 
with TACC1 and Aurora B but not with Aurora A. In the future, it would be necessary 
to dissect the precise role for BARD1 in this part of cell physiology. BARD1 
commands vital cellular functions and is definitely a multifunctional protein that still 
holds many secrets.  
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